

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
WO 01/58923 A2(51) International Patent Classification<sup>7</sup>: C07K

CHANG, Xiao-jia; 25 Round Hill Road, Lincoln, MA 01773 (US).

(21) International Application Number: PCT/US01/00684

(22) International Filing Date: 7 February 2001 (07.02.2001)

(74) Agents: KELBER, Steven, B. et al.; Piper Marbury Rudnick &amp; Wolfe LLP, 1200 Nineteenth Street, N.W., Washington, DC 20036-2412 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/180,669	7 February 2000 (07.02.2000)	US
09/654,499	1 September 2000 (01.09.2000)	US
09/759,152	16 January 2001 (16.01.2001)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(71) Applicant: TROPIX, INC. [US/US]; 47 Wiggins Avenue, Bedford, MA 01730 (US).

(84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: PALMER, Michelle, A., J.; 87 Medford Street, Arlington, MA 02174 (US). GEE, Melissa; 17 Crescent Avenue, Bedford, MA 01730 (US). TILLOTSON, Bonnie; 4 Ripley Road, Belmont, MA 02178 (US).

[Continued on next page]

(54) Title: IMPROVED SYSTEMS FOR SENSITIVE DETECTION OF G-PROTEIN COUPLED RECEPTOR AND ORPHAN RECEPTOR FUNCTION USING REPORTER ENZYME MUTANT COMPLEMENTATION

Agonist Stimulated cAMP Response in C2 Cells Expressing  $\beta 2AR$ - $\beta gal\Delta\alpha$ 

(57) Abstract: Methods for detecting G-protein coupled receptor (GPCR) activity; methods for assaying GPCR activity; and methods for screening for GPCR ligands, G-protein-coupled receptor kinase (GRK) activity, and compounds that interact with components of the GPCR regulatory process are described. Included are methods for expanding ICASST technologies for assaying GPCR activity with applications for ligand fishing, and agonist or antagonist screening. These methods include: engineering seronine/threonine phosphorylation sites into known or orphan GPCR open reading frames in order to increase the affinity of arrestin for the activated form of the GPCR or to increase the reside time of arrestin-on the activated GPCR; engineering mutant arrestin proteins

that bind to activated GPCRs in the absence of G-protein coupled receptor kinases which may be limiting; and engineering mutant super arrestin proteins that have an increased affinity for activated GPCRs with or without phosphorylation. These methods are intended to increase the robustness of the GPCR/ICASST technology in situations in which G-protein coupled receptor kinases are absent or limiting, or in which the GPCR is not efficiently down-regulated or is rapidly resensitized (thus having a labile interaction with arrestin). Included are also more specific methods for using ICASST complementary enzyme fragments to monitor GPCR homo- and hetero- dimerization with applications for drug lead discovery and ligand and function discovery for orphan GPCRs.



**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**TITLE OF THE INVENTION****IMPROVED SYSTEMS FOR SENSITIVE DETECTION OF G-PROTEIN  
COUPLED RECEPTOR AND ORPHAN RECEPTOR FUNCTION  
USING REPORTER ENZYME MUTANT COMPLEMENTATION****BACKGROUND OF THE INVENTION**

This application is a continuation-in-part of U.S. Application Serial No. 09/654,499, filed September 1, 2000, which claims the benefit from Provisional Application Serial No. 60/180,669, filed February 7, 2000. The entirety of U.S. Application Serial No. 09/654,499 and Provisional Application Serial No. 60/180,669 are incorporated herein by reference.

**Field of the Invention**

The present invention relates to methods of detecting G-protein-coupled receptor (GPCR) activity, and provides methods of assaying GPCR activity, methods for screening for GPCR ligands, agonists and/or antagonists, methods for screening natural and surrogate ligands for orphan GPCRs, and methods for screening compounds that interact with components of the GPCR regulatory process.

15

**Background of the Technology**

The actions of many extracellular signals are mediated by the interaction of G-protein- coupled receptors (GPCRs) and guanine nucleotide-binding regulatory proteins (G-proteins). G-protein-mediated signaling systems have been identified in many divergent organisms, such as mammals and yeast. The GPCRs represent a

20

large super family of proteins which have divergent amino acid sequences, but share common structural features, in particular, the presence of seven transmembrane helical domains. GPCRs respond to, among other extracellular signals, neurotransmitters, hormones, odorants and light. Individual GPCR types  
5 activate a particular signal transduction pathway; at least ten different signal transduction pathways are known to be activated via GPCRs. For example, the beta 2-adrenergic receptor ( $\beta 2AR$ ) is a prototype mammalian GPCR. In response to agonist binding,  $\beta 2AR$  receptors activate a G-protein ( $G_s$ ) which in turn stimulates adenylate cyclase activity and results in increased cyclic adenosine  
10 monophosphate (cAMP) production in the cell.

The signaling pathway and final cellular response that result from GPCR stimulation depends on the specific class of G-protein with which the particular receptor is coupled (Hamm, "The Many Faces of G-Protein Signaling." J. Biol. Chem., 273:669-672 (1998)). For instance, coupling to the  $G_s$  class of G-proteins  
15 stimulates cAMP production and activation of the Protein Kinase A and C pathways, whereas coupling to the  $G_i$  class of G-proteins down regulates cAMP. Other second messenger systems such as calcium, phospholipase C, and phosphatidylinositol 3 may also be utilized. As a consequence, GPCR signaling events have predominantly been measured via quantification of these second  
20 messenger products.

The decrease of a response to a persistent stimulus is a widespread biological phenomenon. Signaling by diverse GPCRs is believed to be terminated by a uniform two-step mechanism. Activated receptor is first phosphorylated by a



GPCR kinase (GRK). An arrestin protein binds to the activated and phosphorylated receptor, thus blocking G-protein interaction. This process is commonly referred to as desensitization, a general mechanism that has been demonstrated in a variety of functionally diverse GPCRs. Arrestin also plays a part in regulating GPCR internalization and resensitization, processes that are heterogenous among different GPCRs (Oakley, et al., J. Biol. Chem., 274:32248-32257 (1999)). The interaction between an arrestin and GPCR in processes of internalization and resensitization is dictated by the specific sequence motif in the carboxyl terminus of a given GPCR. Only a subset of GPCRs, which possess clusters of three serine or threonine residues at the carboxyl termini, were found to co-traffick with the arrestins into the endocytic vesicles after ligand stimulation. The number of receptor kinases and arrestins involved in desensitization of GPCRs is rather limited.

A common feature of GPCR physiology is desensitization and recycling of the receptor through the processes of receptor phosphorylation, endocytosis and dephosphorylation (Ferguson, et al., "G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins." Can. J. Physiol. Pharmacol., 74:1095-1110 (1996)). Ligand-occupied GPCRs can be phosphorylated by two families of serine/threonine kinases, the G-protein-coupled receptor kinases (GRKs) and the second messenger-dependent protein kinases such as protein kinase A and protein kinase C. Phosphorylation by either class of kinases serves to down-regulate the receptor by uncoupling it from its corresponding G-protein. GRK-phosphorylation also serves to down-regulate the receptor by recruitment of a

class of proteins known as the arrestins that bind the cytoplasmic domain of the receptor and promote clustering of the receptor into endocytic vesicles. Once the receptor is endocytosed, it will either be degraded in lysosomes or dephosphorylated and recycled back to the plasma membrane as a fully-functional receptor.

Binding of an arrestin protein to an activated receptor has been documented as a common phenomenon of a variety of GPCRs ranging from rhodopsin to  $\beta$ 2AR to the neurotensin receptor (Barak, et al., "A  $\beta$ -arrestin/Green Fluorescent Fusion Protein Biosensor for Detecting G-Protein-Coupled Receptor Activation," J. Biol. Chem., 272:27497-500 (1997)). Consequently, monitoring arrestin interaction with a specific GPCR can be utilized as a generic tool for measuring GPCR activation. Similarly, a single G-protein and GRK also partner with a variety of receptors (Hamm, et al. (1998) and Pitcher et al., "G-Protein-Coupled Receptor Kinases," Annu. Rev. Biochem., 67:653-92 (1998)), such that these protein/protein interactions may also be monitored to determine receptor activity.

Many therapeutic drugs in use today target GPCRs, as they regulate vital physiological responses, including vasodilation, heart rate, bronchodilation, endocrine secretion and gut peristalsis. See, e.g., Lefkowitz et al., Annu. Rev. Biochem., 52:159 (1983). Some of these drugs mimic the ligand for this receptor. Other drugs act to antagonize the receptor in cases when disease arises from spontaneous activity of the receptor.

Efforts such as the Human Genome Project are identifying new GPCRs ("orphan" receptors) whose physiological roles and ligands are unknown. It is estimated that several thousand GPCRs exist in the human genome.

Various approaches have been used to monitor intracellular activity in response to a stimulant, e.g., enzyme-linked immunosorbent assay (ELISA);  
5 Fluorescence Imaging Plate Reader assay (FLIPR™, Molecular Devices Corp., Sunnyvale, CA); EVOscreen™, EVOTEC™, Evotec Biosystems GmbH, Hamburg, Germany; and techniques developed by CELLOMICS™, Cellomics, Inc., Pittsburgh, PA.

10 Germino et al., "Screening for in vivo protein-protein interactions." Proc. Natl. Acad. Sci., 90(3):933-937 (1993), discloses an *in vivo* approach for the isolation of proteins interacting with a protein of interest.

Phizicky et al., "Protein-protein interactions: methods for detection and analysis." Microbiol. Rev., 59(1): 94-123 (1995), discloses a review of  
15 biochemical, molecular biological and genetic methods used to study protein-protein interactions.

Offermanns et al., "Gα<sub>15</sub> and Gα<sub>16</sub> Couple a Wide Variety of Receptors to Phospholipase C." J. Biol. Chem., 270(25):15175-15180 (1995), discloses that Gα<sub>15</sub> and Gα<sub>16</sub> can be activated by a wide variety of G-protein-coupled receptors.  
20 The selective coupling of an activated receptor to a distinct pattern of G-proteins is regarded as an important requirement to achieve accurate signal transduction. Id.

Barak et al., "A β-arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation." J. Biol. Chem., 272(44):27497-

27500 (1997) and U.S. Patents Nos. 5,891,646 and 6,110,693 disclose the use of a  $\beta$ -arrestin/green fluorescent fusion protein (GFP) for imaging protein translocation upon stimulation of GPCR with optical devices.

Each of the references described above has drawbacks. For example,

- 5
- The prior art methodologies require over-expression of the proteins, which could cause artifact and tip the balance of cellular regulatory machineries.
  - The prior art visualization or imaging assays are low throughput and lack thorough quantification. Therefore, they are not suitable for
- 10 high throughput pharmacological and kinetic assays.

In addition, many of the prior art assays require isolation of the GPCR rather than observation of the GPCR in a cell. There thus exists a need for improved methods for monitoring GPCR function.

15

### **SUMMARY OF THE INVENTION**

The present invention provides modifications to the disclosure in U.S. Application Serial No. 09/654,499. In particular, the present invention is directed to modifications of the below aspects of the invention to further enhance assay sensitivity. The modifications include the use of genetically modified arrestins that

20 exhibit enhanced binding to activated GPCR regardless of whether the GPCR is phosphorylated or non-phosphorylated; the use of a serine/threonine cluster strategy to facilitate screening assays for orphan receptors that do not possess this

structural motif on their own; and the use of a combination of the above modifications to achieve even more enhanced detection.

A first aspect of the present invention is a method that monitors GPCR function proximally at the site of receptor activation, thus providing more information for drug discovery purposes due to fewer competing mechanisms. Activation of the GPCR is measured by a read-out for interaction of the receptor with a regulatory component such as arrestin, G-protein, GRK or other kinases, the binding of which to the receptor is dependent upon agonist occupation of the receptor. The present invention involves the detection of protein/protein interaction by complementation of mutant reporter enzymes.

Binding of arrestin to activated GPCR is a common process in the first step of desensitization that has been demonstrated for most, if not all, GPCRs studied so far. Measurement of GPCR interaction with arrestin via mutant enzyme complementation (i.e., ICAST) provides a more generic assay technology applicable for a wide variety of GPCRs and orphan receptors.

A further aspect of the present invention is a method of assessing GPCR pathway activity under test conditions by providing a test cell that expresses a GPCR, e.g., muscarinic, adrenergic, dopamine, angiotensin or endothelin, as a fusion protein to a mutant reporter enzyme and interacting a protein in the GPCR pathway, e.g., G-protein, arrestin or GRK, as a fusion protein with a complementing mutant reporter enzyme. When test cells are exposed to a known agonist to the target GPCR under test conditions, activation of the GPCR will be

monitored by complementation of the reporter enzyme. Increased reporter enzyme activity reflects interaction of the GPCR with its interacting protein partner.

A further aspect of the present invention is a method of assessing GPCR pathway activity in the presence of a test arrestin, e.g.,  $\beta$ -arrestin.

5 A further aspect of the present invention is a method of assessing GPCR pathway activity in the presence of a test G-protein.

A further aspect of the present invention is a method of assessing GPCR pathway activity upon exposure of the test cell to a test ligand.

A further aspect of the present invention is a method of assessing GPCR  
10 activity upon co-expression in the test cell of a second receptor. The second receptor could be the same GPCR or orphan receptor (i.e., homo-dimerization), a different GPCR or orphan receptor (i.e., hetero-dimerization) or could be a receptor of another type.

A further aspect of the present invention is a method for screening for a  
15 ligand or agonist to an orphan GPCR. The ligand or agonist could be contained in natural or synthetic libraries or mixtures or could be a physical stimulus. A test cell is provided that expresses the orphan GPCR as a fusion protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and, for example, an arrestin or mutant form of arrestin as a fusion protein with a complementing mutant reporter  
20 enzyme, e.g., another  $\beta$ -galactosidase mutant. The interaction of the arrestin with the orphan GPCR upon receptor activation is measured by enzymatic activity of the complemented reporter enzyme. The test cell is exposed to a test compound, and an increase in reporter enzyme activity indicates the presence of a ligand or agonist.

A further aspect of the present invention is a method for screening a protein of interest, for example, an arrestin protein (or mutant form of the arrestin protein) for the ability to bind to a phosphorylated, or activated, GPCR. A test cell is provided that expresses a GPCR as a fusion protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and contains arrestin (or a mutant form of arrestin) as a fusion protein with a complementing mutant reporter enzyme, e.g., another  $\beta$ -galactosidase mutant. The interaction of arrestin with the GPCR upon receptor activation is measured by enzymatic activity of the complemented reporter enzyme. The test cell is exposed to a known GPCR agonist and then reporter enzyme activity is detected. Increased reporter enzyme activity indicates that the  $\beta$ -arrestin molecule can bind to phosphorylated, or activated, GPCR in the test cell.

A further aspect of the present invention is a method to screen for an agonist to a specific GPCR. The agonist could be contained in natural or synthetic libraries or could be a physical stimulus. A test cell is provided that expresses a GPCR as a fusion protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and, for example, an arrestin as a fusion protein with a complementing mutant reporter enzyme, e.g., another  $\beta$ -galactosidase mutant. The interaction of arrestin with the GPCR upon receptor activation is measured by enzymatic activity of the complemented reporter enzyme. The test cell is exposed to a test compound, and an increase in reporter enzyme activity indicates the presence of an agonist. The test cell may express a known GPCR or a variety of known GPCRs, or may express an unknown GPCR or a variety of unknown GPCRs. The GPCR may be, for example, an odorant GPCR or a  $\beta$ AR GPCR.

A further aspect of the present invention is a method for screening a test compound for GPCR antagonist activity. A test cell is provided that expresses a GPCR as a fusion protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and, for example, an arrestin as a fusion protein with a complementing mutant reporter enzyme, e.g., another  $\beta$ -galactosidase mutant. The interaction of arrestin with the GPCR upon receptor activation is measured by enzymatic activity of the complemented reporter enzyme. The test cell is exposed to a test compound, and an increase in reporter enzyme activity indicates the presence of an agonist. The cell is exposed to a test compound and to a GPCR agonist, and reporter enzyme activity is detected. When exposure to the agonist occurs at the same time as or subsequent to exposure to the test compound, a decrease in reporter enzyme activity after exposure to the test compound indicates that the test compound has antagonist activity to the GPCR.

A further aspect of the present invention is a method of screening a sample solution for the presence of an agonist, antagonist or ligand to a GPCR. A test cell is provided that expresses GPCR as a fusion protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and contains, for example, a  $\beta$ -arrestin as a fusion protein with a complementing reporter, e.g., another  $\beta$ -galactosidase mutant. The test cell is exposed to a sample solution, and reporter enzyme activity is assessed. Changed reporter enzyme activity after exposure to the sample solution indicates the sample solution contains an agonist, antagonist or ligand for a GPCR expressed in the cell.



A further aspect of the present invention is a method of screening a cell for the presence of a GPCR. According to this aspect, an arrestin fusion protein with a mutant reporter enzyme and a GPCR downstream signaling fusion protein with a mutant reporter enzyme are employed to detect GPCR action. A modification of this aspect of the invention can be employed to provide a method of screening a plurality of cells for those cells which contain a GPCR. According to this aspect, a plurality of cells containing a conjugate comprising a  $\beta$ -arrestin protein as a fusion protein with a reporter enzyme are provided; the plurality of cells are exposed to a GPCR agonist; and activity of reporter enzyme activity is detected. An increase in reporter enzymatic activity after exposure to the GPCR agonist indicates  $\beta$ -arrestin protein binding to a GPCR, thereby indicating that the cell contains a GPCR responsive to the GPCR agonist.

A further aspect of the invention is a method for mapping GPCR-mediated signaling pathways. For instance, the system could be utilized to monitor interaction of c-src with  $\beta$ -arrestin-1 upon GPCR activation. Additionally, the system could be used to monitor protein/protein interactions involved in cross-talk between GPCR signaling pathways and other pathways such as that of the receptor tyrosine kinases or Ras/Raf. According to this aspect, a test cell is provided that expresses a GPCR or other related protein with a mutant reporter enzyme, e.g., a  $\beta$ -galactosidase mutant, and contains a protein from another pathway as a fusion protein with a complementing mutant reporter enzyme, e.g., another  $\beta$ -galactosidase mutant. Increased reporter enzymatic activity indicates protein/protein interaction.

A further aspect of the invention is a method for monitoring homo- or hetero- dimerization of GPCRs upon agonist or antagonist stimulation. Increasing evidence indicates that GPCR dimerization is important for biological activity (AbdAlla, et al., "AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration." Nature, 407:94-98 (2000); Bockaert, et al., "Molecular tinkering of G protein-coupled receptors: an evolutionary success." EMBO J. 18:1723-29 (1999)). Jordan, et al., "G-protein-coupled receptor heterodimerization modulates receptor function." Nature, 399:697-700 (1999), demonstrated that two non-functional opioid receptors,  $\kappa$  and  $\delta$ , heterodimerize to form a functional receptor. Gordon et al., "Dopamine D2 receptor dimers and receptor blocking peptides." Bioch. Biophys. Res. Commun. 227:200-204 (1996), showed different pharmacological properties associated with the monomeric and dimeric forms of Dopamine receptor D2. The D2 receptors exist either as monomers that are selective targets for spiperone or as dimer forms that are targets for nemonapride. Herbert, et al., "A peptide derived from a  $\beta$ 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation." J.B.C. 271:16384-92 (1996), demonstrated that the agonist stimulation was found to stabilize the dimeric state of the receptor, whereas inverse agonists favored the monomeric form. Indeed, the same study showed that a peptide corresponding to the sixth transmembrane domain of the  $\beta$ 2-adrenergic receptor inhibited both receptor dimerization and activation. Further, Angers et al., Detection of beta-2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer, Proc. Natl. Acad. Sci. USA, 97(7):3684-3689, discloses the use of

$\beta$ 2-adrenergic receptor fusion proteins (i.e.,  $\beta$ 2-adrenergic receptor fused to luciferase and  $\beta$ 2-adrenergic receptor fused to an enhanced red-shifted green fluorescent protein) to study  $\beta$ 2-adrenergic receptor dimerization.

GPCR dimerization in the context of cellular physiology and pharmacology can be monitored in accordance with the invention. For example,  $\beta$ -galactosidase complementation can be measured in test cells that co-express GPCR fusion proteins of  $\beta$ -galactosidase mutant enzymes, e.g., GPCR<sub>1</sub> $\Delta\alpha$  and GPCR<sub>2</sub> $\Delta\omega$  (FIGURE 27). According to this aspect, the interconversion between monomeric to dimeric forms of the GPCRs or orphan receptors can be measured by mutant reporter enzyme complementation. FIGURE 27 illustrates a test cell co-expressing GPCR or an orphan receptor as a fusion protein with  $\Delta\alpha$  form of  $\beta$ -galactosidase mutant (e.g., GPCR<sub>1</sub> $\Delta\alpha$ ), and the same GPCR or orphan receptor as a fusion protein with  $\Delta\omega$  form of  $\beta$ -galactosidase mutant (e.g., GPCR<sub>1</sub> $\Delta\omega$ ). Formation of the GPCR homodimer is reflected by formation of an active enzyme, which can be measured by enzyme activity assays, such as the Gal-Screen™ assay. Similarly, hetero-dimerization between two distinct GPCRs, or two distinct orphan receptors, or between one known GPCR and one orphan receptor can be analyzed in test cells co-expressing two fusion proteins, e.g., GPCR<sub>1</sub> $\Delta\alpha$  and GPCR<sub>2</sub> $\Delta\omega$ . The increased  $\beta$ -galactosidase activity indicates that the two receptors can form a heterodimer.

A further aspect of the invention is a method of monitoring the interconversion between the monomeric and dimeric form of GPCRs under the influence of agonist or antagonist treatment. The test receptor(s) can be between the same GPCR or orphan receptor (homodimer), or between two distinct GPCRs

or orphan receptors (heterodimer). The increased  $\beta$ -galactosidase activity after treatment with a compound means that the compound binds to and/or stabilizes the dimeric form of the receptor. The decreased  $\beta$ -galactosidase activity after treatment with a compound means that the compound binds to and/or stabilizes the monomeric form of the receptor.

A further aspect of the invention is a method of screening a cell for the presence of a GPCR responsive to a GPCR agonist. A cell is provided that contains protein partners that interact downstream in the GPCR's pathway. The protein partners are expressed as fusion proteins to the mutant, complementing enzyme and are used to monitor activation of the GPCR. The cell is exposed to a GPCR agonist and then enzymatic activity of the reporter enzyme is detected. Increased reporter enzyme activity indicates that the cell contains a GPCR responsive to the agonist.

The present invention involves the use of a combination of proprietary technologies (including ICAST<sup>TM</sup>, Intercistronic Complementation Analysis Screening Technology, Gal-Screen<sup>TM</sup>, etc.) to monitor protein/protein interactions in GPCR signaling. As disclosed in U.S. Application Serial No. 09/654,499, the method of the invention in part involves using ICAST<sup>TM</sup>, which in turn involves the use of two inactive  $\beta$ -galactosidase mutants, each of which is fused with one of two interacting target protein pairs, such as a GPCR and an arrestin. The formation of an active  $\beta$ -galactosidase complex is driven by interaction of the target proteins. In this system,  $\beta$ -galactosidase activity can be detected using, e.g., the Gal-Screen<sup>TM</sup> assay system, wherein direct cell lysis is combined with rapid

ultrasensitive chemiluminescent detection of  $\beta$ -galactosidase reporter enzyme.

This system uses, e.g., a Galacton-*Star*® chemiluminescent substrate for measurement in a luminometer as a read out of GPCR activity.

FIGURE 23 is a schematic depicting the use of the complementation  
5 technology in the method of the present invention. FIGURE 23 shows two inactive  $\beta$ -galactosidase mutants that become active when they are forced together by specific interactions between the fusion partners of an arrestin molecule and an activated GPCR or orphan receptor. This assay technology will be especially useful in high throughput screening assays for ligand fishing for orphan receptors, a  
10 process called de-orphaning. As illustrated in FIGURE 28, a  $\beta$ -galactosidase fusion protein of an orphan receptor (e.g., GPCR<sub>orphan</sub> $\Delta\alpha$ ) is co-expressed in the test cell with a fusion protein of  $\beta$ -arrestin (e.g.,  $\beta$ -Arr $\Delta\omega$ ). When the test cell is subjected to compounds, which could be natural or synthetic, the increased  $\beta$ -galactosidase activity means the compound is either a natural or surrogate ligand  
15 for this GPCR. The same assay system can be used to find drug leads for the new GPCRs. The increased  $\beta$ -galactosidase activity in the test cell after treatment indicates the agonist activity of the compound. The decreased  $\beta$ -galactosidase activity in the test cell indicates antagonist activity or inverse agonist activity of the compound. In addition, the method of the invention could be used to monitor  
20 GPCR-mediated signaling pathways via other downstream signaling components such as G-proteins, GRKs or the proto-oncogene c-Src.

The invention is achieved in part by using ICAST™ protein/protein interaction screening to map signaling pathways. This technology is applicable to

a variety of known and unknown GPCRs with diverse functions. They include, but are not limited to, the following sub-families of GPCRs:

(a) receptors that bind to amine-like ligands-Acetylcholine muscarinic receptor (M1 to M5), alpha and beta Adrenoceptors, Dopamine receptors (D1, D2, D3 and D4), Histamine receptors (H1 and H2), Octopamine receptor and Serotonin receptors (5HT1, 5HT2, 5HT4, 5HT5, 5HT6, 5HT7);

(b) receptors that bind to a peptide ligand-Angiotensin receptor, Bombesin receptor, Bradykinin receptor, C-C chemokine receptors (CCR1 to CCR8, and CCR10), C-X-C type Chemokine receptors (CXC-R5), Cholecystokinin type A receptor, CCK type receptors, Endothelin receptor, Neurotesin receptor, FMLP-related receptors, Somatostatin receptors (type 1 to type 5) and Opioid receptors (type D, K, M, X);

(c) receptors that bind to hormone proteins-Follic stimulating hormone receptor, Thyrotrophin receptor and Lutropin-choriogonadotropic hormone receptor;

(d) receptors that bind to neurotransmitters-substance P receptor, Substance K receptor and neuropeptide Y receptor;

(e) Olfactory receptors-Olfactory type 1 to type 11, Gustatory and odorant receptors;

(f) Prostanoid receptors-Prostaglandin E2 (EP1 to EP4 subtypes), Prostacyclin and Thromboxane;

(g) receptors that bind to metabotropic substances-Metabotropic glutamate group I to group III receptors;

(h) receptors that respond to physical stimuli, such as light, or to chemical stimuli, such as taste and smell; and

(i) orphan GPCRs-the natural ligand to the receptor is undefined.

Use of the ICAST<sup>TM</sup> technology in combination with the invention provides many benefits to the GPCR screening process, including the ability to monitor protein interactions in any sub-cellular compartment-membrane, cytosol and nucleus; the ability to achieve a more physiologically relevant model without requiring protein overexpression; and the ability to achieve a functional assay for receptor binding allowing high information content.

10

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

FIGURE 1. Cellular expression levels of  $\beta 2$  adrenergic receptor ( $\beta 2AR$ ) and  $\beta$ -arrestin-2 ( $\beta Arr2$ ) in C2 clones. Quantification of  $\beta$ -galactosidase ( $\beta$ -gal) fusion protein was performed using antibodies against  $\beta$ -gal and purified  $\beta$ -gal protein in a titration curve by a standardized ELISA assay. Figure 1A shows expression levels of  $\beta 2AR$ - $\beta gal\Delta\alpha$  clones (in expression vector pICAST ALC). Figure 1B shows expression levels of  $\beta Arr2$ - $\beta gal\Delta\omega$  in expression vector pICAST OMC4 for clones 9-3, -7, -9, -10, -19 and -24, or in expression vector pICAST OMN4 for clones 12-4, -9, -16, -18, -22 and -24.

FIGURE 2. Receptor  $\beta 2AR$  activation was measured by agonist-stimulated cAMP production. C2 cells expressing pICAST ALC  $\beta 2AR$  (clone 5) or parental cells were treated with increasing concentrations of (-)-isoproterenol and 0.1mM

IBMX. The quantification of cAMP level was expressed as pmol/well.

FIGURE 3. Interaction of activated receptor  $\beta$ 2AR and arrestin can be measured by  $\beta$ -galactosidase complementation. Figure 3A shows a time course of  $\beta$ -galactosidase activity in response to agonist (-)-isoproterenol stimulation in C2  
5 expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  ( $\beta$ 2AR alone, in expression vector pICAST ALC), or a pool of doubly transduced C2 co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  (in expression vectors pICAST ALC and pICAST OMC and clones isolated from the same pod (43-1, 43-2, 43-7 and 43-8)). Figure 3B shows a time course of  $\beta$ -galactosidase activity in response to agonist (-)-isoproterenol stimulation in C2 cells  
10 expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  alone (in expression vector pICAST ALC) and C2 clones co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr1- $\beta$ gal $\Delta\omega$  (in expression vectors ICAST ALC and pICAST OMC).

FIGURE 4. Agonist dose response for interaction of  $\beta$ 2AR and arrestin can be measured by  $\beta$ -galactosidase complementation. Figure 4A shows a dose  
15 response to agonists (-)-isoproterenol and procaterol in C2 cells co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  fusion constructs. Figure 4B shows a dose response to agonists (-)-isoproterenol and procaterol in C2 cells co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr1- $\beta$ gal $\Delta\omega$  fusion constructs.

FIGURE 5. Antagonist mediated inhibition of receptor activity can be  
20 measured by  $\beta$ -galactosidase complementation in cells co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr- $\beta$ gal $\Delta\omega$ . Figure 5A shows specific inhibition with adrenergic



antagonists ICI-118,551 and propranolol of  $\beta$ -galactosidase activity in C2 clones co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  fusion constructs after incubation with agonist (-)isoproterenol. Figure 5B shows specific inhibition of  $\beta$ -galactosidase activity with adrenergic antagonists ICI-118,551 and propranolol in  
5 C2 clones co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr1- $\beta$ gal $\Delta\omega$  fusion constructs in the presence of agonist (-)isoproterenol.

FIGURE 6. C2 cells expressing adenosine receptor A2a show cAMP induction in response to agonist (CGS-21680) treatment. C2 parental cells and C2 cells co-expressing A2aR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr1- $\beta$ gal $\Delta\omega$  as a pool or as selected clones  
10 (47-2 and 47-13) were measured for agonist-induced cAMP response (pmol/well).

FIGURE 7. Agonist stimulated cAMP response in C2 cells co-expressing Dopamine receptor D1 (D1- $\beta$ gal $\Delta\alpha$ ) and  $\beta$ -arrestin-2 ( $\beta$ Arr2- $\beta$ gal $\Delta\omega$ ). The clone expressing  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  (Arr2 alone) was used as a negative control in the assay. Cells expressing D1- $\beta$ gal $\Delta\alpha$  in addition to  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  responded agonist  
15 treatment (3-hydroxytyramine hydrochloride at 3  $\mu$ M). D1(PIC2) or D1(PIC3) designate D1 in expression vector pICAST ALC2 or pICAST ALC4, respectively.

FIGURE 8. Variety of mammalian cell lines can be used to generate stable cells for monitoring GPCR and arrestin interactions. FIGURE 8A, FIGURE 8B and FIGURE 8C show the examples of HEK 293, CHO and CHW cell lines co-  
20 expressing adrenergic receptor  $\beta$ 2AR and arrestin fusion proteins of  $\beta$ -

galactosidase mutants. The  $\beta$ -galactosidase activity was used to monitor agonist-induced interaction of  $\beta$ 2AR and arrestin proteins.

FIGURE 9. Beta-gal complementation can be used to monitor  $\beta$ 2  
adrenergic receptor homo-dimerization. FIGURE 9A shows  $\beta$ -galactosidase  
5 activity in HEK 293 clones co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ 2AR- $\beta$ gal $\Delta\omega$ .  
FIGURE 9B shows a cAMP response to agonist (-)-isoproterenol in HEK 293  
clones co-expressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ 2AR- $\beta$ gal $\Delta\omega$ . HEK293 parental cells  
were included in the assays as negative controls.

FIGURE 10A. pICAST ALC: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-  
10 terminal fusion to the target protein. This construct contains the following  
features: MCS, multiple cloning site for cloning the target protein in frame with the  
 $\beta$ -gal $\Delta\alpha$ ; GS Linker, (GGGGS) $_n$ ; NeoR, neomycin resistance gene; IRES, internal  
ribosome entry site; ColE1ori, origin of replication for growth in *E. coli*;  
5'MoMuLV LTR and 3'MoMuLV LTR, viral promoter and polyadenylation  
15 signals from the Moloney Murine leukemia virus.

FIGURE 10B. Nucleotide sequence for pICAST ALC.

FIGURE 11A. pICAST ALN: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as an N-  
terminal fusion to the target protein. This construct contains the following  
features: MCS, multiple cloning site for cloning the target protein in frame with the  
20  $\beta$ -gal $\Delta\alpha$ ; GS Linker, (GGGGS) $_n$ ; NeoR, neomycin resistance gene; IRES, internal  
ribosome entry site; ColE1ori, origin of replication for growth in *E. coli*;

5'MoMuLV LTR and 3'MoMuLV LTR, viral promoter and polyadenylation signals from the Moloney Murine leukemia virus.

FIGURE 11B. Nucleotide sequence for pICAST ALN.

FIGURE 12A. pICAST OMC: Vector for expression of  $\beta$ -gal $\Delta\omega$  as a C-terminal fusion to the target protein. This construct contains the following features: MCS, multiple cloning site for cloning the target protein in frame with the  $\beta$ -gal $\Delta\omega$ ; GS Linker, (GGGGS)<sub>n</sub>; Hygro, hygromycin resistance gene; IRES, internal ribosome entry site; ColE1ori, origin of replication for growth in *E. coli*; 5'MoMuLV LTR and 3'MoMuLV LTR, viral promoter and polyadenylation signals from the Moloney Murine leukemia virus.

FIGURE 12B. Nucleotide sequence for pICAST OMC.

FIGURE 13A. pICAST OMN: Vector for expression of  $\beta$ -gal $\Delta\omega$  as an N-terminal fusion to the target protein. This construct contains the following features: MCS, multiple cloning site for cloning the target protein in frame with the  $\beta$ -gal $\Delta\omega$ ; GS Linker, (GGGGS)<sub>n</sub>; Hygro, hygromycin resistance gene; IRES, internal ribosome entry site; ColE1ori, origin of replication for growth in *E. coli*; 5'MoMuLV LTR and 3'MoMuLV LTR, viral promoter and polyadenylation signals from the Moloney Murine leukemia virus.

FIGURE 13B. Nucleotide sequence for pICAST OMN.

FIGURE 14. pICAST ALC  $\beta$ Arr2: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-terminal fusion to  $\beta$ -arrestin-2. The coding sequence of human  $\beta$ -arrestin-2 (Genebank Accession Number: NM\_004313) was cloned in frame to  $\beta$ -gal $\Delta\alpha$  in a

pICAST ALC vector.

FIGURE 15. pICAST OMC  $\beta$ Arr2: Vector for expression of  $\beta$ -gal $\Delta\omega$  as a C-terminal fusion to  $\beta$ -arrestin-2. The coding sequence of human  $\beta$ -arrestin-2 (Genebank Accession Number: NM\_004313) was cloned in frame to  $\beta$ -gal $\Delta\omega$  in a pICAST OMC vector.

FIGURE 16. pICAST ALC  $\beta$ Arr1: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-terminal fusion to  $\beta$ -arrestin-1. The coding sequence of human  $\beta$ -arrestin-1 (Genebank Accession Number: NM\_004041) was cloned in frame to  $\beta$ -gal $\Delta\alpha$  in a pICAST ALC vector.

FIGURE 17. pICAST OMC  $\beta$ Arr1: Vector for expression of  $\beta$ -gal $\Delta\omega$  as a C-terminal fusion to  $\beta$ -arrestin-1. The coding sequence of human  $\beta$ -arrestin-1 (Genebank Accession Number: NM\_004041) was cloned in frame to  $\beta$ -gal $\Delta\omega$  in a pICAST OMC vector.

FIGURE 18. pICAST ALC  $\beta$ 2AR: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-terminal fusion to  $\beta$ 2 Adrenergic Receptor. The coding sequence of human  $\beta$ 2 Adrenergic Receptor (Genebank Accession Number: NM\_000024) was cloned in frame to  $\beta$ -gal $\Delta\alpha$  in a pICAST ALC vector.

FIGURE 19. pICAST OMC  $\beta$ 2AR: Vector for expression of  $\beta$ -gal $\Delta\omega$  as a C-terminal fusion  $\beta$ 2 Adrenergic Receptor. The coding sequence of human  $\beta$ 2 Adrenergic Receptor (Genebank Accession Number: NM\_000024) was cloned in frame to  $\beta$ -gal $\Delta\omega$  in a pICAST OMC vector.

FIGURE 20. pICAST ALC A2aR: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-terminal fusion to Adenosine 2a Receptor. The coding sequence of human Adenosine 2a Receptor (Genebank Accession Number: NM\_000675) was cloned in frame to  $\beta$ -gal $\Delta\alpha$  in a pICAST ALC vector.

5       FIGURE 21. pICAST OMC A2aR: Vector for expression of  $\beta$ -gal $\Delta\omega$  as a C-terminal fusion to Adenosine 2a Receptor. The coding sequence of human Adenosine 2a Receptor (Genebank Accession Number: NM\_000675) was cloned in frame to  $\beta$ -gal $\Delta\omega$  in a pICAST OMC vector.

10       FIGURE 22. pICAST ALC D1: Vector for expression of  $\beta$ -gal $\Delta\alpha$  as a C-terminal fusion to Dopamine D1 Receptor. The coding sequence of human Dopamine D1 Receptor (Genebank Accession Number: X58987) was cloned in frame to  $\beta$ -gal $\Delta\alpha$  in a pICAST ALC vector.

15       FIGURE 23. A schematic depicting use of the complementation technology in the method of the invention. FIGURE 23 shows two inactive mutant reporter enzymes that become active when the corresponding fusion partners, GPCR and  $\beta$ -arrestin interact.

20       FIGURE 24. Vector for expression of a GPCR with inserted seronine/threonine amino acid sequences as a fusion with  $\beta$ -gal $\Delta\alpha$ . The open reading frame of a known or orphan GPCR is engineered to contain additional seronine/threonine sequences, such as SSS (seronine, seronine, seronine), within the C-terminal tail. The engineered GPCR is cloned in frame with  $\beta$ -gal $\Delta\alpha$  in a pICAST ALC vector. The pICAST ALC vector contains the following features:

MCS, multiple cloning site for cloning the target protein in frame with the  $\beta$ -gal $\Delta\alpha$ ;  
GS Linker, (GGGGS) $_n$ ; NeoR, neomycin resistance gene; IRES, internal ribosome  
entry site; ColE1ori, origin of replication for growth in *E. coli*; 5'MoMuLV LTR  
and 3'MoMuLV LTR, viral promotor and polyadenylation signals from the  
5 Moloney Murine leukemia virus.

FIGURE 25. Vector for expression of mutant (R170E)  $\beta$ -arrestin2 as a  
fusion with  $\beta$ -gal $\Delta\omega$ . The open reading frame of  $\beta$ -arrestin2 is engineered to  
contain a point mutation that converts arginine 170 to a glutamate. The mutant  $\beta$ -  
arrestin2 is cloned in frame with  $\beta$ -gal $\Delta\omega$  in a pICAST OMC vector. The pICAST  
10 OMC vector contains the following features: MCS, multiple cloning site for  
cloning the target protein in frame with the  $\beta$ -gal $\Delta\alpha$ ; GS Linker, (GGGGS) $_n$ ;  
Hygro, hygromycin resistance gene; IRES, internal ribosome entry site; ColE1ori,  
origin of replication for growth in *E. coli*; 5'MoMuLV LTR and 3'MoMuLV LTR,  
viral promotor and polyadenylation signals from the Moloney Murine leukemia  
15 virus.

FIGURE 26. Phosphorylation insensitive Mutant R170E  $\beta$ -Arrestin2 $\Delta\omega$   
binds to  $\beta$ 2AR $\Delta\alpha$  in Response to Agonist Activation. A parental  $\beta$ 2AR $\Delta\alpha$  C2 cell  
line was transduced with the Mutant R170E  $\beta$ -Arrestin2 $\Delta\omega$  construct. Clonal  
populations co-expressing the two constructions were plated at 10,000 cells/well in  
20 96 well plates and treated with 10 $\mu$ M (-)isoproterenol, 0.3mM ascorbic acid for the  
indicated time period.  $\beta$ -galactosidase activity was measured by addition of Tropix  
Gal-Screen<sup>TM</sup> assay system substrate (Applied Biosystems) and luminescence was  
measured using a Tropix TR717<sup>TM</sup> luminometer (Applied Biosystems). Treatments

were performed in triplicate. For comparison, a clonal cell line (43-8) co-expressing  $\beta 2AR\Delta\alpha$  and wild-type  $\beta$ -Arrestin2 $\Delta\omega$  was also plated at 10,000 cells/well and given the same agonist treatment regimen. Minutes of (-)isoproterenol treatment is shown on the X-axis and  $\beta$ -galactosidase activity indicated by relative light units (RLU) is shown on the Y-axis.

FIGURE 27. GPCR dimerization measured by  $\beta$ -galactosidase complementation. A schematic depicting the utilization of the invention for monitoring GPCR homo- or hetero- dimerization. One GPCR is fused to one complement enzyme fragment, while the second GPCR is fused to the second complement enzyme fragment. Interaction of the two GPCRs is monitored by complementation of the enzyme fragments to produce an active enzyme complex (i.e.,  $\beta$ -galactosidase activity). GPCR homo- or hetero- dimerization can be monitored in the absence or presence of ligand, agonists, inverse agonists or antagonists.

FIGURE 28. Ligand fishing for orphan receptors by  $\beta$ -galactosidase mutant complementation in ICAST<sup>TM</sup> system. A schematic depicting the utilization of the invention for ligand fishing and agonist/antagonist screening for orphan GPCRs. As an example, a test cell expressing two  $\beta$ -gal fusion proteins, GPCR<sub>orphan</sub> $\Delta\alpha$  and Arrestin- $\Delta\omega$ , is subjected to treatments with samples from natural or synthetic compound libraries, or from tissue extracts, or from conditioned media of cultured cells. An increased  $\beta$ -gal activity after treatment indicates the activation of the orphan receptor by a ligand in the testing sample. The readout of increased  $\beta$ -gal activity reflects the interaction of an activated

GPCR orphan receptor with a  $\beta$ -arrestin. Therefore, a cognate or a surrogate ligand for the testing receptor is identified.

#### **DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**

5           The present invention provides a method to interrogate GPCR function and pathways. The G-protein-coupled superfamily continues to expand rapidly as new receptors are discovered through automated sequencing of cDNA libraries or genomic DNA. It is estimated that several thousand GPCRs may exist in the human genome. Only a portion have been cloned and even fewer have been  
10       associated with ligands. The means by which these, or newly discovered orphan receptors, will be associated with their cognate ligands and physiological functions represents a major challenge to biological and biomedical research. The identification of an orphan receptor generally requires an individualized assay and a guess as to its function. The present invention involves the interrogation of  
15       GPCR function by monitoring the activation of the receptor using activation dependent protein-protein interactions between the test GPCR or orphan receptor and a  $\beta$ -arrestin. The specific protein-protein interactions are measured using the mutant enzyme complementation technology disclosed herein. This assay system eliminates the prerequisite guessing because it can be performed with and without  
20       prior knowledge of other signaling events. It is sensitive, rapid and easily performed and is applicable to nearly all GPCRs because the majority of these receptors desensitize by a common mechanism.

The present invention provides a complete assay system for monitoring



protein-protein interactions in GPCR pathways. The invention employs the complementation technology, ICAST™ (Intercistronic Complementation Analysis Screening Technology as disclosed in pending U.S. patent application serial no. 053,614, filed April 1, 1998, the entire contents of which are incorporated herein  
5 by reference). The ICAST™ technology involves the use of two mutant forms of a reporter enzyme fused to proteins of interest. When the proteins of interest do not interact, the reporter enzyme remains inactive. When the proteins of interest do interact, the reporter enzyme mutants come together and form an active enzyme. According to an embodiment of the invention, the activity of  $\beta$ -galactosidase may  
10 be detected with the Gal-Screen™ assay system developed by Advanced Discovery Sciences™, which involves the use of Galacton-Star®, an ultrasensitive chemiluminescent substrate. The Gal-Screen™ assay system and the Galacton-Star® chemiluminescent substrate are disclosed in U.S. Patent Nos. 5,851,771; 5,538,847; 5,326,882; 5,145,772; 4,978,614; and 4,931,569, the contents of which  
15 are incorporated herein by reference in their entirety. The invention provides an array of assays, including GPCR binding assays, that can be achieved directly within the cellular environment in a rapid, non-radioactive assay format. The methods of the invention are an advancement over the invention disclosed in U.S. Patent Nos. 5,891,646 and 6,110,693 and the method disclosed in Angers et al.,  
20 supra., which rely on microscopic imaging or spectrometry of GPCR components as fusion with Green-fluorescent-protein. The imaging technique disclosed in U.S. Patent Nos. 5,891,646 and 6,110,693 and spectrometry-based technique in Angers et al. are limited by low-throughput and lack of thorough quantification.

The assay system of the invention combined with Advanced Discovery Sciences™ technologies provide highly sensitive cell-based methods for interrogating GPCR pathways which are amenable to high-throughput screening (HTS). Among some of the technologies developed by Advanced Discovery

5 Sciences™ that may be used with the present invention are the Gal-Screen™ assay system (discussed above) and the cAMP-Screen™ immunoassay system. The cAMP-Screen™ immunoassay system provides ultrasensitive determination of cAMP levels in cell lysates. The cAMP-Screen™ assay utilizes the high-sensitivity chemiluminescent alkaline phosphatase (AP) substrate CSPD® (disodium 3-(4-  
10 methoxy Spiro {1,2-dioxetane-3,2'-(5'-chloro) tricyclo 3.3.1.1.<sup>3,7</sup>} decan-4-yl phenyl phosphate) with Sapphire-II™ luminescence enhancer.

Unlike yeast-based-two-hybrid assays used to monitor protein/protein interactions in high-throughput assays, the present invention (1) is applicable to a variety of cells including mammalian cells, plant cells, protozoa cells such as E.  
15 coli and cells of invertebrate origin such as yeast, slime mold (*Dictyostelium*) and insects; (2) detects interactions at the membrane at the site of the receptor target or in the cytosol at the site of downstream target proteins rather than a limited cellular localization, i.e., nucleus; and (3) does not rely on indirect read-outs such as transcriptional activation. The present invention thus provides assays with greater  
20 physiological relevance and fewer false positives.

The present inventors have developed modifications to the embodiment disclosed in U.S. patent application serial no. 053,614 described above in order to enhance the sensitivity of the inventive GPCR assay. According to an

embodiment, the invention incorporates the use of serine/threonine clusters to enhance and prolong the interaction of GPCR with arrestin in order to make the detection more robust. The clusters can be utilized for orphan receptors or known GPCRs, which do not have this sequence motif. By adding this sequence to the C-terminal tail of the receptor, the activation of the receptor can be detected more readily by readouts of arrestin binding to GPCR, i.e.,  $\beta$ -galactosidase complementation from fusion proteins of target proteins with  $\beta$ -galactosidase mutants.

According to another embodiment, the invention incorporates the use of arrestin point mutations to bypass the requirement of phosphorylation, by the action of specific GRK, on the C-terminal tail or intracellular loops of GPCR upon activation. The applications include i) wherein the cognate GRK for a particular GPCR or orphan receptor is unknown; and ii) wherein the specific GRK for the receptor of interest (or under test) may not be present or may have low activity in the host cell that is used for receptor activation assay.

According to another embodiment, the invention incorporates the use of a super arrestin to increase the binding efficiency of arrestin to an activated GPCR and to stabilize the GPCR/arrestin complex during GPCR desensitization. This application can be used to increase the robustness of ICAST/GPCR applications in cases where the GPCR is normally resensitized rapidly post desensitization.

Each of these methodologies is discussed below.

The invention will now be described in the following non-limiting examples.

EXAMPLE:

According to an embodiment of the invention, GPCR activation is measured through monitoring the binding of arrestin to ligand-activated GPCR. In this assay system, a GPCR, e.g.,  $\beta$ -adrenergic receptor ( $\beta$ 2AR), and an arrestin, e.g.,  $\beta$ -arrestin, are co-expressed in the same cell as fusion proteins with mutant forms of a reporter enzyme, e.g.,  $\beta$ -galactosidase ( $\beta$ -gal). As illustrated in Figure 23, the  $\beta$ 2AR is expressed as a fusion protein with  $\Delta\alpha$  form of  $\beta$ -gal mutant ( $\beta$ 2AR $\Delta\alpha$ ) and the  $\beta$ -arrestin as a fusion protein with the  $\Delta\omega$  form of  $\beta$ -gal mutant ( $\beta$ -Arr $\Delta\omega$ ). The two fusion proteins, which at first exist in a resting (or unstimulated) cell in separate compartments, i.e., the membrane for GPCR and the cytosol for arrestin, cannot form an active  $\beta$ -galactosidase enzyme. When such a cell is treated with an agonist or a ligand, the ligand-occupied and activated receptor becomes a high affinity binding site for arrestin. The interaction between an activated GPCR,  $\beta$ 2AR $\Delta\alpha$ , and arrestin,  $\beta$ -Arr $\Delta\omega$ , drives the  $\beta$ -gal mutant complementation. The enzyme activity can be measured by using an enzyme substrate, which upon cleavage releases a product measurable by colorimetry, fluorescence, or chemiluminescence (e.g., the Gal-Screen™ assay system).

Experiment protocol-

1. In the first step, the expression vectors for  $\beta$ 2AR $\Delta\alpha$  and  $\beta$ Arr2 $\Delta\omega$  were engineered in selectable retroviral vectors pICAST ALC, as described in Figure 18 and pICAST OMC, as described in Figure 15.

2. In the second step, the two expression constructs were transduced into either C2C12 myoblast cells, or other mammalian cell lines, such as COS-7, CHO, A431, HEK 293, and CHW. Following selection with antibiotic drugs, stable clones expressing both fusion proteins at appropriate levels were selected.

5           3. In the last step, the cells expressing both  $\beta 2AR\Delta\alpha$  and  $\beta Arr2\Delta\omega$  were tested for response by agonist/ligand stimulated  $\beta$ -galactosidase activity. Triplicate samples of cells were plated at 10,000 cells in 100 microliter volume into a well of 96-well culture plate. Cells were cultured for 24 hours before assay. For agonist assay (Figures 3 and 4), cells were treated with variable concentrations of agonist, 10   for example, (-) isoproterenol, procaterol, dobutamine, terbutaline or L-L-phenylephrine for 60 min at 37° C. The induced  $\beta$ -galactosidase activity was measured by addition of Tropix Gal-Screen™ assay system substrate (Applied Biosystems) and luminescence measured in a Tropix TR717™ luminometer (Applied Biosystems). For antagonist assay (Figure 5), cells were pre-incubated for 15   10 min in fresh medium without serum in the presence of ICI-118,551 or propranolol followed by addition of 10 micro molar (-) isoproterenol.

#### Serine/Threonine Cluster Strategy

##### Background

20           Based on structure-function relationship studies on  $\beta$ -arrestins, a large region within the amino-terminal half of  $\beta$ -arrestins (termed the activation-recognition domain) recognizes the agonist-activated state of GPCRs. This region of  $\beta$ -arrestin also contains a small positively charged domain (approximately 20

amino acids with net charge +7) called the phosphorylation-recognition domain, which appears to interact with the GRK-phosphorylated carboxyl termini of GPCRs.

GPCRs can be divided into two classes based on their affinities for  $\beta$ -arrestins. Oakley et al., "Association of  $\beta$ -Arrestin with G Protein-Coupled Receptors During Clathrin-Mediated Endocytosis Dictates the Profile of Receptor Resensitization." J. Biol. Chem., 274(45):32248-32257 (1999). The molecular determinants underlying this classification appear to reside in specific serine or threonine residues located in the carboxyl-terminal tail of the receptor. The receptor class that contains serine/threonine clusters (defined as serine or threonine residues occupying three consecutive or three out of four positions) in the carboxyl-termini binds  $\beta$ -arrestin with high affinity upon activation and phosphorylation and remains bound with  $\beta$ -arrestin even after receptor internalization, whereas the receptor class that contains only scattered serine and threonine residues in the carboxy-terminal tail binds  $\beta$ -arrestins with less affinity and disassociates from the  $\beta$ -arrestin upon internalization. Several known GPCRs, such as vasopressin V2 receptor (Oakley, et al.), neurotensin receptor 1 and angiotensin II receptor type 1A (Zhang, et al., "Cellular Trafficking of G Protein-Coupled Receptor/ $\beta$ -Arrestin Endocytic Complexes." J. Biol. Chem., 274(16):10999-11006 (1999)), which possess one or more of such serine/threonine clusters in their carboxyl-termini, were shown to bind  $\beta$ -arrestins with high affinity.

### EXAMPLE

According to an embodiment of the invention, a serine/threonine cluster strategy is used to facilitate screening assays for orphan receptors that do not possess this structural motif of their own. The orphan receptors are easily classified by sequence alignment. Orphan receptors lacking the serine/threonine clusters are each cloned into an expression vector that is modified to introduce one or more serine/threonine cluster(s) to the carboxyl-terminal tail of the receptor (FIGURE 24). The serine/threonine clusters enhance the receptor activation dependent interaction between the activated and phosphorylated receptor (negative charges) and  $\beta$ -arrestin (positive charges in the phosphorylation-recognition domain) through strong ionic interactions, thus prolonging interaction between the receptor and arrestin. The modification of the orphan receptor tail thus makes detection of receptor activation more robust.

#### 15 Experiment protocol -

1. In a first step, the open-reading-frame (ORF) of an orphan receptor, which lacks the serine/threonine clusters, is cloned into a modified expression vector such as pICAST ALC described in Figure 10A. The modified pICAST ALC includes coding sequences for one or more sets of serine/threonine clusters (for example, SSS or SST) located downstream from the insert of the ORF of an orphan receptor (FIGURE 24).

2. In a second step, chimeric orphan receptor,  $\text{ORF}_{\text{orphan R}}-(\text{SSS})_n-\Delta\alpha$ , is co-

expressed in a mammalian cell with a  $\beta$ -arrestin chimera, such as  $\beta$ Arr2 $\Delta\omega$  described in Figure 15.

3. In a third step, the cell is treated with an agonist or a ligand and the activated receptor with phosphorylated serine cluster(s) binds the  $\beta$ -arrestin with high affinity producing strong signals in readouts of  $\beta$ -gal complementation.

This assay, which provides a means for sensitive measurement of functional activation of the orphan receptors, can be used to screen for natural or surrogate ligands for orphan receptors, a process called de-orphaning or target discovery for new GPCRs (FIGURE 28). Furthermore, this assay is also useful in screening for potential agonists and antagonists for lead discovery of GPCRs.

#### Enhanced Binding of Arrestin in the Presence and in the Absence of GPCR

##### Phosphorylation

##### Background

- Six different classes of G-protein coupled receptor kinases (GRKs) have been identified and each of these has been reported to be expressed as multiple splice variants. Krupnick et al., "The role of receptor kinases and arrestins in G protein-coupled receptor regulation." Ann. Rev. Pharmacol. Toxicol., 38:289-319 (1998). Although many cell lines express a variety of GRKs, the specific GRK required for phosphorylation of a given GPCR may not always be present in the cell line used for recombinant GPCR and arrestin expression. This is particularly an issue for applications using orphan receptors, in which case the cognate GRK will likely be unknown. In other cases, the cell line used for recombinant



expression work may have the required GRK, but may express the GRK at low levels. In order to bypass such caveats, genetically modified arrestins that bind specifically to activated GPCRs, but without the requirement of GRK phosphorylation are employed.

5           Mutagenesis studies on arrestins demonstrate that point mutations in the phosphorylation-recognition domain, particularly mutations converting Arg175 (of visual arrestin) to an oppositely charged residue such as glutamate (R175E mutation), result in an arrestin which specifically binds to activated GPCRs, but does so without the requirement for phosphorylation.

10           Numerous observations have led to the hypothesis that arrestin exists in an inactive state that has a low affinity for GPCRs. Once a GPCR is both activated and phosphorylated, the phosphorylated region of the GPCR C-terminus interacts with the phosphorylation-recognition domain of arrestin causing the arrestin to change conformations allowing the activation-recognition region to be exposed for  
15           binding to the activated/ phosphorylated receptor. Vishnivetskiy et al., "How does arrestin respond to the phosphorylated state of rhodopsin?" J. Biol. Chem., 274(17):11451-11454 (1999); Gurevich et al., "Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild-type and mutant arrestins with rhodopsin, beta 2-adrenergic and m2 muscarinic cholinergic receptors." J.  
20           Biol. Chem., 270(2):720-731, (1995); Gurevich et al., "Mechanism of phosphorylation-recognition by visual arrestin and the transition of arrestin into a high affinity binding site." Mol. Pharmacol., 51(1):161-169 (1997); Kovoor et al., "Targeted construction of phosphorylation-independent beta-arrestin mutants with

constitutive activity in cells." J. Biol. Chem., 274(11):6831-6834 (1999). In summary, binding studies of single mutation, double mutation, deletion, and chimerical arrestins with inactive, inactive and phosphorylated, activated but not phosphorylated, or activated and phosphorylated visual or non-visual GPCRs all support this model.

### EXAMPLE

A phosphorylation insensitive mutant of arrestin fused to mutant reporter protein can be produced that will bind to activated GPCRs in a phosphorylation independent manner. As proof of concept, a point mutation for  $\beta$ -arrestin2, R170E  $\beta$ -arrestin2, has been produced and its interaction with  $\beta$ 2AR has been analyzed in accordance with the invention.

### Experimental protocol:

- 1) In the first step,  $\beta$ -arrestin2 was mutated such that Arg170 was converted to Glu. This mutation is equivalent to the R175E mutation of visual arrestin. The mutant  $\beta$ -arrestin2 open reading frame was cloned in frame with  $\Delta\omega$ - $\beta$ -galactosidase in the pICAST OMC expression vector to produce a modified expression vector R170E  $\beta$ -arrestin2 (FIGURE 25).
- 2) In the second step, the R170E  $\beta$ -arrestin2 expression construct was transduced into a C2C12 myoblast cell line that had been engineered to express  $\beta$ 2AR as a fusion to  $\Delta\alpha$ - $\beta$ -galactosidase as described in Figure 18 of U.S. Application Serial No. 09/654,499. Following selection with antibiotic drugs, a

population of clones expressing both fusion proteins was obtained.

- 3) In the last step, this population of cells expressing both R170E  $\beta$ -arrestin2 $\Delta\omega$  and  $\beta$ 2AR $\Delta\alpha$  were tested for response by agonist/ligand stimulated  $\beta$ -galactosidase activity as demonstrated in FIGURE 26. The C2C12 clone 43-8 co-expressing  $\beta$ 2AR $\Delta\alpha$  and wild-type  $\beta$ -arrestin2 $\Delta\omega$  (FIGURE 26) was used as reference control. Triplicate samples of cells were plated at 10,000 cells in 100 microliter volume into wells of a 96-well culture plate. Cells were cultured for 24 hours before assay. For agonist assay as in FIGURE 26, cells were treated with 10 $\mu$ m (-)-isoproterenol stabilized with 0.3mM ascorbic acid 37° C for 0, 5, 10, 15, 30, 45 or 60 minutes. The induced  $\beta$ -galactosidase activity was measured by addition of Tropix Gal-Screen™ assay system substrate (Applied Biosystems) and luminescence measured in a Tropix TR717™ luminometer (Applied Biosystems). As shown in Figure 26, the mutant arrestin interacts with  $\beta$ 2AR in an agonist-dependent manner and was comparable with that of wild-type arrestin.
- 4) To expand the application of phosphorylation-insensitive arrestin, cell lines such as C2C12, CHO or HEK 293, are developed that express the R170E  $\beta$ -arrestin2 $\Delta\omega$  construction. These cell lines can be used to transduce orphan or known GPCRs as fusions with  $\Delta\alpha$ - $\beta$ -galactosidase in order to develop cell lines for agonist and antagonist screening and

## Development of Super Arrestins:

### Background

Attenuation of GPCR signaling by the arrestin pathway serves to ensure that a cell or organism does not over-react to a stimulus. At the same time, the arrestin pathway often serves to recycle the GPCR such that it can be temporarily inactivated but then quickly resensitized to allow for sensitivity to new stimuli. The down-regulation process involves phosphorylation of the receptor, binding to arrestin and endocytosis. Following endocytosis of the desensitized receptor, the receptor is either degraded in lysosomes or resensitized and sent back to the membrane. Resensitization involves release of arrestin from the receptor, dephosphorylation and cycling back to the membrane. The actual route a GPCR follows upon activation depends on its biological function and the needs of the organism. Because of these diverse pathways that may be required of the down-regulation pathway, arrestin affinities for activated GPCRs vary from receptor to receptor. It would thus be very advantageous to engineer super arrestins that have a higher affinity and avidity for activated GPCRs than what nature has provided.

Although mutational, deletion and chimerical studies of arrestins have focused on understanding regulatory switches in the molecule that respond to GPCR phosphorylation states, several of these altered recombinant forms of arrestin have resulted in molecules with enhanced binding to activated, phosphorylated GPCRs. Conversion of Arg175 to histidine, tyrosine, phenylalanine or threonine results in significantly higher amounts of binding to phosphorylated, activated rhodopsin than wild-type arrestin or R175E arrestin,

although these mutations result in less binding to activated, non-phosphorylated receptor. Gurevich et al. (1997). In addition, conversion of Valine 170 to alanine increased the constitutive affect of the R175E mutation, but also nearly doubled the amount of interaction of wild-type arrestin with activated, phosphorylated rhodopsin. Gurevich et al. (1997).

Truncation of  $\beta$ -arrestin1 at amino acid 382 has been reported to enhance binding of both R169E (equivalent to arrestin R175E) and wild-type  $\beta$ -arrestin1 to activated or activated and phosphorylated receptor, respectively. Kovoor et al. Chimerical arrestins in which functional regions of visual arrestin were swapped with those of  $\beta$ -arrestin1 have been reported to be altered in binding affinity to activated, phosphorylated GPCRs. Gurevich et al. (1995). Several of these chimeras, such as  $\beta$ -arrestin1 containing the visual arrestin extreme N-terminus, show increased specific binding to phosphorylated activated GPCRs compared to wild-type  $\beta$ -arrestin1 (Gurevich et al. (1995)). Modifications that enhance arrestin affinity for the activated GPCR such as described above, whether phosphorylated or non-phosphorylated, could also enhance signal to noise of  $\beta$ -galactosidase activity since the arrestin/GPCR complex is stabilized and/or more long-lived. The use of mutant arrestins with higher activated-GPCR affinity would improve the inventive technology for GPCR targets, without compromising receptor/ligand biology.

In addition, this "super arrestin" approach can be combined with the use of arrestin point mutations to provide a stronger signal to noise with or without GRK requirements.

### EXAMPLE

An arrestin mutant fused to mutant reporter protein can be produced to enhance binding of the arrestin to an activated GPCR to enhance sensitivity of detection.

5 Experiment protocol -

- 1) In the first step, mutant  $\beta$ -arrestin2 constructions will be generated which include R170E/T/Y/or H, V165A, substitution of a.a. 1-43 with a.a. 1-47 of visual arrestin, or deletion of the C-terminal and combinations of these alterations. The mutant  $\beta$ -arrestin2 open reading frames will be cloned in frame with  $\Delta\omega$ - $\beta$ -galactosidase in the pICAST OMC expression vector similar to cloning of the R170E  $\beta$ -arrestin2 mutation shown in FIGURE 25.
- 10 2) In the second step, mutant expression constructs will be transduced into a C2C12 myoblast cell line that has been engineered to express  $\beta$ 2AR as a fusion to  $\Delta\alpha$ - $\beta$ -galactosidase. Following selection with antibiotic drugs, a population of clones expressing both fusion proteins will be obtained. Wild type and R170E  $\beta$ -arrestin2 constructions will be transduced to generate control, reference clonal populations.
- 15 3) In the third step, populations of cells expressing both  $\beta$ -arrestin2 $\Delta\omega$  (mutant or wild type) and  $\beta$ 2AR $\Delta\alpha$  will be tested for response by agonist/ligand stimulated  $\beta$ -galactosidase activity.
- 20 4) In the next step, mutant (super)  $\beta$ -arrestin2 $\Delta\omega$  constructions that show a significantly higher signal to noise ratio in the agonist assay compared with wild-type  $\beta$ -arrestin2 $\Delta\omega$  will be chosen. These constructions will be used to develop

stable cell lines expressing the "super"  $\beta$ -arrestin2 $\Delta\omega$  that can be used for transducing in known or orphan GPCRs. Use of a super  $\beta$ -arrestin2 $\Delta\omega$  could increase the signal to noise of ICAST/GPCR applications allowing improved screening capabilities for lead and ligand discovery.

5            Super Arrestin is used to increase the binding efficiency of arrestin to an activated GPCR and to stabilize the GPCR/arrestin complex during GPCR desensitization. This application can be used to increase the robustness of ICAST/GPCR applications in cases where the GPCR is normally resensitized rapidly post desensitization.

10           The assays of this invention, and their application and preparation have been described both generically, and by specific example. The examples are not intended as limiting. Other substituent identities, characteristics and assays will occur to those of ordinary skill in the art, without the exercise of inventive faculty. Such modifications remain within the scope of the invention, unless excluded by  
15           the express recitation of the claims advanced below.

**WHAT IS CLAIMED IS:**

1. A method of assessing the effect of a test condition on G-protein-coupled receptor (GPCR) pathway activity, comprising:

5 a) providing a cell that expresses a GPCR as a fusion protein to one mutant form of reporter enzyme and an interacting protein partner as a fusion to another mutant form of enzyme,

wherein said cell also expresses an arrestin, wherein said arrestin is modified to enhance binding of said arrestin to said GPCR, wherein said enhanced binding between said arrestin and said GPCR increases sensitivity of detection of  
10 said effect of said test condition;

b) exposing the cell to a ligand for said GPCR under said test condition; and

c) monitoring activation of said GPCR by complementation of said reporter enzyme;

wherein increased reporter enzyme activity in the cell compared to that  
15 which occurs in the absence of said test condition indicates increased GPCR interaction with its interacting protein partner compared to that which occurs in the absence of said test condition, and decreased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates decreased GPCR interaction with its interacting protein partner compared to that  
20 which occurs in the absence of said test condition.

2. A method of assessing the effect of a test condition on G-protein-coupled receptor (GPCR) pathway activity, comprising:

a) providing a cell that expresses a GPCR as a fusion protein to one mutant



form of reporter enzyme and an interacting protein partner as a fusion to another mutant form of enzyme;

wherein said GPCR fusion protein is modified to include one or more sets of serine/threonine clusters, wherein said one or more sets of serine/threonine clusters enhance binding of said GPCR to arrestin, wherein said enhanced binding between said GPCR and said arrestin increases sensitivity of detection of said effect of said test condition;

b) exposing the cell to a ligand for said GPCR under said test condition; and

c) monitoring activation of said GPCR by complementation of said reporter enzyme;

wherein increased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates increased GPCR interaction with said interacting protein partner compared to that which occurs in the absence of said test condition, and decreased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates decreased GPCR interaction with interacting protein partner compared to that which occurs in the absence of said test condition.

3. A DNA molecule comprising a sequence encoding a biologically active hybrid GPCR, wherein said hybrid GPCR comprises a GPCR as a fusion protein to one mutant form of reporter enzyme and wherein said hybrid GPCR is modified to include one or more sets of serine/threonine clusters, wherein said one or more sets of serine/threonine clusters enhance binding of said hybrid GPCR to arrestin.

4. A DNA construct capable of directing the expression of a biologically

active hybrid GPCR in a cell, comprising the following operatively linked elements:

a promoter; and

a DNA molecule comprising a sequence encoding a biologically active hybrid GPCR, wherein said hybrid GPCR comprises a GPCR as a fusion protein to one mutant form of reporter enzyme and wherein said hybrid GPCR is modified to include one or more sets of serine/threonine clusters, wherein said one or more sets of serine/threonine clusters enhance binding of said hybrid GPCR to arrestin.

5. A cell transformed with a DNA construct capable of expressing a biologically active hybrid GPCR in a cell, comprising the following operatively linked elements:

a promoter; and

a DNA molecule comprising a sequence encoding a biologically active hybrid GPCR, wherein said hybrid GPCR comprises a GPCR as a fusion protein to one mutant form of reporter enzyme and wherein said hybrid GPCR is modified to include one or more sets of serine/threonine clusters, wherein said one or more sets of serine/threonine clusters enhance binding of said hybrid GPCR to arrestin.

6. A DNA molecule comprising a sequence encoding a biologically active hybrid arrestin, wherein said hybrid arrestin comprises an arrestin as a fusion to one mutant form of reporter enzyme and wherein said hybrid arrestin is modified to enhance binding of said arrestin to GPCR.

7. A DNA construct capable of directing the expression of a biologically active hybrid arrestin in a cell, comprising the following operatively linked

elements:

a promoter; and

a DNA molecule comprising a sequence encoding a biologically active hybrid arrestin, wherein said hybrid arrestin comprises an arrestin as a fusion to one mutant form of reporter enzyme and wherein said hybrid arrestin is modified to enhance binding of said arrestin to GPCR.

8. A cell transformed with a DNA construct capable of expressing a biologically active hybrid arrestin in a cell, comprising the following operatively linked elements:

a promoter; and

a DNA molecule comprising a sequence encoding a biologically active hybrid arrestin, wherein said hybrid arrestin comprises an arrestin as a fusion to one mutant form of reporter enzyme and wherein said hybrid arrestin is modified to enhance binding of said arrestin to GPCR.

9. A method of assessing the effect of a test condition on G-protein-coupled receptor (GPCR) pathway activity, comprising:

a) providing a cell that expresses a GPCR as a fusion protein to one mutant form of reporter enzyme and an interacting protein partner as a fusion to another mutant form of enzyme,

wherein said cell also expresses an arrestin, wherein said arrestin is modified by introducing a point mutation in a phosphorylation-recognition domain to remove a requirement for phosphorylation of said GPCR for arrestin binding to permit binding of said arrestin to said GPCR in said cell regardless of whether said

GPCR is phosphorylated,

b) exposing the cell to a ligand for said GPCR under said test condition; and

c) monitoring activation of said GPCR by complementation of said reporter enzyme;

5            wherein increased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates increased GPCR interaction with its interacting protein partner compared to that which occurs in the absence of said test condition, and decreased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates  
10           decreased GPCR interaction with its interacting protein partner compared to that which occurs in the absence of said test condition.

10. The method of Claim 9, wherein said arrestin is mutated to increase a property selected from affinity and avidity for activated, non-phosphorylated GPCR.

15           11. The method of Claim 10, wherein said arrestin is  $\beta$ -arrestin2 and wherein said  $\beta$ -arrestin2 is mutated to convert Arg169 to an oppositely charged residue.

12. The method of Claim 11, wherein said oppositely charged residue is selected from the group consisting of histidine, tyrosine, phenylalanine and  
20           threonine.

13. The method of Claim 9, wherein said arrestin is mutated to increase a property selected from affinity and avidity for activated and phosphorylated GPCR.

14. A method of assessing the effect of a test condition on G-protein-

coupled receptor (GPCR) pathway activity, comprising:

a) providing a cell that expresses a GPCR as a fusion protein to one mutant form of reporter enzyme and an interacting protein partner as a fusion to another mutant form of enzyme;

5            wherein said GPCR fusion protein is modified to include one or more sets of serine/threonine clusters, said one or more serine/threonine clusters defined as serine or threonine residues occupying three consecutive or three out of four positions in a carboxyl-termini of said GPCR, wherein said one or more sets of serine/threonine clusters enhance binding of said GPCR to arrestin, wherein said  
10        enhanced binding between said GPCR and said arrestin increases sensitivity of detection of said effect of said test condition;

b) exposing the cell to a ligand for said GPCR under said test condition; and

c) monitoring activation of said GPCR by complementation of said reporter enzyme;

15            wherein increased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates increased GPCR interaction with said interacting protein partner compared to that which occurs in the absence of said test condition, and decreased reporter enzyme activity in the cell compared to that which occurs in the absence of said test condition indicates  
20        decreased GPCR interaction with interacting protein partner compared to that which occurs in the absence of said test condition.

15. The method of Claim 1, wherein said modified arrestin exhibits enhanced binding to activated, phosphorylated GPCR.

25. The method of Claim 14, wherein said modified arrestin comprises conversion of Arg170 to an amino acid selected from the group consisting of histidine, tyrosine, phenylalanine and threonine.

Cellular Expression of  $\beta_2$ AR- $\beta$ gal $\Delta\alpha$  Fusion Protein in C2 Clones  
(measured by anti- $\beta$ -gal ELISA)




FIGURE 1A

Cellular expression of  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  fusion protein in C2 clones  
(measured by anti- $\beta$  gal ELISA)




FIGURE 1B




Agonist Stimulated cAMP Response in C2 Cells Expressing  $\beta 2AR$ - $\beta gal\Delta\alpha$ 

FIGURE 2

$\beta$ -galactosidase Complementation as a Measurement for  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  interacting with  $\beta$ Arrestin2- $\beta$ gal $\Delta\omega$  upon agonist Stimulation




FIGURE 3A

$\beta$ -galactosidase Complementation as a Measurement for  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  Interaction with  $\beta$ Arrestin1- $\beta$ gal $\Delta\omega$  upon Agonist Stimulation




FIGURE 3B

$\beta$ -galactosidase Activity in Response to Agonist in C2 Cells  
Coexpressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin2- $\beta$ gal $\Delta\omega$  Fusion Proteins




FIGURE 4A

$\beta$ -galactosidase Activity in Response to Agonist in C2 Cells  
Coexpressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin1- $\beta$ gal $\Delta\omega$  Fusion Proteins




FIGURE 4B

Inhibition of  $\beta$ -galactosidase activity in C2 Cells Coexpressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin2- $\beta$ gal $\Delta\omega$  Fusion Proteins




FIGURE 5A

Antagonist Inhibition of  $\beta$ -galactosidase Activity in C2 Cells  
Coexpressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin1- $\beta$ gal $\Delta\omega$  Fusion Proteins




Figure 5B

Agonist Stimulated cAMP Response in Clones or Pools of C2 Cells  
Coexpressing A2aR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin1- $\beta$ gal $\Delta\omega$  Fusion Proteins




FIGURE 6



Agonist Stimulated cAMP Response in Clones or Pools of C2 Cells  
Expressing D1- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arrestin2- $\beta$ gal $\Delta\omega$  Fusion Proteins




FIGURE 7

$\beta_2$ AR- $\beta$ gal $\Delta\omega$  and  $\beta$ arr2- $\beta$ gal $\Delta\alpha$  Interaction in HEK293  
Clones in Response to Isoproterenol Treatment (1  $\mu$ M)




FIGURE 8A

$\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr1- $\beta$ gal $\Delta\omega$  Interaction in a CHO Pool  
in Response to Isoproterenol Treatment(10uM)




FIGURE 8B

$\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ Arr2- $\beta$ gal $\Delta\omega$  Interaction in CHW Clone  
in Response to Isoproterenol Treatment (10 $\mu$ M)




FIGURE 8C

$\beta$ -galactosidase Complementation as a Measurement for  
Adrenergic Receptor Homodimerization in HEK 293 Cells  
Coexpressing  $\beta$ 2AR- $\beta$ gal $\Delta\alpha$  and  $\beta$ 2AR- $\beta$ gal $\Delta\omega$ .




FIGURE 9A

Agonist Stimulated cAMP Response in HEK 293 Cells  
Coexpressing  $\beta 2AR$ - $\beta gal\Delta\alpha$  and  $\beta 2AR$ - $\beta gal\Delta\omega$




FIGURE 9B




Figure 10A

```

1  CTGCAGCCTG AATATGGGCC AAACAGGATA TCTGTGGTAA GCAGTTCCTG
   GACGTCCGGAC TTATACCCGG TTGTCTCTAT AGACACCATT CGTCAAGGAC
-----
51  CCCC GGCTCA GGGCCAAGAA CAGATGGAAC AGCTGAATAT GGGCCAAACA
   GGGGCCGAGT CCCGGTCTT GTCTACCTTG TCGACTTATA CCGGTTTGT
-----
101 GGATATCTGT GGTAAAGCAGT TCCTGCCCCG GCTCAGGGCC AAGAACAGAT
   CCTATAGACA CCATTCTGTC AGGACGGGGC CGAGTCCCGG TTCTTGCTTA
-----
151 GGTCCCCAGA TGCGGTCCAG CCCTCAGCAG TTTCTAGAGA ACCATCAGAT
   CCAGGGGTCT ACGCCAGGTC GGGAGTCGTC AAAGATCTCT TGCTAGTCTA
-----
201 GTTCCAGGG TGCCCCAAGG ACCTGAAATG ACCCTGTGCC TTATTTGAAC
   CAAAGGTCCC ACGGGGTTC TGGACTTTAC TGGGACACGG AATAAACTTG
-----
251 TAACCAATCA GTTCGCTTCT CGCTTCTGTT CGCGCGCTTC TGCTCCCGA
   ATTGGTTAGT CAAGCGAAGA GCGAAGACAA GCGCGCGAAG ACGAGGGGCT
-----
301 GCTCAATAAA AGAGCCACA ACCCTCACT CGGGGCGCCA GTCCCTCCGAT
   CGAGTTATTT TCTCGGGTGT TGGGGAGTGA GCCCCGCGGT CAGGAGGCTA
-----
351 TGACTGAGTC GCCCGGGTAC CCGTGTATCC AATAAACCCCT CTGTCAGTTG
   ACTGACTCAG CGGGCCCATG GGCACATAGG TTATTTGGGA GAACGTCAAC
-----
401 CATCCGACTT GTGGTCTCGC TGTTCTTGG GAGGGTCTCC TCTGAGTGAT
   GTAGGCTGAA CACCAGAGCG ACAAGGAACC CTCCCAGAGG AGACTCTACTA
-----
451 TGACTACCCG TCAGCGGGGG TCTTTCATTT GGGGGCTCGT CCGGGATCGG
   ACTGATGGGC AGTCGCCCCC AGAAAGTAAA CCCCCGAGCA GGCCCTAGCC
-----
501 GAGACCCCTG CCCAGGGACC ACCGACCCAC CACCGGGAGG CAAGCTGGCC
   CTCGGGGGAC GGGTCCCTGG TGGCTGGGTG GTGGCCCTCC GTTCGACCGG
-----
551 AGCAACTTAT CTGTGTCTGT CCGATTGTCT AGTGTCTATG ACTGATTTA
   TCGTTGAATA GACACAGACA GGCTAACAGA TCACAGATAC TGACTAAAT
-----
601 TGCGCCTGCG TCGGTACTAG TTAGCTRACT AGCTCTGTAT CTGGCGGACC
   ACGCGGACGC AGCCATGATC AATCGATTGA TCGAGACATA GACCGCCTGG
-----
651 CGTGGTGGAA CTGACGAGTT CTGAACACCC GGCCGCAACC CTGGGAGACG
   GCACCACCTT GACTGTCTAA GACTTGTGGG CCGGCGTGG GACCTCTGC
-----
701 TCCCAGGGAC TTTGGGGGCC GTTTTGTGG CCCGACCTGA GGAAGGGAGT
   AGGGTCCCTG AAACCCCGG CAAAAACACC GGGCTGGACT CCTTCCCTCA
-----
751 CGATGTGGAA TCCGACCCG TCAGGATATG TGGTCTGGT AGGAGACGAG
   GCTACACCTT AGGCTGGGGC AGTCCTATAC ACCAAGACCA TCCTCTGCTC
-----
801 AACCTAAAC AGTTCCCGCC TCCGTCTGAA TTTTGTCTT CGGTTTGGAA
   TTGGATTTTG TCAAGGGCGG AGGCAGACTT AAAAACGAAA GCCAAACCTT
-----
851 CCGAAGCCGC GCGTCTTGTG TGCTGCAGCA TCGTTCTGTG TTGTCTCTGT
   GGCTTCGGCG CGCAGAACAG ACGACGTCGT AGCAAGACAC AACAGAGACA
-----
901 CTGACTGTGT TTCTGTATTT GTCTGAAAAT TAGGGCCAGA CTGTTACCAC
   GACTGACACA AAGACATAAA CAGACTTTTA ATCCCGGTCT GACAAATGGT
-----

```

FIGURE 10B



951 TCGCTTAAAGT TTGACCTTAA GTAACTGGAA AGATGTGGAG GCGCTCGCTC  
AGGGAATTCA AACTGGAATC CATTGACCTT TCTACAGCTC GCCGAGCGAG

1001 ACAACCAGTC GGTGATGTC AAGAAGAGAC GTTGGGTAC CTCTGCTCT  
TGTGTGTCAG CCATCTACAG TTCTTCTCTG CAACCCAATG GAAGACGAGA

1051 GCAGAATGGC CAACCTTTAA CGTCGGATGG CCGCGAGACG GCACCTTTAA  
CGTCTTACCG GTTGGAATG GCAGCCTACC GCGCTCTGC CGTGGAATG

1101 CCGAGACCTC ATCACCAGG TTAAGATCAA GGTCTTTTCA CCTGGCCCGC  
GGCTCTGGAG TAGTGGGTCC AATTCTAGTT CCAGAAAAGT GGACCGGGCG

1151 ATGGACACCC AGACCAGGTC CCCTACATCG TGACCTGGGA AGCCTTGGCT  
TACCTGTGGG TCTGTCCAG GGGATGTAGC ACTGGACCCT TCGGAACCGA

1201 TTTGACCCCC CTCCCTGGGT CAAGCCCTTT GTACACCCTA AGCCTCCGCC  
AAACTGGGGG GAGGGACCCA GTTCGGGAAA CATGTGGGAT TCGGAGGCGG

1251 TCCTCTTCTT CCATCCGCCC CGTCTCTCCC CTTTGAACCT CCTCGTTTCA  
AGGAGRAGGA GGTAGGCGGG GCAGAGAGGG GGAACCTGGA GGAGCAAGCT

1301 CCGCGCCTCG ATCCTCCCTT TATCCAGCCC TCACTCCTTC TCTAGGCGCC  
GGGCGGAGC TAGGAGGGAA ATAGGTCCGG AGTGAGGAG AGATCCGCGG

1351 GGCGCTCTA GCCCATTAAT ACGACTCACT ATAGGGCGAT TCGAATCAGG  
CCGCGAGAT CGGTAATTA TGCTGAGTGA TATCCCGCTA AGCTTAGTCC

1401 CCTTGGCGCG CCGGATCCTT AATTAGCGC AATTGGGAGG TGGCGGTAGC  
GGAACCGCGC GGCCTAGGAA TTAATTCGCG TTAACCTCC ACCGCCATCG

+2 M G V I T D S L A V V A R T D

1451 CTCGAGATGG GCGTGATTAC GGATCACTG GCCGTCGTGG CCCGCACCGA  
GAGCTCTACC CGCACTAATG CCTAAGTGAC CGGCAGCACC GGGCGTGGCT

+2 R P S Q Q L R S L N G E W R F A

1501 TCGCCCTTCC CAACAGTTAC GCAGCCTGAA TGGCGAATGG CGCTTGCCT  
AGCGGGAAGG GTTGTCAATG CGTCGGACTT ACCGCTTACC GCGAAACGGA

+2 W F P A P E A V P E S W L E C D L

1551 GGTTCCTGGC ACCAGAAGCG GTGCCGAAA GCTGGCTGGA GTGCGATCTT  
CCAAAGGCGG TGGTCTTGC CACGGCCTTT CGACCGACCT CACGCTAGAA

+2 P E A D T V V V P S N W Q M H G Y

1601 CCTGAGGCGC ATACTGTCTG CTCCCCTCA AACTGGCAGA TGCACGGTTA  
GGACTCCGCG TATGACAGCA GCAGGGGAGT TTGACCGTCT ACGTGCCAT

+2 D A P I Y T N V T Y P I T V N P

1651 CGATGCGCCC ATCTACACCA ACGTGACCTA TCCCATIACG GTCAATCCGC  
GCTACGCGGG TAGATGTGGT TGCACTGGAT AGGTAATGC CAGTTAGGCG

```

+2 P F V P T E N P T G C Y S L T F N
-----
1701 CGTTTGTTC CACGGAGAAT CCGACGGGTT GTTACTCGCT CACATTTAAT
    GCAACAAGG GTGCCTCTTA GGCTGCCCAA CAATGAGCGA GTGTAAATTA
-----
+2 V D E S W L Q E G Q T R I I F D G
-----
1751 GTTGATGAAA GCTGGCTACA GGAAGGCCAG ACGCGAATTA TTTTGATGG
    CAACTACTTT CGACCGATGT CCTTCCGGTC TGGCTTAAT AAAAATACC
-----
+2 V N S A F H L W C N G R W V G Y
-----
1801 CGTTAACTCG GCGTTTCATC TGTGGTGCAA CGGCGCTGG GTCGGTTACG
    GCAATTGAGC CGCAAAGTAG ACACCAGTT GCCCGCGACC CAGCCAATGC
-----
+2 G Q D S R L P S E F D L S A F L R
-----
1851 GCCAGGACAG TCGTTTGCCG TCTGAATTG ACCTGAGCGC ATTTTACGC
    CGGTCTGTG AGCAAACGGC AGACTTAAAC TGGACTCGCG TAAAAATGCG
-----
+2 A G E N R L A V M V L R W S D G S
-----
1901 GCCGGAGAAA ACCGCCTCGC GGTGATGGTG CTGCGCTGGA GTGACGGCAG
    CGGCCTCTTT TGGCGGAGCG CCACTACCAC GACGCGACCT CACTGCCGTC
-----
+2 Y L E D Q D M W R M S G I F R D
-----
1951 TTATCTGGAA GATCAGGATA TGTGGCGGAT GAGCGGCATT TTCCGTGACG
    AATAGACCTT CTAGTCCTAT ACACCGCCTA CTCGCCGTAA AAGGCACTGC
-----
+2 V S L L H K P T T Q I S D F H V A
-----
2001 TCTCGTTGCT GCATAAACCG ACTACACAAA TCAGCGATTT CCATGTTGCC
    AGAGCAACGA CGTATTGGC TGATGTGTTT AGTCGCTAAA GGTACAACGG
-----
+2 T R F N D D F S R A V L E A E V Q
-----
2051 ACTCGCTTTA ATGATGATTT CAGCCGCGCT GTACTGGAGG CTGAAGTTCA
    TGAGCGAAAT TACTACTAAA GTCGGCGCGA CATGACCTCC GACTTCAAGT
-----
+2 M C G E L R D Y L R V T V S L W
-----
2101 GATGTGCGGC GAGTTGCGTG ACTACCTACG GGTAACAGTT TCTTTATGGC
    CTACACGCCG CTCACGCGAC TGATGGATGC CCATTGTCAA AGAAATACCG
-----
+2 Q G E T Q V A S G T A P F G G E I
-----
2151 AGGGTGAAAC GCAGGTGCGC AGCGGCACCG CGCCTTTCGG CGGTGAAATT
    TCCCACCTTG CGTCCAGCGG TCGCCGTGGC GCGGAAGCC GCCACTTTAA
-----
+2 I D E R G G Y A D R V T L R L N V
-----
2201 ATCGATGAGC GTGGTGTTA TGCCGATCGC GTCACACTAC GTCTGAACGT
    TAGCTACTCG CACCACCAAT ACGGCTAGCG CAGTGTGATG CAGACTTGCA
-----
+2 E N P K L W S A E I P N L Y R A
-----
2251 CGAAAACCCG AACTGTGGA GCGCCGAAAT CCCGAATCTC TATCGTGCGG
    GCTTTTGGGC TTTGACACCT CGCGGCTTTA GGGCTTAGAG ATAGCACGCC

```

+2 V V E L H T A D G T L I E A E A C  
-----  
2301 TGGTTGAACT GCACACCGCC GACGGCAGCG TGATTGAAGC AGAAGCCTGC  
ACCAACTTGA CGTGTGGCGG CTGCCGTGCG ACTAACTTCG TCTTCGGACG  
-----  
+2 E V G F R E V R I E N G L L L L N  
-----  
2351 GATGTCGGTT TCCGCGAGGT GCGGATTGAA AATGGTCTGC TGCTGCTGAA  
CTACAGCCAA AGGCGCTCCA CGCCTAACTT TTACCAGACG ACGACGACTT  
-----  
+2 G K P L L I R G V N R H E H H P  
-----  
2401 CGGCAAGCCG TTGCTGATTC GAGGCGTTAA CCGTCACGAG CATCATCCTC  
GCCGTTCGGC AACGACTAAG CTCCGCAATT GGCAGTGCTC GTAGTAGGAG  
-----  
+2 L H G Q V M D E Q T M V Q D I L L  
-----  
2451 TGCAATGGTCA GGTCAATGGAT GAGCAGACGA TGGTGCAGGA TATCCTGCTG  
ACGTACCACT CCAGTACCTA CTCGTCTGCT ACCACGTCCT ATAGGACGAC  
-----  
+2 M K Q N N F N A V R C S H Y P N H  
-----  
2501 ATGAAGCAGA ACAACTTTAA CGCCGTGCGC TGTTTCGCATT ATCCGAACCA  
TACTTCGTCT TGTGAAATTT GCGGCACGCG ACAAGCGTAA TAGGCTTGGT  
-----  
+2 P L W Y T L C D R Y G L Y V V D  
-----  
2551 TCCGCTGTGG TACACGCTGT GCGACCGCTA CGGCCTGTAT GTGGTGGATG  
AGGCGACACC ATGTGCGACA CGCTGGCGAT GCGGACATA CACCACCTAC  
-----  
+2 E A N I E T H G M V P M N R L T D  
-----  
2601 AAGCCAATAT TGAACCCAC GGCATGGTGC CAATGAATCG TCTGACCGAT  
TTGGTTTATA ACTTTGGGTG CCGTACCAGG GTTACTTAGC AGACTGGCTA  
-----  
+2 D P R W L P A M S E R V T R M V Q  
-----  
2651 GATCCGCGCT GGCTACCGGC GATGAGCGAA CGCGTAACGC GAATGGTGCA  
CTAGGCGCGA CCGATGGCCG CTACTCGCTT GCGCATTGCG CTTACCACGT  
-----  
+2 R D R N H P S V I I W S L G N E  
-----  
2701 GCGCGATCGT AATCACCCGA GTGTGATCAT CTGGTCGCTG GGGAAATGAAT  
CGCGCTAGCA TTAGTGGGCT CACACTAGTA GACCAGCGAC CCCTTACTTA  
-----  
+2 S G H G A N H D A L Y R W I K S V  
-----  
2751 CAGGCCACGG CGCTAATCAC GACGCGCTGT ATCGCTGGAT CAAATCTGTC  
GTCCGGTGCC GCGATTAGTG CTGCGCGACA TAGCGACCTA GTTTAGACAG  
-----  
+2 D P S R P V Q Y E G G G A D T T A  
-----  
2801 GATCCTTCCC GCCCGGTGCA GTATGAAGC GCGGAGCCG ACACCACGGC  
CTAGGAAGGG CGGGCCACGT CATACTTCG CCGCCTCGGC TGTGGTGCCG  
-----  
+2 T D I I C P M Y A R V D E D Q P  
-----  
2851 CACCGATATT ATTTGCCCCA TGTACGCGCG CGTGGATGAA GACCAGCCCT  
GTGGCTATAA TAAACGGGCT ACATGCGCGC GCACCTACTT CTGGTCGGGA  
-----

```

+2 F P A V P K W S I K K W L S L P G
2901 TCCCGGCTGT GCCGAAATGG TCCATCAAAA AATGGCTTTC GCTACCTGGA
AGGGCCGACA CGGCTTTACC AGGTAGTTT TTACCGAAAG CGATGGACCT
-----
+2 E T R P L I L C E Y A H A N G N S
2951 GAGACGCGCC CGCTGATCCT TTGCGAATAC GCCCAGCGCA TGGGTAACAG
CTCTGCGCGG GCGACTAGGA AACGCTTATG CGGGTGCGCT ACCCATTTGC
-----
+2 L G G F A K Y N Q A F R C Y P R
3001 TCTTGGCGGT TTCGCTAAAT ACTGGCAGGC GTTTCGTCAG TATCCCGTT
AGAACCGCCA AAGCGATTTA TGACCGTCCG CAAAGCAGTC ATAGGGGCAA
-----
+2 L Q G G F V W D W V D Q S L I K Y
3051 TACAGGGCGG CTTGCTCTGG GACTGGGTGG ATCAGTCGCT GATTAAATAT
ATGTCCCGCC GAAGCAGACC CTGACCCACC TAGTCAGCGA CTAATTTATA
-----
+2 D E N G N P W S A Y G G D F G D T
3101 GATGAAAACG GCAACCCGTG GTCGGCTTAC GCGGTGATT TTGGCGATAC
CTACTTTTGC CGTTGGGCAC CAGCCGAATG CCGCCACTRA AACCGCTATG
-----
+2 P N D R Q F C M N G L V F A D R
3151 GCCGAACGAT CGCCAGTTCT GTATGAACGG TCTGGTCTTT GCCGACCGCA
CGGCTTGCTA GCGGTCAAGA CATACTTGCC AGACCAGAAA CGGCTGGCGT
-----
+2 T P H P A L T E A K H Q Q Q F F Q
3201 CGCCGCATCC AGCGCTGACG GAAGCAAAC ACCAGCAGCA GTTTTCCAG
GCGGCGTAGG TCGCGACTGC CTTGCTTTG TGGTCGTCGT CAAAAAGGTC
-----
+2 F R L S G Q T I E V T S E Y L F R
3251 TTCCGTTTAT CCGGGCAAAC CATCGAAGTG ACCAGCGAAT ACCTGTTCCG
AAGGCAAATA GGGCCGTTG GTAGCTTAC TGGTCGCTTA TGGACRAGGC
-----
+2 H S D N E L L E W M V A L D G K
3301 TCATAGCGAT AACGAGCTCC TGCCTGGAT GGTGGCGCTG GATGGTAAGC
AGTATCGCTA TTGCTCGAGG ACGTGACCTA CCACCGCGAC CTACCATTOG
-----
+2 P L A S G E V P L D V A P Q G K Q
3351 CGCTGGCAAG CGGTGAAGTG CCTCTGGATG TCGCTCCACA AGGTAAACAG
GCGACCGTTC GCCACTTCAC GGAGACCTAC ACCGAGGTGT TCCATTTGTC
-----
+2 L I E L P E L P Q P E S A G Q L W
3401 TTGATTGAAC TGCCTGAACT ACCGCAGCCG GAGAGCGCCG GGCAACTCTG
AACTAACTTG ACGGACTTGA TGGCGTCGGC CTCTCGCGGC CCGTTGAGAC
-----
+2 L T V R V V Q P N A T A W S E A
3451 GCTCACAGTA CGGTAGTGC AACCGAACGC GACCGCATGG TCAGAAGCCG
CGAGTGTCTAT GCGCATCAGG TTGGCTTGGC CTGGCGTACC AGTCTTCGGC
-----

```

+2 G H I S A W Q Q W R L A E N L S V  
3501 GGCACATCAG CGCCTGGCAG CAGTGGCGTC TGGCGGAAAA CCTCAGTGTG  
CCGTGTAGTC GCGGACCGTC GTCACCGCAG ACCGCCTTTT GGAGTCACAC

+2 T L P A A S E A I P H L T T S E M  
3551 ACGCTCCCCG CCGCGTCCCA CGCCATCCCG CATCTGACCA CCAGCGAAAT  
TGCGAGGGGC GCGCGAGGGT GCGGTAGGGC GTAGACTGGT GGTGCGTTTA

+2 D F C I E L G N K R W Q F N R Q  
3601 GGATTTTTGC ATCGAGCTGG GTAATAAGCG TTGGCAATTT AACCGCCAGT  
CCTAAAAACG TAGCTCGACC CATTATTGCG AACCGTAAA TTGGCGGTCA

+2 S G F L S Q M W I G D K K Q L L T  
3651 CAGGCTTTCT TTCACAGATG TGGATTGGCG ATAAAAACA ACTGCTGACG  
GTCCGAAAGA AAGTGTCTAC ACCTAACCGC TATTTTTTGT TGACGACTGC

+2 P L R D Q F T R A P L D N D I G V  
3701 CCGCTGCGCG ATCAGTTCAC CCGTGCACCG CTGGATAACG ACATTGGCGT  
GGCGACGCGC TAGTCAAGTG GGCACGTGGC GACCTATTGC TGTAAACGCA

+2 S E A T R I D P N A W V E R W K  
3751 AAGTGAAGCG ACCCGCATTG ACCCTAACGC CTGGGTGAA CGCTGGAGG  
TTCATTGCG TGGGCGTAAC TGGGATTGCG GACCCAGCTT GCGACCTTC

+2 A A G H Y Q A E A A L L Q C T A D  
3801 CCGCGGGCCA TTACCAGGCC GAAGCAGCGT TGTGTCAGTG CACGGCAGAT  
GCCGCCCGGT AATGGTCCGG CTTCGTGCGA ACAACGTCAC GTGCCGTCTA

+2 T L A D A V L I T T A H A W Q H Q  
3851 ACACTTGCTG ATGCGGTGCT GATTACGACC GCTCAGCGT GGCAGCATCA  
TGTGAACGAC TACGCCACGA CTAATGCTGG CGAGTGCACA CCGTCGTAGT

+2 G K T L F I S R K T Y R I D G S  
3901 GGGGAAAACC TTATTATCA GCCGAAAAC CTACCGGATT GATGGTAGTG  
CCCCTTTTGG AATAAATAGT CGGCCTTTTG GATGGCTTAA CTACCATCAC

+2 G Q M A I T V D V E V A S D T P H  
3951 GTCAATGGC GATTACCGTT GATGTTGAAG TGGCGAGCGA TACACCGCAT  
CAGTTTACCG CTAATGGCAA CTACAACTTC ACCGCTCGCT ATGTGGCGTA

+2 P A R I G L N C Q L A Q V A E R V  
4001 CCGGCGCGGA TTGGCCTGAA CTGCCAGCTG GCGCAGGTAG CAGAGCGGGT  
GGCCGCGCCT AACCGGACTT GACGGTCGAC CGCGTCCATC GTCTCGCCCA

+2 N W L G L G P Q E N Y P D R L T  
4051 AAACGGCTC GGATTAGGGC CGCAAGAAAA CTATCCCGAC CGCCTTACTG  
TTTGACCGAG CCTAATCCCG GCGTTCCTTT GATAGGGCTG GCGGAATGAC

+2 A A C F D R W D L P L S D M Y T P  
-----  
4101 CCGCCTGTTT TGACCGCTGG GATCTGCCAT TGTCAGACAT GTATACCCCG  
GGCGGACAAA ACTGGCGACC CTAGACGGTA ACAGTCTGTA CATATGGGGC  
-----  
+2 Y V F P S E N G L R C G T R E L N  
-----  
4151 TACGTCTTCC CGAGCGAAAA CGGTCTGCGC TCGGGGACGC GCGAATTGAA  
ATGCAGAAGG GCTCGCTTTT GCCAGACGCG ACGCCCTGCG CGCTTAACCT  
-----  
+2 Y G P H Q W R G D F Q F N I S R  
-----  
4201 TTATGGCCCA CACCAGTGGC GCGGCGACTT CCAGTTCAAC ATCAGCCGCT  
AATACCGGGT GTGGTCACCG CGCCGCTGAA GGTCAGTTG TAGTCGGCGA  
-----  
+2 Y S Q Q Q L M E T S H R H L L H A  
-----  
4251 ACAGTCAACA GCAACTGATG GAAACCAGCC ATCGCCATCT GCTGCACGCG  
TGTCAGTTGT CGTTGACTAC CTTTGGTCCG TAGCGGTAGA CGACGTGCGC  
-----  
+2 E E G T W L N I D G F H M G I G G  
-----  
4301 GAAGAAGGCA CATGGCTGAA TATCGACGGT TTCCATATGG GGATTGGTGG  
CTTCTTCCGT GTACCGACTT ATAGCTGQCA AAGGTATAAC CCTAACCAAC  
-----  
+2 D D S W S P S V S A E F Q L S A  
-----  
4351 CGAGCACTCC TGGAGCCCGT CAGTATCGGC GGAATTCCAG CTGAGCGCCG  
GCTGCTGAGG ACCTCGGGCA GTCATAGCCG CCTTAAGGTC GACTCGCGGC  
-----  
+2 G R Y H Y Q L V W C Q K R S D Y K  
-----  
4401 GTCGCTACCA TTACCAGTTG GTCTGGTGTC AAAAAAGATC TGACTATAAA  
CAGCGATGGT AATGGTCAAC CAGACCACAG TTTTCTTAG ACTGATATT  
-----  
+2 D E D L D H H H H H H R  
-----  
4451 GATGAGGACC TCGACCATCA TCATCATCAT CACCGGTAAT AATAGGTAGA  
CTACTCCTGG AGCTGGTAGT AGTAGTAGTA GTGGCCATTA TTATCCATCT  
-----  
4501 TAAGTGACTG ATTAGATGCA TTGATCCCTC GACCAATICC GGTATTATTC  
ATTCACTGAC TAATCTACGT AACTAGGGAG CTGGTTAAGG CCAATAAAAG  
-----  
4551 CACCATATTG CCGTCTTTTG GCAATGTGAG GGCCCGGAAA CCTGGCCCTG  
GTGGTATAAC GGCAGAAAAC CGTTACACTC CCGGGCCCTT GGACCGGGAC  
-----  
4601 TCTTCTTGAC GAGCATTCCT AGGGGTCTTT CCCCTCTCGC CAAAGGAATG  
AGAAGAAGTG CTCGTAAGGA TCCCCAGAAA GGGGAGAGCG GTTTCCTTAC  
-----  
4651 CAAGGTCTGT TGAATGTCGT GAAGGAAGCA GTTCTCTGG AAGCTTCTTG  
GTTCCAGACA ACTTACAGCA CTTCTTCGT CAAGGAGGCC TTCGAAGAAC  
-----  
4701 AAGCAACA ACGTCTGTAG CGACCCCTTG CAGGCAGCGG AACCCCCRC  
TTCGTGTTGT TGCAGACATC GCTGGGAAAC GTCCGTCGCC TTGGGGGGTG  
-----  
4751 CTGGCGACAG GTGCCTCTGC GGCCAAAAGC CACGTGTATA AGATACACCT  
GACCGCTGTC CACGGAGACG CCGGTTTTCG GTGCACATAT TCTATGTGGA  
-----

4801 GCAAAGGCGG CACAACCCCA GTGCCACGTT GTGAGTTGGA TAGTTGTGGA  
CGTTTCCGCC GTGTTGGGGT CACGGTGCAA CACTCAACCT ATCAACACCT

4851 AAGAGTCAAA TGGCTCTCCT CAAGCGTATT CAACAAGCGG CTGAAGGATG  
TTCTCAGTTT ACCGAGAGGA GTTCGCATAA GTTGTTCOCG GACTTCCTAC

4901 CCCAGAAAGT ACCCCATTGT ATGGGATCTG ATCTGGGGCC TCGGTGCACA  
GGGTCTTCCA TGGGGTAACA TACCCTAGAC TAGACCCCGG AGCCACGTGT

4951 TGCTTTACAT GTGTTTAGTC GAGGTTAAAA AACGTCATGG CCCCCGAAC  
ACGAAATGTA CACAAATCAG CTCCAATTTT TTGCAGATCC GGGGGGCTTG

5001 CACGGGGACG TGGTTTTCTT TTGAAAAACA CGATGATAAT ACCATGATTG  
GTGCCCCGCG ACCAAAAGGA AACTTTTGT GCTACTATTA TGGTACTAAC

5051 AACAGATGG ATTGCACGCA GGTCTCTCCG CCGCTTGGCT GGAGAGGCTA  
TTGTTCTACC TAACGTGCGT CCAAGAGGCC GCGCAACCCA CCTCTCCGAT

5101 TTGGGTATG ACTGGGCACA ACAGACAATC GGCTGCTCTG ATGCCGCCGT  
AAGCCGATAC TGACCCGTGT TGTCTGTTAG CCGACGAGAC TACGGCGGCA

5151 GTTCCGGCTG TCAGCGCAGG GCGCCCGGT TCTTTTGTG AAGACCGACC  
CAAGGCCGAC AGTCGCGTCC CCGCGGGCCA AGAAAAACAG TTCTGGCTGG

5201 TGTCCGGTGC CCTGAATGAA CTGCAGGACG AGGCAGCGCG GCTATCGTGG  
ACAGGCCAAG GGACTTACTT GACGTCCTGC TCCGTGCGCG CGATAGCACC

5251 CTGGCCACGA CGGGCGTTCC TTGCGCAGCT GTGCTCGACG TTGTCACTGA  
GACCGGTGCT GCCCGCAAGG AACGCGTCGA CACGAGCTGC AACAGTGACT

5301 AGCGGGAAGG GACTGGCTGC TATTGGGCGA AGTGCCGGGG CAGGATCTCC  
TCGCCCCTCC CTGACCGACG ATAACCGCT TCACGGCCCC GTCCTAGAGG

5351 TGTCATCTCA CCTTGCTCCT GCCGAGAAAG TATCCATCAT GGCTGATGCA  
ACAGTAGAGT GGAACGAGGA CGGCTCTTC ATAGGTAGTA CCGACTACGT

5401 ATGCGGCGGC TGCATACGCT TGATCCGGCT ACCTGCCAT TCGACCACCA  
TACGCCGCGG ACGTATGCGA ACTAGGCCGA TGGACGGGTA AGCTGGTGGT

5451 AGCGAAACAT CGCATCGAGC GAGCACGTAC TCGGATGGAA GCCGGTCTTG  
TCGCTTTGTA GCGTAGCTCG CTCGTGCATG AGCCTACCTT CGGCCAGAAC

5501 TCGATCAGGA TGATCTGGAC GAAGAGGATC ACGGGCTCGC GCCAGCCGAA  
AGCTAGTCCT ACTAGACCTG CTTCTCGTAG TCCCCGAGCG CGGTCCGCTT

5551 CTGTTCCGCA GGCTCAAGGC GCGCATGCCG GACGGCGAGG ATCTCGTCGT  
GACAGCGGCT CCGAGTTCG CCGGTACGGG CTGCCGCTCC TAGAGCAGCA

5601 GACCCATGGC GATGCCTGCT TGCCGAATAT CATGGTGGAA AATGGCCGCT  
CTGGGTACCG CTACGGACGA ACGGCTTATA GTACCACCTT TTACCGGCGA

5651 TTTCTGGATT CATCGACTGT GGCCGGCTGG GTGTGGGCGA CCGCTATCAG  
AAGACCTAA GTAGCTGACA CCGGCCGACC CACACCGCCT GCGGATAGTC

5701 GACATAGCGT TGGCTACCCG TGATATTGCT GAAGAGCTTG GCGGCGAATG  
CTGTATCGCA ACCGATGGGC ACTATAACGA CTTCTCGAAC CCGCGCTTAC

5751 GGCTGACCGC TTCCTCGTGC TTTACGGTAT CGCCGCTCCC GATTCCGAGC  
CCGACTGGCG AAGGAGCACG AATGCCATA GCGGCGAGGG CTAAGCGTGC  
-----  
5801 GCATCGCCTT CTATCGCCTT CTGACGAGT TCTTCTGAGC GGGACTCTGG  
CGTAGCGGAA GATAGCGGAA GAACTGCTCA AGAAGACTCG CCTTGAGACC  
-----  
5851 GGTTGCGATC GATAAAATAA AAGATTTTAT TTAGTCTCCA GAAAAAGGGG  
CCAAGCGTAG CTATTTTAT TTTAAATA AATCAGAGGT CTTTTCCCC  
-----  
5901 GGAATGAAAG ACCCCACCTG TAGGTTTGGC AAGCTAGCTT AAGTAACGCC  
CCTTACTTTC TGGGGTGGAC ATCCAAACCG TTCGATCGAA TTCATTGCGG  
-----  
5951 ATTTTGCAAG GCATGGAAAA ATACATAACT GAGAATAGAG AAGTTCAGAT  
TAAACGTTTC CGTACCTTTT TATGTATTGA CTCTTATCTC TTCAAGTCTA  
-----  
6001 CAAGGTCAAG AACAGATGGA ACAGCTGAAT ATGGGCCAAA CAGGATATCT  
GTTCCAGTCC TTGTCTACCT TGTCGACTTA TACCCGGTTT GTCTATAGA  
-----  
6051 GTGGTAAGCA GTTCTGCCC CGGCTCAGGG CCAAGAACAG ATGGAACAGC  
CACCATTCTG CAAGGACGGG GCCGAGTCCC GGTCTTGTG TACCTTGTGG  
-----  
6101 TGAATATGGG CCAAACAGGA TATCTGTGGT AAGCAGTTCC TGCCCCGGCT  
ACTTATACCC GGTGTGCTCT ATAGACACCA TTCGTCAAGG ACGGGGCGGA  
-----  
6151 CAGGGCCAAG AACAGATGGT CCCAGATGC GGTCCAGCCC TCAGCAGTTT  
GTCCCGGTTT TTGTCTACCA GGGGTCTACG CCAGGTGCGG AGTCGTCAA  
-----  
6201 CTAGAGAACC ATCAGATGTT TCCAGGGTGC CCCAAGGACC TGAATGACC  
GATCTCTTGG TAGCTACAA AGGTCCACG GGGTCTCTGG ACTTTACTGG  
-----  
6251 CTGTGCTTAA TTTGAACTAA CCAATCAGTT CGCTTCTCGC TTCTGTTGCG  
GACACGGAAT AAATTTGATT GGTAGTCAA GCGAAGAGCG AAGACAAGCG  
-----  
6301 GCGCTTCTGC TCCCGAGCT CAATAAAGA GCCCACAACC CCTCACTCGG  
CGCGAAGAGC AGGGGCTCGA GTTATTTTCT CGGGTGTGG GGAGTGAGCC  
-----  
6351 GGCGCCAGTC CTCCGATTGA CTGAGTCGCC CGGGTACCGG TGTATCCAAT  
CCGCGGTCAG GAGGCTAACT GACTCAGCGG GCCCATGGGC ACATAGGTTA  
-----  
6401 AAACCTCTT CGAGTTGCAT CCGACTTGTG GTCTCGCTGT TCCTTGGGAG  
TTTGGGAGAA CGTCAACGTA GGCTGAACAC CAGAGCGACA AGGAACCTC  
-----  
6451 GGTCTCTCT GAGTGATTGA CTACCGTCA GCGGGGGTCT TTCATTCTG  
CCAGAGGAGA CTCCTAACT GATGGGCACT CGCCCCAGA AAGTAAGTAC  
-----  
6501 CAGCATGTAT CAAAATTAAT TTGGTTTTT TTCTTAAGTA TTTACATTAA  
GTCGTACATA GTTTAATTA AACCAAAAA AAGAATTCAT AATGTAATT  
-----  
6551 ATGGCCATAG TTGCATTAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT  
TACCGGTATC AACGTAATTA CTAGCCGGT TCGCGGCCCC TCTCCGCCAA  
-----  
6601 TGCGTATTGG CGCTTTCGG CTTCCTCGCT CACTGACTCG CTGCGCTCGG  
ACGCATACCC GCGAGAAGGC GAAGGAGCGA GTGACTGAGC GACGCGAGCC  
-----  
6651 TCGTTCGGCT CCGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAAACGG  
AGCAAGCCGA CGCGCTCGC CATAGTCGAG TGAGTTTCCG CCATTATGCC  
-----






Figure 11A

```

1  CTGCAGCCTG AATATGGGCC AAACAGGATA TCTGTGGTAA GCAGTTCTCTG
   GACGTCGGAC TTATACCCGG TTTGTCTTAT AGACACCATT CGTCAAGGAC
-----
51  CCCCCGCTCA GGGCCAAGAA CAGATGGAAC AGCTGAATAT GGGCCAAACA
   GGGGCCGAGT CCGGTTCTT GTCTACCTTG TCGACTTATA CCGGTTTGT
-----
101 GGATATCTGT GGTAAAGCAGT TCCTGCCCCG GCTCAGGGCC AAGAACAGAT
   CCTATAGACA CCATTCTGTC AGGACGGGGC CGAGTCCCGG TTCTTGTCTA
-----
151 GGTCCCCAGA TGCGGTCCAG CCCTCAGCAG TTTCTAGAGA ACCATCAGAT
   CCAGGGGTCT ACGCCAGGTC GGGAGTCGTC AAAGATCTCT TGGTAGTCTA
-----
201 GTTCCAGGGG TGCCCCAAGG ACCTGAAATG ACCCTGTGCC TTATTTGAAC
   CAAAGGTCCC ACGGGGTTCC TGGACTTTAC TGGGACACGG AATAAACTTG
-----
251 TAACCAATCA GTTCGCTTCT CGTTCTGTG CGCGCGCTTC TGCTCCCCGA
   ATTGGTTAGT CAAGCGAAGA GCGAAGACAA GCGCGGAAG ACGAGGGGCT
-----
301 GCTCAATAAA AGAGCCCAACA ACCCTCACT CGGGCGGCCA GTCTCTCGAT
   CGAGTTATTT TCTCGGGTGT TGGGGAGTGA GCGCCCGGT CAGGAGGCTA
-----
351 TGACTGAGTC GCGCGGTAC CCGTGATCC AATAAACCTT CTTGCAGTTG
   ACTGACTCAG CGGGCCCATG GGCACATAGG TTATTTGGGA GAACGTCAAC
-----
401 CATCCGACTT GTGGTCTCGC TGTTCCTTG GAGGGTCTCC TCTGAGTGAT
   GTAGGCTGAA CACCAGAGCG ACAAGGAACC CTCCAGAGG AGACTCACTA
-----
451 TGACTACCCG TCAGCGGGGG TCTTTCATTT GGGGGCTCGT CCGGGATCGG
   ACTGATGGGC AGTCGCCCCC AGAAAGTAAA CCCCCAGCA GGCCTAGCC
-----
501 GAGACCCCTG CCCAGGGACC ACCGACCCAC CACCGGGAGG CAAGCTGGCC
   CTCTGGGGAC GGTCCCTGG TGGCTGGGTG GTGGCCCTCC GTTCGACCGG
-----
551 AGCAACTTAT CTGTGTCTGT CCGATTGTCT AGTGTCTATG ACTGATTTTA
   TCGTTGAATA GACACAGACA GGTAAACAGA TCACAGATAC TGACTAAAAT
-----
601 TCGCCCTGCG TCGGTACTAG TTAGCTAACT AGCTCTGTAT CTGGCGGACC
   ACGCGGACGC AGCCATGATC AATCGATTGA TCGAGACATA GACCGCTTGG
-----
651 CGTGGTGGAA CTGACGAGTT CTGAACACCC GGCGGCAACC CTGGGAGACG
   GCACCACTT GACTGCTCAA GACTTGTGGG CCGGCGTTGG GACCCTCTGC
-----
701 TCCAGGGGAC TTTGGGGGCC GTTTTGTGG CCGAOCCTGA GGAAGGGAGT
   AGGGTCCCTG AAACCCCGG CAAAACACC GGGCTGGACT CCTTCCCTCA
-----
751 CGATGTGGAA TCCGACCCCG TCAGGATATG TGGTCTGGT AGGAGACGAG
   GCTACACCTT AGGCTGGGGC AGTCTTATAC ACCAAGACCA TCCTCTGCTC
-----
801 AACCTAAAC AGTTCCCGCC TCCGTCTGAA TTTTGTCTT CGGTTTGGAA
   TTGGATTTT TCAAGGGCGG AGGCAGACTT AAAACGAA GCAAACCTT
-----
851 CCGAAGCCGC GCGTCTTGTG TGCTGCAGCA TCGTCTGTG TTGTCTCTGT
   GGCTTCGGC CGCAGAACAG ACGACGTCGT AGCAAGACAC AACAGAGACA
-----
901 CTGACTGTGT TTCTGTATTT GTCTGAAAT TAGGGCCAGA CTGTTACCAC
   GACTGACACA AAGACATAAA CAGACTTTTA ATCCCGGTCT GACAATGGTG
-----

```

FIGURE 11B

951 TCCCTTAAGT TTGACCTTAG GTAACGGAA AGATGTCGAG CGGCTCGCTC  
AGGGAATTCA AACTGGGAATC CATTGACCTT TCTACAGCTC GCCGAGCGAG

-----

1001 ACAACCAGTC GGTAGATGTC AAGAAGAGAC GTTGGGTTAC CTCTGCTCT  
TGTTGGTCTAG CCATCTACAG TTCTTCTCTG CAACCCAAATG GAAGACGAGA

-----

1051 GCAGAAATGGC CAACCTTTAA CGTCGGATGG CCGCGAGACG GCACCTTTAA  
CGTCTTACCG GTTGGAAATT GCAGCCTACC GGCCTCTGCTC CGTGGAAATT

-----

1101 CCGAGACCTC ATCACCAGG TTAAGATCAA GGTCTTTTCA CCTGGCCCCG  
GGCTCTGGAG TAGTGGGTCC AATTCTAGTT CCAGAAAATG GGACCGGGCG

-----

1151 ATGGACACCC AGACCAGGTC CCCTACATCG TGACCTGGGA AGCCTTGGCT  
TACCTGTGGG TCTGGTCCAG GGGATGTAGC ACTGGACCCT TCGGAACCGA

-----

1201 TTGACCCCC CTCCCTGGGT CAGCCCTTT GTACACCTTA AGCCTCCGCC  
AAACTGGGGG GAGGGACCCA GTTCGGGAAA CATGTGGGAT TCGGAGGCGG

-----

1251 TCCTCTTCTT CCATCCGCCG CGTCTCTCCC CCTTGAACCT CCTCGTTTCA  
AGGAGAAGGA GGTAGGCGGG GCAGAGAGGG GGAACCTTGA GGAGCAAGCT

-----

1301 CCCCGGCTCG ATCCTCCCTT TATCCAGCCC TCACTCCTTC TCTAGGCGCG  
GGGGCGGAGC TAGGAGGGAA ATAGGTGCGG AGTGAGGAAG AGATCCGCGG

-----

1351 GGCGCTCTTA GCCCATTAAT ACGACTCACT ATAGGGCGAT TCGAACACCA  
CGGGCGAGAT CGGGTAATTA TGCTGAGTGA TATCCCGCTA AGCTTGTGGT

-----

1401 TGCACCATCA TCATCATCAC GTCGACTATA AAGATGAGGA CCTCGAGATG  
ACGTGGTAGT AGTAGTAGTG CAGCTGATAT TTCTACTCCT GGAGCTCTAC

-----

1451 GGCGTGATTA CGGATTCCTT GGCGGTCGTG GCCCGCACCG ATCGCCCTTC  
CCGCACTAAT GCCTAAGTGA CCGGCAGCAC CGGCGGTGTC TAGCGGGAAG

-----

1501 CCAACAGTTA CGCAGCCTGA ATGGCGAATG GCGCTTGGC TGGTTTCCGG  
GGTTGTCAAT CGGTCGGACT TACCGCTTAC CGCGAAACGG ACCAAAGGCC

-----

1551 CACCAGAAAG GGTGCCGGAA AGCTGGCTGG AGTGCGATCT TCCTGAGGCC  
GTGGTCTTGG CCACGGCCTT TCGACCGACC TCACGCTAGA AGGACTCCGG

-----

1601 GATACTGTGG TCGTCCCCTC AACTGGCAG ATGCACGGTT ACGATGCGCC  
CTATGACAGC AGCAGGGGAG TTTGACCGTC TACGTGCCAA TGCTACGGCG

-----

1651 CATCTACACC AACGTGACCT ATCCCATTAC GGTCAATCGG CCGTTTGTTC  
GTAGATGTGG TTGCACTGGA TAGGGTAATG CCACTTAGGC GGCACCAAG

-----

1701 CCACGGAGAA TCCGACGGGT TGTACTCGC TCACATTTAA TGTGATGAA  
GGTGCTCTTT AGCCTGCCCA ACAATGAGCG AGTGTAATTT ACAACTACTT

-----

1751 AGCTGGCTAC AGGAAGGCCA GACGCGAATT ATTTTGTATG GCGTTAATC  
TCGACCGATG TCCTTCCGGT CTGCGCTTAA TAAAACTAC CGCAATTGAG

-----

1801 GGCGTTTCAT CTGTGGTGCA ACGGGCGCTG GGTGGGTAC GGCCAGGACA  
CCGCAAGTA GACACCAGT TGCCCGCGAC CCAGCCAATG CCGGTCCTGT

-----

1851 GTCGTTTGCC GTCTGAATTT GACCTGAGCG CATTTTACG CGCCGAGAA  
CAGCAACCG CAGACTTAAA CTGGACTCGC GTAAAAATTC GCGGCTCTT

-----

1901 AACCGCCTCG CGGTGATGGT GCTGGGCTGG AGTGACGGCA GTTATCTGGA  
TTGGCGGAGC GCCACTACCA CGATGAGACC TCACTGCCGT CAATAGACCT  
-----  
1951 AGATCAGGAT ATGTGGCGGA TGAGCGGCAT TTTCCGTGAC GTCTCGTTGC  
TCTAGTCCTA TACACCGCCT ACTCGCCGTA AAAGGCACTG CAGAGCAACG  
-----  
2001 TGCATAAACC GACTACACAA ATCAGCGATT TCCATGTTGC CACTCGCTTT  
ACGTATTGG CTGATGTGTT TAGTCGCTAA AGGTACACG GTGAGCGAAA  
-----  
2051 AATGATGATT TCAGCCGCGC TGTACTGGAG GCTGAAGTTC AGATGTGCGG  
TTACTACTAA AGTCGGCGCG ACATGACCTC CGACTTCAAG TCTACACGCC  
-----  
2101 CGAGTTGCGT GACTACCTAC GGGTAACAGT TTCTTTATGG CAGGGTGAAA  
GCTCAACGCA CTGATGGATG CCCATTGTCA AAGAAATACC GTCCCACTTT  
-----  
2151 CGCAGGTGCG CAGCGGCACC GCGCCTTTTC GCGGTGAAAT TATCGATGAG  
GCGTCCAGCG GTCGCCGTGG CCGGAAAGC CGCCACTTTA ATAGCTACTC  
-----  
2201 CGTGGTGGTT ATGCCGATCG CGTCACACTA CGTCTGAACG TCGAAAACCC  
GCACCACCAA TACGGCTAGC GCAGTGTGAT GCAGACTTGC AGCTTTTGGG  
-----  
2251 GAAACTGTGG AGCGCCGAAA TCCCGAATCT CTATCGTGCG GTGGTTGAAC  
CTTTGACACC TCGCGGCTTT AGGGCTTAGA GATAGCACGC CACCAACTTG  
-----  
2301 TGACACCGCG CGACGGCAGC CTGATTGAAG CAGAAGCCTG CGATGTCGGT  
ACGTGTGGCG GTCGCCGTGC GACTAACTTC GTCTTCGGAC GCTACAGCCA  
-----  
2351 TTCCCGGAGG TGCGGATTGA AATGGTCTG CTGCTGCTGA ACGGCAAGCC  
AAGGCGCTCC ACGCCTAAT TTTACCAGAC GACGACGACT TGCCGTTCGG  
-----  
2401 GTTGCTGATT CGAGGCGTTA ACCGTACGGA GCATCATCCT CTGCATGGTC  
CAACGACTAA GCTCCGCAAT TGGCAGTGCT CGTAGTAGGA GACGTACCAG  
-----  
2451 AGGTCATGGA TGAGCAGACG ATGGTGCAGG ATATCCTGCT GATGAAGCAG  
TCCAGTACCT ACTCGTCTGC TACCACGTCC TATAGGACGA CTACTTCGTC  
-----  
2501 AACCACTTTA ACGCCGTGCG CTGTTGCGAT TATCCGAACC ATCCGCTGTG  
TTGTTGAAAT TGCGGCACGC GACAAGCGTA ATAGGCTTGG TAGGCGACAC  
-----  
2551 GTACACGCTG TGCGACCGCT ACGGCCTGTA TGTGGTGGAT GAAGCCAATA  
CATGTGCGAC ACGCTGGCGA TGCCGGACAT ACACCACCTA CTTCGGTTAT  
-----  
2601 TTGAARCCCA CGGCATGGTG CCAATGAATC GTCTGACCGA TGATCCGCGC  
AACTTTGGGT GCCGTACCAC GGTTACTTAG CAGACTGGCT ACTAGGCGCG  
-----  
2651 TGGCTACCGG CGATGAGCGA ACGCGTAACG CGAATGGTGC AGCGCGATCG  
ACCGATGGCC GCTACTCGCT TGCGCATTGC GCTTACCACG TCGCGCTAGC  
-----  
2701 TAATCACCCG AGTGTGATCA TCTGGTCGCT GGGGAATGAA TCAGGCCACG  
ATTAGTGGGC TCACACTAGT AGACCAGCGA CCCCTTACTT AGTCCGGTGC  
-----  
2751 GCGCTAATCA CGACGCGCTG TATCGCTGGA TCAATCTGT CGATCCTTCC  
CGCGATTAGT GCTGCGCGAC ATAGCGACCT AGTTTAGACA GCTAGGAAGG  
-----  
2801 CGCCCGGTGC AGTATGAAGG CGGCGGAGCC GACACCAOGG CCACCGATAT  
GCGGGCCAGC TCATACTTCC GCGCCTCGG CTGTGGTGCC GGTGGCTATA  
-----

2851 TATTTGCCCG ATGTACGCGC GCGTGGATGA AGACCAGCCC TTCCCGGCTG  
ATAAACGGGC TACATGCGCG CGCACCTACT TCTGGTCGGG AAGGGCCGAC

2901 TGCCGAAATG GTCCATCAAA AATGGCTTT CGCTACCTGG AGAGACGCGC  
ACGGCTTTAC CAGGTAGTTT TTTACCGAAA GCGATGGACC TCTCTGCGCG

2951 CCGCTGATCC TTGCGAATA CGCCACGCG ATGGGTAACA GTCTTGGCGG  
GGCGACTAGG AAACGCTTAT GCGGGTGGC TACCCATTGT CAGAACC GCC

3001 TTTCGCTAAA TACTGGCAGG CGTTTCGTCA GTATCCCGT TTACAGGGCG  
AAAGCGATTT ATGACCGTCC GCAAGCAGT CATAGGGGCA AATGTCCCGC

3051 GCTTCGTCTG GGACTGGGTG GATCAGTCG TGATTAATA TGATGAAAC  
CGAAGCAGAC CCTGACCCAC CTAGTCAGCG ACTAATTAT ACTACTTTG

3101 GGCAACCCGT GGTCCGGCTTA CGCGGTGAT TTTGGCGATA CGCCGAAOCA  
CCGTGGGCA CCAGCCGAAT GCGCCACTA AAACCGCTAT GCGGCTTGCT

3151 TCGCCAGTTC TGTATGAACG GTCTGGTCTT TGCCGACCGC ACGCCGCATC  
AGCGGTCAAG ACATACTTGC CAGACCAGAA ACGGCTGGCG TGCGGCGTAG

3201 CAGCGCTGAC GGAAGCAAAA CACCAGCAGC AGTTTTTCCA GTTCCGTTTA  
GTCGCGACTG CCTTCGTTTT GTGGTCGTG TCAAAAAGGT CAAGGCAAT

3251 TCCGGGCAAA CCATCGAAGT GACCAGCGAA TACCTGTTCC GTCATAGCGA  
AGGCCCGTTT GGTAGCTTCA CTGGTCGCTT ATGGACAAGG CAGTATCGCT

3301 TAACGAGCTC CTGCACTGGA TGGTGGCGCT GGATGGTAAG CCGCTGGCAA  
ATTGCTCGAG GACGTGACCT ACCACCGCGA CCTACCATTG GCGGACCGTT

3351 GCGGTGAAGT GCCTCTGGAT GTCGCTCCAC AAGGTAACA GTTGATTGAA  
CGCCACTTCA CGGAGACCTA CAGCGAGTGC TTCCATTTGT CAACTAATT

3401 CTGCCTGAAC TACCGCAGCC GGAGAGCGCC GGGCAACTCT GGCTCACAGT  
GACGGACTTG ATGGCGTCGG CCTCTCGCG CCCGTTGAGA CCGAGTGTCA

3451 ACGCGTAGTG CAACCGAAGC CGACCGCATG GTCAGAAGCC GGGCACATCA  
TGCGCATCAC GTTGGCTTGC GCTGGCGTAC CAGTCTTGG CCCGTGTAGT

3501 GCGCTTGGCA GCAGTGGCGT CTGGCGGAAA ACCTCAGTGT GACGCTCCCC  
CGCGGACCGT CGTACCGCA GACCGCCTTT TGGAGTCACA CTGCGAGGGG

3551 GCGCGTCCC ACGCCATCCC GCATCTGACC ACCAGCGAAA TGGATTTTGT  
CGGCGCAGGG TCGGCTAGGG CGTAGACTGG TGGTCGCTTT ACCTAAAAAC

3601 CATCGAGCTG GGTAAATAAGC GTTGGCAATT TAACCGCCAG TCAGGCTTTC  
GTAGCTCGAC CCATTATTG CAACCGTTAA ATTGGCGGTC AGTCCGAAAG

3651 TTTACAGAT GTGGATTGGC GATAAAAAAC AACTGCTGAC GCCGCTGCCG  
AAAGTGTCTA CACTAACCG CTATTTTTTG TTGACGACTG CGGCGACGCG

3701 GATCAGTTCA CCGGTGCACC GCTGGATAAC GACATTGGCG TAAGTGAAGC  
CTAGTCAAGT GGGCACGTGG CGACCTATTG CTGTAACCGC ATTCACTTGC

3751 GACCCGCATT GACCCTAACG CCTGGGTCGA ACGCTGGAAG GCGCGGGGCC  
CTGGGCGTAA CTGGGATTGC GGACCCAGCT TGCGACCTTC CGCGGCCCGG

3801 ATTACCAGGC CGAAGCAGCG TTGTTGCAGT GCACGGCAGA TACACTTGCT  
TAATGGTCCG GCTTCGTGCG AACAACTCA CGTGCCGTCT ATGTGAACGA

3851 GATGCGGTGC TGATTACGAC CGCTCACGCG TGGCAGCATC AGGGGAAAAC  
CTACGCCACG ACTAATGCTG GCGAGTGCGC ACCGTCTGAG TCCCTTTTG

3901 CTTATTTATC AGCCGGAAAA CCTACCGGAT TGATGGTAGT GGTCAAATGG  
GAATAAATAG TCGGCCTTTT GGATGGCCTA ACTACCATCA CCAGTTTACC

3951 CGATTACCGT TGATGTTGAA GTGGCGAGCG ATACACCGCA TCCGGCGCGG  
GCTAATGGCA ACTACAACTT CACCGCTCGC TATGTGGCGT AGGCCGCGCC

4001 ATTGGCCTGA ACTGCCAGCT GCGCGAGGTA GCGAGCGGG TAACTGGCT  
TAACCGGACT TGACGGTCTA CCGCTCCAT GTCTCGCCC ATTTGACCGA

4051 CGGATTAGGG CCGCAAGAAA ACTATCCGA CCGCCTTACT GCGCCTGTT  
GCCTAATCCC GCGTCTCTTT TGATAGGGCT GCGGGAATGA CCGCGGACAA

4101 TTGACCGCTG GGATCTGCCA TTGTCAGACA TGTATACCCC GTACGTCTTC  
AACTGGCGAC CCTAGACGGT AACAGTCTGT ACATATGGGG CATGCAGAAG

4151 CCGAGCGAAA ACGGTCTGCG CTGCGGGACG CCGGAATTGA ATTATGGCCC  
GGCTCGCTTT TGCCAGACGC GACGCCCTGC GCGCTTAACT TAATACGGGG

4201 ACACCACTGG CCGCGCGACT TCCAGTTCAA CATCAGCGCG TACAGTCAAC  
TGTGGTCAAC CCGCCGCTGA AGGTCAAGTT GTAGTCGGCG ATGTCAGTTG

4251 AGCAACTGAT GGAACCAGC CATCGCCATC TGCTGCACGC GGAAGAAGGC  
TCGTTGACTA CCTTTGGTCG GTAGCGGTAG ACGACGTGCG CCTTCTTCCG

4301 ACATGGCTGA ATATCGACGG TTTCCATATG GGGATTGGTG GCGACGACTC  
TGTACCGACT TATAGCTGCC AAAGTATAC CCTAACCAC CGCTGCTGAG

4351 CTGGAGCCCG TCAGTATCGG CGGAATTCCA GCTGAGCGCC GGTGCTACC  
GACCTCGGGC AGTCATAGCG GCCTTAAGGT CCACTCGCGG CCAGCGATGG

4401 ATTACCAGTT GGTCTGGTGT CAAAAAGAT CTGGAGGTGG TGGCAGCAGG  
TAATGGTCAA CCAGACCACA GTTTTTCTA GACCTCCACC ACCGTCTGCC

4451 CCTTGGCGCG CCGGATCCTT AATTAACAAT TGACCGGTAA TAATAGGTAG  
GGAACCGCGC GGCCTAGGAA TTAATTGTTA ACTGGCCATT ATTATCCATC

4501 ATAAGTGACT GATTAGATGC ATTGATCCCT CGACCAATTC CGGTTATTTT  
TATTCCTGA CTAATCTACG TAACTAGGGA GCTGGTTAAG GCCAATAAAA

4551 CCACCATATT GCCGTCTTTT GGCAATGTGA GGGCCCGGAA ACCTGGCCCT  
GGTGGTATAA CCGCAGAAAA CCGTTACACT CCCGGGCCTT TGGACCGGGA

4601 GTCTTCTTGA CGAGCAITCC TAGGGGTCTT TCCCTCTCG CCAAAGGAAT  
CAGAAGAACT GCTCGTRAAG ATCCCAGAA AGGGGAGAGC GGTTCCTTA

4651 GCAAGGTCTG TTGAATGTCG TGAAGGAAGC AGTTCCTCTG GAAGCTTCTT  
CGTTCAGAC AACTTACAGC ACTTCCTTCG TCAAGGAGAC CTTGGAAGAA

4701 GAAGACAAAC AACGTCTGTA GCGACCCCTT GCAGGCAGCG GAACCCCCCA  
CTTCTGTTG TTGAGACAT CGCTGGGAAA CGTCCGTGCG CTTGGGGGGT

4751 CCTGGCGACA GGTGCCTCTG CGGCCAAAAG CCACGTGTAT AAGATACACC  
GGACCGCTGT CCACGGAGAC GCCGGTTTTC GGTGCACATA TTCTATGTGG  
-----  
4801 TGCAAAGGCG GCACAACCCC AGTGCCACGT TGTGAGTTGG ATAGTTGTGG  
ACGTTTCCGC CGTGTGGGG TCACGGTGCA AACTCAACC TATCAACACC  
-----  
4851 AAAGAGTCAA ATGGCTCTCC TCAAGCGTAT TCAACAAGGG GCTGAAGGAT  
TTTCTCAGTT TACCGAGAGG AGTTCGCATA AGTTGTTCCC CGACTTCCTA  
-----  
4901 GCCCAGAAGG TACCCCATTC TATGGGATCT GATCTGGGGC CTCGGTGCAC  
CGGGTCTTCC ATGGGGTAAC ATACCCTAGA CTAGACCCCG GAGCCACGTG  
-----  
4951 ATGCTTTACA TGTGTTTAGT CGAGGTTAAA AAACGCTAG GCCCCCCGAA  
TACGAAATGT ACACAAATCA GCTCCAATT TTTGCAGATC CGGGGGGCTT  
-----  
5001 CCACGGGGAC GTGGTTTTCC TTTGAAAAAC ACGATGATAA TACCATGATT  
GGTGCCCTG CACCAAAAGG AAACTTTTG TGCTACTATT ATGGTACTAA  
-----  
5051 GAACAAGATG GATTGCACGC AGGTTCTCCG GCCGCTTGGG TGGAGAGGCT  
CTTGTTCTAC CTAACGTGGG TCCAAGAGGC CGGCGAACCC ACCTCTCCGA  
-----  
5101 ATTCCGGCTAT GACTGGGCAC AACAGACAACT CGGCTGCTCT GATGCCGCGG  
TAAGCCGATA CTGACCCGTG TTGTCTGTTA GCGACGAGA CTACGGCGGG  
-----  
5151 TGTCCGGCT GTACGCGCAG GGGCGCCCGG TTCTTTTGT CAAGACCGAC  
ACAAGGCCGA CAGTCGCGTC CCCGCGGGCC AAGAAAAACA GTTCTGGCTG  
-----  
5201 CTGTCCGGTG CCCTGAATGA ACTGCAGGAC GAGGCGCGC GGCTATCGTG  
GACAGGCCAC GGGACTTACT TGACGTCTG CTCCGTCGCG CCGATAGCAC  
-----  
5251 GCTGGCCACG ACGGGCGTTC CTTCGCGAGC TGTGCTCGAC GTTGTCAGTG  
CGACCGGTGC TGCCCGCAAG GAACGCGTCG ACACGAGCTG CAACAGTGAC  
-----  
5301 AAGCGGAAG GGAATGGCTG CTATTGGCGG AAGTGCCGGG GCAGGATCTC  
TTGCCCCTTC CCTGACCGAC GATAACCCGC TTCACGGCCC CGTCCTAGAG  
-----  
5351 CTGTCTCTC ACCTTGCTCC TGCCGAGAAA GTATCCATCA TGGCTGATGC  
GACAGTAGAG TGGACGAGG ACGGCTCTT CATAGGTAGT ACCGACTACG  
-----  
5401 AATGCGGGCG CTGCATACGC TTGATCCGGC TACCTGCCA TTCGACCACC  
TTACGCCGCC GACGTATGCG AACTAGGCGG ATGGACGGGT AAGCTGGTGG  
-----  
5451 AAGCGAACA TCGCATCGAG CGAGCACGTA CTCGGATGGA AGCCGGTCTT  
TTGCTTTGT AGCGTAGCTC GCTCGTGAT GAGCCTACCT TCGGCCAGAA  
-----  
5501 GTCGATCAGG ATGATCTGGA CGAAGAGCAT CAGGGGCTCG CGCCAGCCGA  
CAGCTAGTCC TACTAGACCT GCTTCTCGTA GTCCCGGAGC GCGGTGGCT  
-----  
5551 ACTGTTCCGC AGGCTCAAGG CGCGCATGCC CGACGGCGAG GATCTCGTGG  
TGACAAGCGG TCCGAGTTCC GCGGTACGG GCTGCCGCTC CTAGAGCAGC  
-----  
5601 TGACCCATGG CGATGCCCTGC TTGCCGAATA TCATGGTGGA AAATGGCCGC  
ACTGGGTACC GCTACGGACG AACGGCTTAT AGTACCACCT TTTACGGCGC  
-----  
5651 TTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG ACCGCTATCA  
AAAAGACCTA AGTAGCTGAC ACCGGCCGAC CCACACCGCC TGCGATAGT  
-----

5701 GGACATAGCG TTGGCTACCC GTGATATTGC TGAAGAGCTT GGCGGCGAAT  
CCTGTATCGC AACCGATGGG CACTATAACG ACTTCTCGAA CCGCCGCTTA

5751 GGGCTGACCC CTTCCTCGTG CTTTACGGTA TCGCCGCTCC CGATTGCGAG  
CCCGACTGGC GAAGGAGCAC GAAATGCCAT AGCGGCGAGG GCTAAGCGTC

5801 CGCATCGCCT TCTATCGCCT TCTTGACGAG TTCTTCTGAG CGGGACTCTG  
GCGTAGCGGA AGATAGCGGA AGAAGTCTC AAGAAGACTC GCCCTGAGAC

5851 GGGTTCGCAT CGATAAAATA AAAGATTTTA TTTAGTCTCC AGAAAAAGGG  
CCCAAGCGTA GCTATTTTAT TTTCTAAAT AAATCAGAGG TCTTTTCC

5901 GGGAAATGAAA GACCCACCT GTAGGTTTGG CAAGCTAGCT TAAGTAACGC  
CCCTTACTTT CTGGGTGGA CATCAAACC GTTCGATCGA ATTCAATTGCG

5951 CATTITGCAA GGCATGGAAA AATCATAAC TGAGAATAGA GAAGTTCAGA  
GTAAACGTT CCGTACCTTT TTATGTATTG ACTCTTATCT CTTCAGTCT

6001 TCAAGGTCAG GAACAGATGG AACAGCTGAA TATGGGCCAA ACAGGATATC  
AGTTCCAGTC CTGTCTACC TTGTCGACTT ATACCGGTT TGTCTATAG

6051 TGTGTAAGC AGTTCCTGCC CCGGCTCAGG GCCAAGACA GATGGAACAG  
ACACCATTCC TCAAGGACGG GGCCGAGTCC CGGTTCTTGT CTACCTTGT

6101 CTGAATATGG GCCAAACAGG ATATCTGTGG TAAGCAGTTC CTGCCCGGC  
GACTTATACC CGGTTTGTCC TATAGACACC ATTCGTCAAG GACGGGGCCG

6151 TCAGGGCCAA GAACAGATGG TCCCAGATG CGGTCCAGCC CTCAGCAGTT  
AGTCCCGGTT CTGTCTACC AGGGGTCTAC GCCAGGTCGG GAGTCGTCAA

6201 TCTAGAGAAC CATCAGATGT TTCCAGGGTG CCCAAGGAC CTGAAATGAC  
AGATCTCTTG GTAGTCTACA AAGGTCCAC GGGGTTCCTG GACTTTACTG

6251 CCTGTGCCCT ATTGAACTA ACCAATCAGT TCGCTTCTCG CTCTGTTCG  
GGACACGGAA TAACTTGAT TGGTTAGTCA AGCGAAGAGC GAAGACAAGC

6301 CGCGCTTCTG CTCCCGAGC TCAATAAAG AGCCCAAC CCCTCACTCG  
GCGCGAAGAC GAGGGGCTCG AGTTATTTT TCGGGTGTG GGGAGTGAGC

6351 GGGCGCCAGT CCTCCGATTG ACTGAGTCGC CCGGTACCC GTGTATCAA  
CCCGCGGTCA GGAGGCTAAC TGAATCAGC GGCCCATGG CACATAGGTT

6401 TAAACCTCT TGCAGTTGCA TCCGACTTGT GGTCTCGCTG TTCCTTGGGA  
ATTTGGGAGA ACGTCAACGT AGGCTGAACA CCAGAGCGAC AAGGAACCCT

6451 GGGTCTCCTC TGAGTGATTG ACTACCGTC AGCGGGGTC TTTCATTCT  
CCCAGAGGAG ACTCACTAAC TGATGGGCG TCGCCCCAG AAGTAAGTA

6501 GCAGCATGTA TCAAAATTA TTTGGTTTT TTTCTAAGT ATTTACATTA  
CGTCGTACAT AGTTTAAAT AAACCAAAA AAAGATTCA TAAATGTAAT

6551 AATGGCCATA GTTGCAATTA TGAATCGCC AACCGCGGG GAGAGGCGGT  
TTACCGGTAT CAACGTAAT ACTAGCCGG TTGCGCGCC CTCTCCGCCA

6601 TTGCGTATTG GCGCTCTTC GCTTCCTCG TCACTGACTC GCTGCGCTCG  
AAGCATAAC CCGGAGAAG CGAAGGAGCG AGTGACTGAG CGACGCGAGC



6651 GTCGTTCCGGC TGC GCGCAGC GGTATCAGCT CACTCAAAGG CGGTAATACG  
CAGCAAGCCG ACGCCGCTCG CCATAGTCCG GTGAGTTCC GCCATTATGC  
-----  
6701 GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TCAGCAAAAG  
CAATAGGTGT CTTAGTCCCC TATTGCGTCC TTCTGTGAC ACTCGTTTTC  
-----  
6751 GCCAGCAAAA GGGCAGGAAC CGTAAAAAGG CCGCGTTGCT GCGGTTTTTC  
CGGTCTGTTT CCGGTCTTTG GCATTTTTCC GCGCGCACGA CCGCAAAAAG  
-----  
6801 CATAGGCTCC GCGCCCTGA CGAGCATCAC AAAATCGAC GCTCAAGTCA  
GTATCCGAGG CCGGGGGACT GCTCGTAGTG TTTTAGCTG CGAGTTCAGT  
-----  
6851 GAGGTGGCGA AACCCGACAG GACTATAAG ATACCAGGCG TTCCCCCTG  
CTCCACCGCT TTGGGCTGTC CTGATATTTC TATGGTCCGC AAAGGGGGAC  
-----  
6901 GAAGCTCCCT CGTGCGCTCT CCTGTCCGA CCTGCGCGT TACCGGATAC  
CTTCGAGGGA GCACGCGAGA GGACAAGGCT GGGACGGCGA ATGGCCTATG  
-----  
6951 CTGTCCGCTT TTCTCCCTTC GGGAAAGCGTG GCGCTTTCTC ATAGCTCAGG  
GACAGGCGGA AAGAGGGGAG CCTTCGCAC CGCGAAGAG TATCGAGTGC  
-----  
7001 CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG  
GACATCCATA GAGTCAAGCC ACATCCAGCA AGCGAGGTTG GACCCGACAC  
-----  
7051 TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACAT  
ACGTGCTTGG GGGGCAAGTC GGGCTGGCGA CGCGGATAG GCCATTGATA  
-----  
7101 CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC TGGCAGCAGC  
GCAGAACTCA GGTGGGGCCA TTCTGTGCTG AATAGCGGTG ACCGTCGTG  
-----  
7151 CACTGGTAAC AGGATTACCA GAGCGAGGTA TGTAGGCGGT GCTACAGAGT  
GTGACCATTG TCGTAATCGT CTCGCTCCAT ACATCCGCGA CGATGTCTCA  
-----  
7201 TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC AGTATTTGGT  
AGAACTTCA CACCGGATTG ATGCCGATGT GATCTTCTG TCATAAACCA  
-----  
7251 ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC  
TAGACGCGAG ACGACTTCGG TCAATGGAAG CCTTTTCTC AACCATCGAG  
-----  
7301 TTGATCCGGC AACRAACCA CCGCTGGTAG CCGTGGTTTT TTTGTTTGCA  
AATAGGCCG TTTGTTTGGT GCGGACCATC GCCACCAAAA AAACAACGCT  
-----  
7351 AGCAGCAGAT TACCGCGAGA AAAAAGGAT CTCAAGAAGA TCCTTTGATC  
TCGTGCTCTA ATGGGCTCT TTTTTCCTA GAGTCTTCT AGGAACTAG  
-----  
7401 TTTCTACGG GGTCTGACGC TCAGTGAAC GAAACTCAC GTTAAGGGAT  
AAAAGATGOC CCAGACTGCG AGTCACCTTG CTTTGAGTG CAATTCCCTA  
-----  
7451 TTTGGTCATG AGATTATCAA AAAGATCTT CACCTAGATC CTTTGGCGC  
AAACCAGTAC TCTAATAGTT TTTCTAGAA GTGGATCTAG GAAAACGCCG  
-----  
7501 CGCAATCAA TCTAAAGTAT ATATGAGTAA ACTTGGTCTG ACAGTTACCA  
GCGTTTAGTT AGATTTTATA TATACTCATT TGAACCAGAC TGTCAATGGT  
-----  
7551 ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA TTTGCTTCAT  
TACGAATTAG TCACTCGTG GATAGAGTCG CTAGACAGAT AAAGCAAGTA  
-----

7601 CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC  
GGTATCAACG GACTGAGGGG CAGCACATCT ATTGATGCTA TGCCCTCCCG  
-----  
7651 TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC  
AATGGTAGAC CGGGGTCACG ACGTTACTAT GGCGCTCTGG GTGCGAGTGG  
-----  
7701 GGCTCCAGAT TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA  
CCGAGGTCTA AATAGTCGTT ATTTGGTCGG TCGGCCTTCC CGGCTCGCGT  
-----  
7751 GAAGTGGTCC TGCRACTTTA TCCGCCTCCA TCCAGTCTAT TAATTGTTGC  
CTTCACCAGG ACGTTGAAAT AGGCGGAGGT AGGTCAGATA ATTAACAACG  
-----  
7801 CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT AATAGTTTGC GCAACGTTGT  
GCCCTTCGAT CTCATTCTAT AAGCGGTCAA TTATCAAACG CGTTGCAACA  
-----  
7851 TGCCATTGCT ACAGGCATCG TGGTGTACG CTCGTCTGTT GGTATGGCTT  
ACGGTAACGA TGTCCTAGC ACCACAGTGC GAGCAGCAAA CCATACCGAA  
-----  
7901 CATTAGCTC CGGTTCCCAA CGATCAAGGC GAGTACATG ATCCCCCATG  
GTAAGTCGAG GCCAAGGGTT GCTAGTTCCG CTCAATGTAC TAGGGGGTAC  
-----  
7951 TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAAGAG  
AACACGTTTT TTCGCCAATC GAGGAAGCCA GGAGGCTAGC AACAGTCTTC  
-----  
8001 TAAGTTGGCC GCAGTGTTAT CACTCATGGT TATGCCAGCA CTGCATAAT  
ATTCAACCGG CGTCACAATA GTGAGTACCA ATACGTCGT GACGTATTAA  
-----  
8051 CTCTTACTGT CATGCCATCC GTAAGATGCT TTTCTGTGAC TGGTGAGTAC  
GAGAAATGCA GTACGGTAGG CATTCTACGA AAAGACACTG ACCACTCATG  
-----  
8101 TCAACCAAGT CATTCTGAGA ATAGTGTATG CGGCGACCGA GTTGCTCTTG  
AGTTGGTTCA GTAAGACTCT TATCACATAC GCCGCTGGCT CAACGAGAAC  
-----  
8151 CCGGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA ACTTTAAAAG  
GGGCGCGAGT TATGCCCTAT TATGGCGCGG TGTATCGTCT TGAAATTTTC  
-----  
8201 TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAACTCTC AAGGATCTTA  
ACGAGTAGTA ACCTTTTGCA AGAAGCCCGG CTTTTGAGAG TTCTAGAAAT  
-----  
8251 CCGCTGTGTA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC  
GGCGACAACT CTAGGTCAAG CTACATTGGG TGAGCACGTG GGTGACTAG  
-----  
8301 TTCAGCATCT TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA  
AAGTCGTAGA AAATGAAAGT GGTGCAAGG ACCCACTCGT TTTTGTCTTT  
-----  
8351 GGCAAAATGC CGCAAAAAG GGAATAGGG CGACAAGGAA ATGTTGAATA  
CCGTTTTACG GCGTTTTTTC CCTTATTTCC GCTGTGCTTT TACAACTTAT  
-----  
8401 CTCATACTCT TCCTTTTCA ATATTATTGA AGCATTIATC AGGGTTATTG  
GAGTATGAGA AGGAAAAAGT TATAATAACT TCGTAAATAG TCCCAATAAC  
-----  
8451 TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG  
AGAGTACTCG CCTATGTATA AACTTACATA AATCTTTTAA TTTGTTTATC  
-----  
8501 GGGTCCCGC CACATTTT  
CCCAAGGCGC GTGTAAG




Figure 12A

```

1  CTGCAGCCTG AATATGGGCC AAACAGGATA TCTGTGGTAA GCAGTTCCTG
   GACGTCCGGAC TTATACCCGG TTTGTCTAT AGACACCATT CGTCAAGGAC
-----
51  CCCC GGCTCA GGGCCAAGAA CAGATGGAAC AGCTGAATAT GGGCCAAACA
   GGGGCCGAGT CCCGGTCTT GTCTACCTTG TCGACTTATA CCCGGTTTGT
-----
101 GGATATCTGT GGTAAGCAGT TCCTGCCCGG GCTCAGGGCC AAGAACAGAT
   CCTATAGACA CCATTCTGTA AGGACGGGGC CGAGTCCCGG TTCTTGCTTA
-----
151 GGTCCCCAGA TGCGGTCCAG CCCTCAGCAG TTTCTAGAGA ACCATCAGAT
   CCAGGGGTCT ACGCCAGGTC GGGAGTCGTC AAAGATCTCT TGGTAGTCTA
-----
201 GTTTCAGGG TGCCCCAAGG ACCTGAAATG ACCCTGTGCC TTATTGAAAC
   CAAAGGTCCC ACGGGGTTC TGGACTTAC TGGGACACGG AATAAACTTG
-----
251 TAACCAATCA GTTCGCTTCT CGCTTCTGTT CGCGCGCTTC TGCTCCCGA
   ATTGGTTAGT CAAGCGAAGA GCGAAGACAA GCGCGCGAAG ACGAGGGGCT
-----
301 GCTCAATAAA AGAGCCACA ACCCTCACT CGGGCGGCCA GTCTCCGAT
   CGAGTTAATT TCTCGGGTGT TGGGGAGTGA GCCCGCGGT CAGGAGGCTA
-----
351 TGA CTGAGTC GCCCGGGTAC CCGTGATCC AATAAACCTT CTGCACTTG
   ACTGACTCAG CGGGCCCATG GGCACATAGG TTATTGGA GAACGTCAAC
-----
401 CATCCGACTT GTGGTCTCGC TGTTCTTGG GAGGGTCTCC TCTGAGTGAT
   GTAGGCTGAA CACCAGAGCG ACAAGGAACC CTCCAGAGG AGACTCTACTA
-----
451 TGA CTACCCG TCAGCGGGGG TCTTTCATT GGGGGCTCGT CCGGGATCGG
   ACTGATGGGC AGTCGCCCCC AGAAAGTAA CCCCCGACG GGCCTAGCC
-----
501 GAGACCCCTG CCCAGGGACC ACGACCCAC CACCGGGAGG CAAGCTGGCC
   CTCTGGGGAC GGGTCCCTGG TGGCTGGGTG GTGGCCCTCC GTTCGACCGG
-----
551 AGCAACTTAT CTGTGTCTGT CCGATTGTCT AGTGTCTATG ACTGATTTTA
   TCGTTGAATA GACACAGACA GGCTAACAGA TCACAGATAC TGAATAAAT
-----
601 TCGCCTGCG TCGGTACTAG TTAGCTAACT AGCTCTGTAT CTGGCGGACC
   ACGCGGACGC AGCCATGATC AATCGATTGA TCGAGACATA GACCGCCTGG
-----
651 CGTGGTGGAA CTGACGAGT CTGAACACC GCGCGCAACC CTGGGAGACG
   GCACCACCTT GACTGCTCAA GACTTGTGG CCGGCGTTGG GACCCTCTGC
-----
701 TCCAGGGGAC TTTGGGGGCC GTTTTGTGG CCGACCTGA GGAAGGGAGT
   AGGTCCCTG AAACCCCGG CAAAACACC GGGCTGCACT CCTTCCCTCA
-----
751 CGATGTGGAA TCCGACCCCG TCAGGATATG TGTTCTGCT AGGAGACGAG
   GCTACACCTT AGGCTGGGGC AGTCTATAC ACCAAGACCA TCCTCTGCTC
-----
801 AACCTAAAC AGTCCCGGC TCCGTCTGAA TTTTGTCTT CGGTGGA
   TTGGATTTT TCAAGGGCGG AGGCGACTT AAAACGAAA GCCAAACCTT
-----
851 CCGAAGCGCG CGCTCTTGTG TGCTGCAGCA TCGTTCTGTG TTGTCTCTGT
   GGGTTCGGCG CGCAGAACAG ACGACGTCGT AGCAAGACAC AACAGAGCA
-----
901 CTGACTGTGT TTCTGTATTT GTCTGAAAT TAGGGCCAGA CTGTACCAC
   GACTGACACA AAGACATAAA CAGACTTTTA ATCCCGTCT GACAATGGTG
-----

```

FIGURE 12B

951 TCCCTTAACT TTAGCCTTAG GTAACGGAA AGATGTCGAG CGGCTCGCTC  
AGGGAATTCA AACTGGAATC CATTGACCTT TCTACAGCTC GCCGAGCGAG  
-----  
1001 ACAACCACTC GGTAGATGTC AAGAAGAGAC GTTGGGTTAC CTTCTGCTCT  
TGTTGGTCAG CCATCTACAG TTCTTCTCTG CAACCCAATG GAAGACGAGA  
-----  
1051 GCAGAATGGC CAACCTTTAA CGTCGGATGG CCGCGAGACG GCACCTTTAA  
CGTCTTACCG GTTGGAAATT GCAGCCTACC GCGCTCTGCG CGTGGAAATT  
-----  
1101 CCGAGACCTC ATCACCAGG TTAAGATCAA GGTCTTTTCA CCTGGCCCGC  
GGCTCTGGAG TAGTGGGTCC AATTCTAGTT CCAGAAAAGT GGACCGGGCG  
-----  
1151 ATGGACACCC AGACCAGGTC CCTACATCG TGAACGGGA AGCCTTGGCT  
TACCTGTGGG TCTGGTCCAG GGGATGTAGC ACTGGACCTT TCGGACCGA  
-----  
1201 TTTGACCCCC CTCCTGGGT CAAGCCCTTT GTACCCCTA AGCCTCCGCC  
AAACTGGGGG GAGGGACCCA GTTCGGGAAA CATGTGGGAT TCGGAGCGCG  
-----  
1251 TCCTCTTCCT CCATCCGCCC CGTCTCTCCC CCTTGAACCT CCTCGTTCGA  
AGGAGAAGGA GGTAGGCGGG GCAGAGAGGG GGAACCTTGA GGAGCAAGCT  
-----  
1301 CCCCCTCTCG ATCTCCCTT TATCCAGCCC TCACTCCTTC TCTAGGCGCC  
GGGCGCGAGC TAGGAGGGAA ATAGGTCGGG AGTGAGGAAG AGATCCGCGG  
-----  
1351 GGCCTCTCTA GCCCATTAAAT ACGACTCACT ATAGGGCGAT TCGAATCAGG  
CCGGCGAGAT CCGGTAATTA TGCTGAGTGA TATCCGCTA AGCTTAGTCC  
-----  
1401 CCTTGGCGCG CCGGATCCTT AATTAAGCGC AATTGGGAGG TGGCGGTAGC  
GGAACCGCGC GGCCTAGGAA TTAATTGCGG TTAACCTCC ACCGCCATCG  
-----  
1451 CTCGAGATGG GCGTGATTAC GGATTCACCT GCGCTCGTTT TACAACGTCG  
GAGCTCTACC CGCACTAATG CCTAAGTGAC CGGCAGCAAA ATGTTGCAGC  
-----  
1501 TGACTGGGAA AACCTGGCG TTACCCAACT TAATCGCCTT GCAGCACATC  
ACTGACCTT TTGGGACCGC AATGGGTGA ATTAGCGGAA CGTCTGTAG  
-----  
1551 CCCCTTTCGC CAGCTGGCGT AATAGCGAAG AGGCCCGCAC CGATCGCCCT  
GGGGAAGCG GTCGACCGCA TTATCGCTTC TCCGGGCGTG GCTAGCGGGA  
-----  
1601 TCCCAACAGT TACGCAGCCT GAATGGCGAA TGGCGCTTTG CCTGGTTTCC  
AGGGTTGTCA ATGCGTCGGA CTTACCGCTT ACCGCGAAAC GGACCAAGG  
-----  
1651 GGCACCAGAA GCGGTGCCGG AAAGCTGGCT GGAGTGCAT CTTCTGAGG  
CCGTGGTCTT CGGCACGGCC TTTCGACCGA CCTCAGCTA GAAGGACTCC  
-----  
1701 CCGATACTGT CGTCGTCCCC TCRAACTGGC AGATGCACGG TTACGATCGG  
GGCTATGACA GCAGCAGGGG AGTTTGACCG TCTACGTGCC AATGCTACGC  
-----  
1751 OCCATCTACA CCAACGTGAC CTATCCCAT ACGGTCAATC CGCCGTTTGT  
GGTAGATGT GGTGCACTG GATAGGGTAA TGCCAGTTAG GCGGCAACA  
-----  
1801 TCCACAGGAG AATCCGACGG GTTGTACTC GCTCACATT AATGTTGATG  
AGGGTGCCCTC TTAGGCTGCC CAACAATGAG CGAGTGTAAT TTACAATAC  
-----  
1851 AAAGCTGGCT ACAGGAAGGC CAGACGCGAA TTATTTTGA TGGCGTTAAC  
TTTCGACCGA TGTCTTCCG GTCTGCGCTT AATAAAACT ACCGCAATG  
-----

1901 TCGGCGTTTC ATCTGTGGTG CAACGGGCGC TGGGTCGGTT ACGGCCAGGA  
AGCCGCAAAAG TAGACACCAC GTTGCCCGCG ACCCAGCCAA TGCCGGTCCT  
-----  
1951 CAGTCGTTTG CCGTCTGAAT TTGACCTGAG CGCATTTTTA CGCGCCGGAG  
GTCAGCAAAC GGCAGACTTA AACTGGACTC GCGTAAAAAT GCGCGGCCTC  
-----  
2001 AAAACCGCCT CGCGGTGATG GTGCTGCGCT GGAGTGACGG CAGTTATCTG  
TTTTGGCGGA GCGCCACTAC CACGACGCGA CCTCACTGCC GTCATAGAC  
-----  
2051 GAAGATCAGG ATATGTGGCG GATGAGCGGC ATTTCCGTG ACGTCTCGTT  
CTTCTAGTCC TATACACCGC CTACTCGCCG TAAAGGCAC TGCAGAGCAA  
-----  
2101 GCTGCATAAA CCGACTACAC AAATCAGCGA TTTCCATGTT GCCACTCGCT  
CGACGTATTT GGCTGATGTG TTTAGTCGCT AAAGGTACAA CGGTGAGCGA  
-----  
2151 TTAATGATGA TTTCAGCCGC GCTGTACTGG AGGCTGAAGT TCAGATGTGC  
AATTACTACT AAAGTCGGCG CGACATGACC TCCGACTTCA AGTCTACAG  
-----  
2201 GCGGAGTTGC GTGACTACCT ACGGGTAACA GTTCTTTTAT GGCAGGGTGA  
CCGCTCAACG CACTGATGGA TGCCCATGT CAAAGAAATA CCGTCCCACT  
-----  
2251 AACGCAGGTC GCCAGCGGCA CCGCGCCTTT CGGCGGTGAA ATTATCGATG  
TTGGCTCCAG CGGTGCGCGT GCGCGGAAA GCCGCCACTT TAATAGCTAC  
-----  
2301 AGCGTGGTGG TTATGCCGAT CGCGTCACAC TACGTCTGAA CGTCGAAAAC  
TCGCACCACC AATACGGCTA GCGCAGTGTG ATGCAGACTT GCAGCTTTTG  
-----  
2351 CCGAAACTGT GGAGCGCCGA AATCCCGAAT CTCTATCGTG CGGTGGTTGA  
GGCTTTGACA CCTCGCGGCT TTAGGGCTTA GAGATAGCAC GCCACCACT  
-----  
2401 ACTGCACACC GCCGACGGCA CGCTGATTGA AGCAGAAGCC TCGATGTGCG  
TGACGTGTGG CGGCTGCCGT GCGACTAACT TCGTCTTCGG ACGCTACAGC  
-----  
2451 GTTTCGCGCA GGTGCGGATT GAAAAATGGT TGCTGCTGCT GAACGGCAAG  
CAAAGGCGCT CCACGCCTAA CTTTACCAG ACGACGACGA CTGCGCGTTC  
-----  
2501 CCGTTGCTGA TTCGAGGCGT TAACCGTCAC GAGCATCATC CTCTGCATGG  
GGCAACCACT AAGCTCCGCA ATTGGCAGTG CTCGTAGTAG GAGACGTACC  
-----  
2551 TCAGGTCATG GATGAGCAGA CGATGGTGCA GGATATCCTG CTGATGAAGC  
AGTCCAGTAC CTACTCGTCT GCTACCAGCT CCTATAGGAC GACTACTTCG  
-----  
2601 AGAACAACTT TAACGCCGTG CGCTGTTGCG ATTATCCGAA CCATCCGCTG  
TCTTGTGAA ATTGCGGCAC GCGACAAGCG TAATAGGCTT GGTAGGCGAC  
-----  
2651 TGGTACACGC TGTGCGACCG CTACGGCCTG TATGTGGTGG ATGAAGCCAA  
ACCATGTGCG ACACGCTGGC GATGCCGGAC ATACACCACC TACTTCGGTT  
-----  
2701 TATTGAAACC CACGGCATGG TGCCAATGAA TCGTCTGACC GATGATCOGC  
ATAACTTTGG GTGCCGTACC ACGGTTACTT AGCAGACTGG CTACTAGGCG  
-----  
2751 GCTGGCTACC GCGGATGAGC GAACGCGTAA CGCGAATGGT GCAGCGCGAT  
CGACCGATGG CCGCTACTCG CTTGCGCATT GCGCTTACCA CGTCGCGCTA  
-----  
2801 CGTAATCACC CGAGTGTGAT CATCTGGTGG CTGGGGAATG AATCAGGCCA  
GCATTAGTGG GCTCACACTA GTAGACCAGC GACCCCTTAC TTAGTGGCGT  
-----

2851 CGGCGCTAAT CACGACGCGC TGTATCGCTG GATCAAATCT GTCGATCCTT  
GCCGCGATTA GTGCTGCGCG ACATAGCGAC CTAGTTTAGA CAGCTAGGAA  
-----  
2901 CCCGCCCGGT GCAGTATGAA GCGCGCGGAG CCGACACCAC GGCACCGAT  
GGGCGGGCCA CGTCATACCT CCGCCGCCCTC GGCTGTGGTG CCGGTGGCTA  
-----  
2951 ATTATTGGCC CGATGTACGC GCGCGTGGAT GAAGACCAGC CCTTCCCGGC  
TAATAAACGG GCTACATGCG CCGGCACCTA CTCTGTGGTG GGAAGGGCCG  
-----  
3001 TGTGCCGAAA TGGTCCATCA AAAAATGGCT TTCGCTACCT GGAGAGACGC  
ACACGGCTTT ACCAGGTAGT TTTTACCAGA AAGCGATGGA CCTCTGCG  
-----  
3051 GCCCGCTGAT CCTTTGCGAA TACGCCACAG CGATGGGTAA CAGTCTTGGC  
CGGCGGACTA GGAACGCTT ATGCGGGTGC GCTACCCATT GTCAGAACCG  
-----  
3101 GGTTCGCTA AATACTGGCA GCGGTTTCGT CAGTATCCCC GTTACAGGG  
CCAAAGCGAT TTATGACCGT CCGCAAAGCA GTCATAGGGG CAATGTCC  
-----  
3151 CGGCTTCGTC TGGGACTGGG TGGATCAGTC GCTGATTAAA TATGATGAAA  
GCCGAAGCAG ACCCTGACCC ACCTAGTCAG CGACTAATT ATACTACTTT  
-----  
3201 ACGGCACCCC GTGGTCGGCT TACGGCGGTG ATTTGGCGA TACGCCGAAC  
TGCCGTTGGG CACCAGCCGA ATGCCGCCAC TAAACCGCT ATGCGGCTTG  
-----  
3251 GATCGCCAGT TCTGTATGAA CGGTCTGGTC TTGCGGACC GCACGCGCA  
CTAGCGGTCA AGACATACTT GCCAGACCAG AACGGGCTGG CGTGGCGCT  
-----  
3301 TCCAGCGCTG ACGGAAGCAA AACACCAGCA GCAGTTTTTC CAGTTCGTT  
AGGTGCGCAC TGCCTTCGTT TTGTGGTCGT CGTCAAAAG GTCAGGCAA  
-----  
3351 TATCCGGGCA AACCATCGAA GTGAOCAGCG AATACCTGTT CCGTCATAGC  
ATAGGCCCGT TTGGTAGCTT CACTGGTCGC TTATGGACAA GGCAGTATCG  
-----  
3401 GATAACGAGC TCCTGCACTG GATGGTGGCG CTGGATGGTA AGCCGCTGGC  
CTATTGCTCG AGGACGTGAC CTACCACCGC GACCTACCAT TCGGCGACCG  
-----  
3451 AAGCGGTGAA GTGCCTCTGG ATGTGCTCC ACAAGGTAAA CAGTTGATTG  
TTGCCCACTT CACGGAGACC TACAGCGAGG TGTTCCATT GTCAACTAAC  
-----  
3501 AACTGCCTGA ACTACCGCAG CCGGAGAGCG CCGGGCAACT CTGGCTCACA  
TTGACGGACT TGATGGCGTC GGCCTCTCGC GGCCCGTTGA GACCGAGTGT  
-----  
3551 GTACGCGTAG TGCAACCGAA CCGACCCGCA TGGTCAGAG CCGGGCACAT  
CATGCGCATC ACCTTGGCTT GCGCTGGCGT ACCAGTCTTC GGCCCGTGA  
-----  
3601 CAGCGCCTGG CAGCAGTGGC GTCTGGCGGA AACCTCAGT GTGACGCTCC  
GTGCGGGACC GTCGTCACCG CAGACCGCCT TTGGAGTCA CACTGCGAGG  
-----  
3651 CCGCCGCGTC CCACGCCATC CCGCATCTGA CCACCAGOGA AATGGATTTT  
GGCGGCGCAG GGTGCGGTAG GCGGTAGACT GGTGGTGGT TTACCTAAAA  
-----  
3701 TGCATCGAGC TGGGTAATAA GCGTTGGCAA TTTAACCGCC AGTCAGGCTT  
ACGTAGCTCG ACCCATATT CGCAACCGTT AAATTGGGG TCACTCCGAA  
-----  
3751 TCTTTCACAG ATGTGGATTG GCGATAAAAA ACAACTGCTG ACGCCGCTGC  
AGAAAGTGTG TACACCTAAC CGCTATTTT TGTGACGAC TCGGCGGACG  
-----

3801 GCGATCAGTT CACCCGTGTC GATAGATCTG AACAGAACT CATTTCGGA  
CGCTAGTCAA GTGGGCACAG CTATCTAGAC TTGTCTTTGA GTAAAGGCTT

3851 GAAGACCTAG TCGACCATCA TCATCATCAT CACCGGTAAT AATAGGTAGA  
CTTCTGGATC AGCTGGTAGT AGTAGTAGTA GTGGCATTAT TTATCCATCT

3901 TAAGTGACTG ATTAGATGCA TTTCGACTAG ATCCCTCGAC CAATTCCGGT  
ATTCACCTGAC TAATCTACGT AAAGCTGATC TAGGGAGCTG GTTAAGGCCA

3951 TATTTTCCAC CATATTGCCG TCTTTGGCA ATGTGAGGGC CCGGAAACCT  
ATAAAAGGTG GTATAACGGC AGAAAACCGT TACACTCCCG GGCCTTTGGA

4001 GGCCTGTCT TCTTGACGAG CATTCTAGG GGTCTTTCCC CTCTCGCCAA  
CCGGGACAGA AGAAGTGTCT GTAAGGATCC CCAGAAAGGG GAGAGCGGT

4051 AGGAATGCAA GGTCTGTTGA ATGTCTGTAA GGAAGCAGTT CCTCTGGAAG  
TCCTTACGTT CCAGACAAC TACAGCACTT CCTTCGTCAA GGAGACCTTC

4101 CTTCTTGAAG ACAACAACG TCTGTAGCGA CCCTTTGCAG GCAGCGGAAC  
GAAGAACTTC TGTGTTGTC AGACATCGCT GGGAAACGTC CGTCGCCTTG

4151 CCCCCACCTG GCGACAGGTG CCTCTGCGGC CAAAAGCCAC GTGTATAAGA  
GGGGGTGGAC CGCTGTCCAC GGAGACGCCG GTTTTCGGTG CACATATTCT

4201 TACACCTGCA AAGCGGCAC AACCCAGTG CCACGTTGTG AGTTGGATAG  
ATGTGGACGT TTCCGCCGTG TTGGGGTCAC GGTGCAACAC TCAACCTATC

4251 TGTGGAAAG AGTCAAATGG CTCTCTCAA GCGTATTCAA CAAGGGGCTG  
AACACCTTTC TCAGTTTACC GAGAGGAGTT GGCATAAGTT GTTCCCCGAC

4301 AAGGATGCCC AGAAGGTACC CCATTGTATG GGATCTGATC TGGGGCCTCG  
TTCCTACGGG TCTTCCATGG GGTAAACATAC CCTAGACTAG ACCCCGGAGC

4351 GTGCACATGC TTTACATGTG TTTAGTCGAG GTTAAAAAC GTCTAGGCCC  
CAGCTGTACG AATGTACAC AATCAGCTC CAATTTTTTG CAGATCCGGG

4401 CCCGAACAC GGGGACGTGG TTTTCCTTG AAAAAACGA TGATAATACC  
GGGCTTGGTG CCCCTGCACC AAAAGGAAAC TTTTGTGCT ACTATTATGG

4451 ATGAAAAAGC CTGAACAC CGCGACGCT GTCGAGAAGT TTCTGATCGA  
TACTTTTTCG GACTTGAGTG GCGCTGCAGA CAGCTCTTA AAGACTAGCT

4501 AAAGTTCGAC AGCGTCTCCG ACCTGATGCA GCTCTCGAG GCGGAAGAAT  
TTTCAAGCTG TCGCAGAGGC TGGACTACGT CGAGAGCCTC CCGCTTCTTA

4551 CTCGTGCTTT CAGCTTCGAT GTAGGAGGGC GTGGATATGT CCTGCGGGTA  
GAGCACGAAA GTCGAAGCTA CATCCTCCCG CACCTATACA GGACGCCCAT

4601 AATAGCTGCG CCGATGGTTT CTACAAAGAT CGTTATGTTT ATCGGCACTT  
TTATCGACGC GGCTACCAA GATGTTTCTA GCAATACAAA TAGCCGTGAA

4651 TGCATCGGCC GCGCTCCCGA TTCCGGAAGT GCTTGACRTT GGGGAATTTA  
ACGTAGCCGG CCGAGGGGCT AAGGCCCTCA CGAACTGTAA CCCCTTAAAT

4701 GCGAGAGCCT GACCTATTGC ATCTCCGCC GTGCACAGGG TGTCAGTTG  
CGCTCTCGGA CTGGATAACG TAGAGGGCGG CAGGTGTCCC ACAGTGCAAC



```

4751 CAAGACCTGC CTGAAACCGA ACTGCCCCGCT GTTCTGCAGC CGGTGCGGGA
      GTTCTGGACG GACTTTGGCT TGACGGGCGA CAAGACGTCG GCCAGCGCCT
-----
4801 GGCCATGGAT GCGATCGCTG CGGCCGATCT TAGCCAGACG AGCGGGTTCG
      CCGGTACCTA CGCTAGCGAC GCCGGCTAGA ATCGGTCTGC TCGCCCAAGC
-----
4851 GCCCATTCCG ACCGCAAGGA ATCGGTCAAT ACACTACATG GCGTGATTTC
      CGGGTAAGCC TGGCGTTCCT TAGCCAGTTA TGTGATGTAC CGCACTAAAG
-----
4901 ATATGCGCGA TTGCTGATCC CCATGTGTAT CACTGGCAAA CTGTGATGGA
      TATACGCGCT AACGACTAGG GGTACACATA GTGACCGTTT GACACTACCT
-----
4951 CGACACCGTC AGTGCGTCCG TCGCGCAGGC TCTCGATGAG CTGATGCTTT
      GCTGTGGCAG TCACGCAGGC AGCGCGTCCG AGAGCTACTC GACTACGAAA
-----
5001 GGGCCGAGGA CTGCCCCGAA GTCCGGCACC TCGTGACGCG GGATTTCGGC
      CCCGGCTCCT GACGGGGCTT CAGGCCGTGG AGCACGTGCG CCTAAAGCCG
-----
5051 TCCAACAATG TCCTGACGGA CAATGGCCGC ATAACAGCGG TCATTGACTG
      AGGTTGTTAC AGGACTGCCT GTTACCGGCG TATTGTCGCC AGTAACTGAC
-----
5101 GAGCGAGGCG ATGTTGGGGG ATTCCCAATA CGAGGTCGCC AACATCTTCT
      CTCGCTCCGC TACAAGCCCC TAAGGGTTAT GCTCCAGCGG TTGTAGAAGA
-----
5151 TCTGGAGGCC GTGGTTGGCT TGTATGGAGC AGCAGACGCG CTACTTCGAG
      AGACCTCCGG CACCAACCGA ACATACCTCG TCGTCTGCGC GATGAAGCTC
-----
5201 CGGAGGCATC CGGAGCTTGC AGGATCGCCG CGGCTCCGGG CGTATATGCT
      GCCTCCGTAG GCCTCGAAGC TCCTAGCGGC GCCGAGGCCG GCATATACGA
-----
5251 CCGCATTGGT CTTGACCAAC TCTATCAGAG CTTGGTTGAC GGCAATTTGG
      GCGGTAACCA GAATGCTTG AGATAGTCTC GAACCAACTG CCGTTAAAGC
-----
5301 ATGATGCAGC TTGGGCGCAG GGTGATGCGG ACGCAATCGT CCGATCCGGA
      TACTACGTGC AACCCGCGTC CCAGCTACGC TGCCTTAGCA GGCTAGGCCT
-----
5351 GCCGGGACTG TCGGGCGTAC ACAAATCGCC CGCAGAGCGG CGGCCGTCTG
      CGGCCCTGAC AGCCCCGATG TGTTTAGCGG GCGTCTTCGC GCCGGCAGAC
-----
5401 GACCGATGGC TGTGTAGAAG TACTCGCCGA TAGTGGAAC CGACGCCCA
      CTGGCTACCG ACACATCTTC ATGAGCGGCT ATCACCTTTG GCTCGGGGCT
-----
5451 GCACTCGTCC GAGGGCAAGG GAATAGAGTA GATGCCGACC GGGATCTATC
      CGTGAGCAGG CTCGCGTTTC CTTATCTCAT CTACGGCTGG CCTTAGATAG
-----
5501 GATAAAATAA AAGATTTTAT TTAGTCTCCA GAAAAAGGGG GGAATGAAAG
      CTATTTTATT TTCTAAAATA AATCAGAGGT CTTTTTCCCC CCTTACTTTC
-----
5551 ACCCCACCTG TAGGTTTGGC AAGCTAGCTT AAGTAACGCC ATTTTGCAAG
      TGGGGTGGAC ATCCAAACCG TTCGATCGAA TTCATTGCGG TAAACGTTTC
-----
5601 GCATGGAAAA ATACATAACT GAGATAGAG AAGTTCAGAT CAAGGTCAGG
      CGTACCTTTT TATGTATTGA CTCTTATCTC TTCAAGTCTA GTTCCAGTCC
-----
5651 AACAGATGGA ACAGCTGAAT ATGGGCCAAA CAGGATATCT GTGGTAAGCA
      TTGTCTACCT TGTGACTTA TACCCGGTTT GTCCTATAGA CACCATTCTG
-----

```

5701 GTTCCTGCCC CGGCTCAGGG CCAAGAACAG ATGGAACACC TGAATATGGG  
CAAGGACGGG GCCGAGTCCC GGTCTTTGTC TACCTTGTGC ACTTATACCC  
-----  
5751 CCAAACAGGA TATCTGTGGT AAGCAGTTCC TGCCCCGGCT CAGGGCCAAG  
GGTTTGTCTT ATAGACACCA TTCGTCAAGG ACGGGGCCGA GTCCCGTTC  
-----  
5801 AACAGATGGT CCCCAGATGC GGTCCAGCCC TCAGCAGTTT CTAGAGAACC  
TTGTCTACCA GGGGTCTACG CCAGGTCCGG AGTCGTCAA GATCTCTTGG  
-----  
5851 ATCAGATGTT TCCAGGGTGC CCCAAGGACC TGAATGACC CTGTGCCTTA  
TAGTCTACAA AGGTCCACG GGGTTCCTGG ACTTTACTGG GACACCGAAT  
-----  
5901 TTTGAACTAA CCAATCAGTT CGCTTCTCGC TTCTGTTCGC GCGCTTCTGC  
AAACTTGATT GGTAGTCAA GCGAAGAGCG AAGACAAGCG CGCGAAGACG  
-----  
5951 TCCCCGAGCT CAATAAAGA GCCACAACC CCTCACTCGG GCGGCCAGTC  
AGGGGCTCGA GTTATTTTCT CCGGTGTTGG GGAGTGAGCC CCGCGGTGAG  
-----  
6001 CTCCGATTGA CTGAGTCGCC CGGGTACCCG TGTATCCAAT AAACCCCTTT  
GAGGCTAACT GACTCAGCGG GCCCATGGGC ACATAGGTTA TTTGGGAGAA  
-----  
6051 GCAGTTGCAT CCGACTTGTG GTCTCGCTGT TCCTTGGGAG GGTCTCCTCT  
CGTCAACGTA GGCTGAACAC CAGAGCGACA AGGAACCCCTC CCAGAGGAGA  
-----  
6101 GAGTGATTGA CTACCCGTCA GCGGGGGTCT TTCATTCTAG CAGCATGTAT  
CTCACTAACT GATGGGCAGT CGCCCCAGA AAGTAAGTAC GTCGTACATA  
-----  
6151 CAAAATTAAT TTGGTTTTTT TTCTTAAGTA TTTACATTAA ATGGCCATAG  
GTTTTAATTA AACCAAAAAA AAGAATTCAT AAATGTAATT TACCGGTATC  
-----  
6201 TTGCATTAAAT GAATCGGCCA ACGCGCGGGG AGAGCGGCTT TGCGTATTGG  
AACGTAATTA CTAGCCGGT TCGCGCGCCC TCTCGCCAA ACGCATAACC  
-----  
6251 CGCTCTTCCG CTTCCTCGCT CACTGACTCG CTGCGCTCGG TCGTTCGGCT  
GCGAGAAGGC GAAGGAGCGA GTGACTGAGC GACGCGAGCC AGCAAGCCGA  
-----  
6301 GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAAATACG TTATCCACAG  
CGCCGCTCGC CATAGTCGAG TGAGTTTCCG CCATTATGCC AATAGGTGTC  
-----  
6351 AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG  
TTAGTCCCTT ATTGCGTCTT TTCTTGATCA CTCGTTTTCC GGTGTTTTTC  
-----  
6401 GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG  
CGGTCTTGG CATTTTTCCG GCGCAACGAC CGCAAAAAGG TATCCGAGGC  
-----  
6451 CCCCCCTGAC GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA  
GGGGGGACTG CTCGTAGTGT TTTAGCTGC GAGTTCAGTC TCCACCGCTT  
-----  
6501 ACCCGACAGS ACTATAAAGA TACCAGGCGT TTCCCCCTGG AAGCTCCCTC  
TGGGCTGTCC TGATATTTCT ATGGTCCGCA AAGGGGGACC TTCGAGGGAG  
-----  
6551 GTGCGCTCTC CTGTTCCGAC CTTGCCGCTT ACCGGATACC TGTCCGCTT  
CACGCGAGAG GACAAGGCTG GAGCGGCGAA TGGCCTATGG ACAGGCGGAA  
-----  
6601 TCTCCCTTCG GGAAGGCTGG CGCTTTCTCA TAGCTCACGC TGTAGGTATC  
AGAGGGAGC CCTTCGCACC GCGAAAGAGT ATCGAGTGGC ACATCCATAG  
-----

5651 TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGIGT GCACGAACCC  
AGTCAAGCCA CATCCAGCAA GCGAGGTTCC ACCCGACACA CGTGCTTGGG

5701 CCCGTTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGACTC  
GGGCAAGTCG GGCTGGCGAC GCGGAATAGG CCATTGATAG CAGAACTCAG

5751 CAACCCGGTA AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA  
GTTGGGCCAT TCTGTGCTGA ATAGCGGTGA CCGTCGTCGG TGACCATGT

5801 GGATTAGCAG AGCGAGGTAT GTAGGCGGTG CTACAGAGTT CTTGAAGTGG  
CCTAATCGTC TCGCTCCATA CATCCGCCAC GATGTCTCAA GAACTTCACC

5851 TGGCCTAACT ACGGCTACAC TAGAAGAACA GTATTTGGTA TCTGCGCTCT  
ACCGGATTGA TGCCGATGTG ATCTTCTTGT CATAAACCAT AGACGCGAGA

5901 GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA  
CGACTTCGGT CAATGGAAGC CTTTTTCTCA ACCATCGAGA ACTAGGCCGT

5951 AACAAACCAC CGCTGSTAGC GGTGGTTTTT TTGTTTGCAA GCACGAGATT  
TTGTTTGGTG GCGACCATCG CCACCAAAAA AACAAACGTT CGTCGTCTAA

7001 ACGCGCAGAA AAAAAGGATC TCAAGAGAT CCTTTGATCT TTTCTACGGG  
TGCGCGTCTT TTTTCCCTAG AGTTCCTCTA GGAACTAGA AAAGATGCCC

7051 GTCTGACGCT CAGTGAACG AAACTCAGC TTAAGGGATT TTGGTCATGA  
CAGACTGCGA GTCACCTTGC TTTTGAGTGC AATTCCTAA AACCACTACT

7101 GATTATCAAA AAGGATCTTC ACCTAGATCC TTTTAAATTA AAAATGAAGT  
CTAATAGTTT TTCCTAGAAG TGGATCTAGG AAAATTAAAT TTTTACTTCA

7151 TTGCGGCCGC AAATCAATCT AAAGTATATA TGAGTAACT TGGTCTGACA  
AACGCCGCGC TTTAGTTAGA TTTCAATAT ACTCATTGA ACCAGACTGT

7201 GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT  
CAATGGTTAC GAATTAGTCA CTCCGTGGAT AGAGTCGCTA GACAGATAAA

7251 CGTTTCATCCA TAGTTGCCCTG ACTCCCGCTC GTGTAGATAA CTACGATACG  
GCAAGTAGGT ATCAACGGAC TGAGGGGCAG CACATCTATT GATGCTATGC

7301 GGAGGGCTTA CCATCTGGCC CCACTGCTGC AATGATACCG CGAGACCCAC  
CCTCCCGAAT GGTAGACCGG GGTACAGACG TTAATATGGC GCTCTGGGTG

7351 GCTCACCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC  
CGAGTGGCCG AGGTCTAAAT AGTCGTTATT TGGTCGGTCG GCCTTCCCGG

7401 GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA  
CTCGCGTCTT CACCAGGACG TTGAAATAGG CGGAGGTAGG TCAGATAATT

7451 TTGTTGCGCG GAGCTAGAG TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA  
AACACGGCC CTTGATCTC ATTCATCAAG CGGTCAATTA TCAAACGCGT

7501 ACGTTGTTGC CATTGCTACA GGCATCGTG TGTACGCTC GTCGTTTGGT  
TGCAACAACG GTAACGATGT CCGTAGCACC ACAGTCCGAG CAGCAAACCA

7551 ATGGCTTCAT TCAGCTCCGG TTCOACAAGA TCAAGGCGAG TTACATGATC  
TACCGAAGTA AGTCGAGGCC AAGGTTGCT AGTTCGCTC AATGTACTAG

7601 CCCCATGTTG TGCAAAAAG CGGTTAGCTC CTTGGTCCT CCGATCGTTG  
GGGGTACAAC ACGTTTTTTC GCCAATCGAG GAAGCCAGGA GGCTAGCAAC  
-----  
7651 TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG  
AGTCTTCATT CAACCGGCGT CACAATAGTG AGTACCAATA CCGTCGTGAC  
-----  
7701 CATRAATCTC TTAATGTCAT GCCATCCGTA AGATGCTTTT CTGTGACTGG  
GTATTAAGAG AATGACAGTA CCGTAGGCAT TCTACGAAPA GACACTGACC  
-----  
7751 TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCCG CGACCGAGTT  
ACTCATGAGT TGGTTCAGTA AGACTCTTAT CACATACGCC GCTGGCTCAA  
-----  
7801 GCTCTTGCCC GCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT  
CGAGAACGGG CCGCAGTTAT GCCCTATTAT GGC CGGTGT ATCGTCTTGA  
-----  
7851 TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG  
AATTTTCACG AGTAGTAACC TTTTGCAAGA AGCCCCGCTT TTGAGAGTTC  
-----  
7901 GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA  
CTAGAATGGC GACAACCTA GGTCAAGCTA CATTGGGTGA GCACGTGGGT  
-----  
7951 ACTGATCTTC AGCATCTTTT ACTTCAOCA GCGTTCTGCG GTGAGCAAAA  
TGACTAGAAG TCGTAGAAAA TGAAAGTGGT CGCAAAGACC CACTCGTTTT  
-----  
8001 ACAGGAAGGC AAAATGCCGC AAAAAGGGA ATAAGGGCGA CACGGAAATG  
TGTCTTCCG TTTTACGGCG TTTTTCCT TATTCCCGCT GTGCCTTTAC  
-----  
8051 TTGAATACTC ATACTCTTCC TTTTCAATA TTATTGAAGC ATTTATCAGG  
AACTTATGAG TATGAGAAGG AAAAAGTTAT AATBACTTCG TAAATAGTCC  
-----  
8101 GTTATTGTCT CATGAGCGGA TACATATTG AATGTATTTA GAAAAATAA  
CAATAACAGA GTACTCGCCT ATGTATAAAC TTACATAAAI CTTTTATTT  
-----  
8151 CAAATAGGGG TTCCGCGCAC ATTTT  
GTTTATCCCC AAGGCGCGTG TAAAG  
-----




Figure 13A

```

1  CTGCAGCCTG AATATGGGCC AAACAGGATA TCTGTGGTAA GCAGTTCCTG
   GACGTCGGAC TTATACCCGG TTGTCTCTAT AGACACCATT CGTCAAGGAC
-----
51  CCCC GGCTCA GGGCCAAGAA CAGATGGAAC AGCTGAATAT GGGCCAAACA
   GGGGCCGAGT CCCGGTTCTT GTCTACCTTG TCGACTTATA CCCGGTTTGT
-----
101 GGATATCTGT GGTAAAGCAGT TCCTGCCCCG GCTCAGGGCC AAGAACAGAT
   CCTATAGACA CCATTCTGTA AGGACGGGGC CGAGTCCCGG TTCTTGTCTA
-----
151 GGTCCCCAGA TGC GGTCAG CCCTCAGCAG TTTCTAGAGA ACCATCAGAT
   CCAGGGGTCT ACGCCAGGTC GGGAGTCGTC AAAGATCTCT TGGTAGTCTA
-----
201 GTTTCAGGG TGGCCCAAGG ACCTGAAATG ACCCTGTGCC TTATTGAAC
   CAAAGGTCCC ACGGGGTTC TGGACTTTAC TGGGACACGG AATAAACTTG
-----
251 TAACCAATCA GTTCGCTTCT CGCTTCTGTT CGCGCGCTTC TGCTCCCGA
   ATTGGTTAGT CAAGCGAAGA GCGAAGACAA GCGCGCGAAG ACGAGGGGCT
-----
301 GCTCAATAAA AGAGCCCAACA ACCCTCACT CGGGGCGCCA GTCCTCCGAT
   CGAGTTATTT TCTCGGGTGT TGGGAGTGA GCCCGCGGT CAGGAGGCTA
-----
351 TGACTGAGTC GCCCGGGTAC CCGTGTATCC AATAAACCTT CTTCAGTTG
   ACTGACTCAG CCGGCCCATG GGCACATAGG TTATTGGGA GAACGTCAAC
-----
401 CATCGACTT GTGGTCTCGC TGTTCCTTGG GAGGGTCTCC TCTGAGTGAT
   GTAGGCTGAA CACCAGAGCG ACAAGGAACC CTCCAGAGG AGACTCACTA
-----
451 TGACTACCG TCAGCGGGGG TCTTTCATT GGGGGCTCGT CCGGGATCGG
   ACTGATGGGC AGTCGCCCC AGAAAGTAA CCCCCGAGCA GGCCCTAGCC
-----
501 GAGACCCCTG CCCAGGGACC ACCGACCAC CACCGGGAGG CAAGCTGGCC
   CTCTGGGGAC GGTCCCTGG TGGCTGGGTG GTGGCCCTCC GTTCGACCGG
-----
551 AGCAACTTAT CTGTGTCTGT CCGATTGTCT AGTGTCTATG ACTGATTTA
   TCGTTGAATA GACACAGACA GGCTAACAGA TCACAGATAC TGACTAAAT
-----
601 TCGCCCTGCG TCGGTACTAG TTAGCTAAT AGCTCTGTAT CTGGCGGACC
   ACGCGGACGC AGCCATGATC AATCGATTGA TCGAGACATA GACCGCCTGG
-----
651 CGTGGTGGAA CTGACGAGTT CTGAACACCC GGCCGCAACC CTGGGAGACG
   GCACCACCTT GACTGCTCAA GACTTGTGGG CCGGCGTTGG GACCCTCTGC
-----
701 TCCAGGGAC TTTGGGGGCC GTTTTGTGG CCGACCTGA GGAAGGGAGT
   AGGGTCCCTG AAACCCCGG CAAAACACC GGGCTGGACT CCTTCCCTCA
-----
751 CGATGTGGAA TCCGACCCG TCAGGATATG TGGTCTGGT AGGAGACGAG
   GCTACACCTT AGGCTGGGGC AGTCCTATAC ACCAAGACCA TCCTCTGCTC
-----
801 AACCTAAAAC AGTCCCGCC TCCGTCTGAA TTTTGTCTT CGGTTTGGAA
   TTGGATTTT TCAAGGGCGG AGGCAGACTT AAAACGAAA GCCAAACCTT
-----
851 CCGAAGCCGC CGTCTTGTG TGCTGCAGCA TCGTTCTGTG TTGTCTCTGT
   GGCTTCGGCG CGCAGAACAG ACGACGTCGT AGCAAGACAC AACAGAGACA
-----
901 CTGACTGTGT TTCTGTATTT GTCTGAAAAT TAGGGCCAGA CTGTTACCAC
   GACTGACACA AAGACATAAA CAGACTTTTA ATCCCGGTCT GACAATGGTG
-----

```

FIGURE 13B

951 TCCCTTAAGT TTGACCTTAG. GTAACCTGGAA AGATGTCGAG CGGCTCGCTC  
AGGGAATTCA AACTGGAATC CATTGACCTT TCTACAGCTC GCCGAGCGAG  
-----  
1001 ACAACCAGTC GGTAGATGTC AAGAAGAGAC GTTGGGTTAC CTTCTGCTCT  
TGTTGGTCAG CCATCTACAG TTCTTCTCTG CAACCCAATG GAAGACGAGA  
-----  
1051 GCAGARTGGC CAACCTTTAA CGTCGGATGG CCGCGAGACG GCACCTTTAA  
CGTCTTAGCG GTTGGAAATG GCAGCCTACC GGCCTCTGTC CGTGGAAATG  
-----  
1101 CCGAGACCTC ATCACCAGG TTAAGATCAA GGTCTTTTCA CCTGGCCCGC  
GGCTCTGGAG TAGTGGGTCC AATTCTAGTT CCAGAAAAGT GGACCGGGCG  
-----  
1151 ATGGACACCC AGACCAGGTC CCCTACATCG TGACCTGGGA AGCCTTGGCT  
TACCTGTGGG TCTGGTCCAG GGGATGTAGC ACTGGACCCT TCGGAACCGA  
-----  
1201 TTTGACCCCC CTCCTGGGT CAGGCCCTT GTACACCCTA AGCCTCCGCC  
AAACTGGGGG GAGGGACCCA GTTCGGGAAA CATGTGGGAT TCGGAGGCGG  
-----  
1251 TCCTCTTCCT CCATCCGCC CGTCTCTCCC CCTTGAACCT CCTCGTTCGA  
AGGAGAAGGA GGTAGGCGGG GCAGAGAGGG GGAACCTGGA GGAGCAAGCT  
-----  
1301 CCCCCTCTCG ATCCTCCCTT TATCCAGCCC TCACTCCTTC TCTAGGCGCC  
GGGCGGAGC TAGGAGGGAA ATAGGTCCGG AGTGAGGAAG AGATCCGCGG  
-----  
1351 GGCCGCTCTA GCCCATTAAT ACGACTCACT ATAGGGCGAT TCGAACACCA  
CCGCGGAGAT CCGGTAATTA TGCTGAGTGA TATCCCGCTA AGCTTGTGGT  
-----  
1401 TGCACCATCA TCATCATCAC GTCGACGAAC AGAACTCAT TTCCGAAGAA  
ACGTGGTAGT AGTAGTAGTG CAGCTGCTTG TCTTTGAGTA AAGGCTTCTT  
-----  
1451 GACCTACTCG AGATGGGCGT GATTACGAT TCACTGGCCG TCGTTTACA  
CTGGATGAGC TCTACCCGCA CTAATGCCTA AGTGACCGGC AGCAAAATGT  
-----  
1501 ACGTCGTGAC TGGGAAAACC CTGGCGTTAC CCAACTTAAT CGCCTTGCAG  
TGCAGCACTG ACCCTTTTGG GACCGCAATG GGTGAAATTA CGGGAACGTC  
-----  
1551 CACATCCCCC TTTCGCCAGC TGGCGTAATA GCGAAGAGGC CCGCACCGAT  
GTGTAGGGGG AAAGCGGTCTG ACCGCATTAT CGCTTCTCCG GCGGTGGCTA  
-----  
1601 CGCCCTTCCC AACAGTTACG CAGCCTGAAT GGCGAATGGC GCTTTGCCTG  
GCGGGAAGGG TTGTCAATGC GTCGGACTTA CCGCTTACCG CGAAACGGAC  
-----  
1651 GTTTCGGGCA CCAGAAGCGG TGCCGGAAAG CTGGCTGGAG TCGATCTTC  
CAAAGGCCGT GGTCTTCGCC ACGGCCTTTC GACCGACCTC ACGCTAGAAG  
-----  
1701 CTGAGGCCGA TACTGTCGTC GTCCCTCAA ACTGGCAGAT GCACGGTTAC  
GACTCCGGCT ATGACAGCAG CAGGGGAGTT TGACCGTCTA CGTGCCAATG  
-----  
1751 GATGCGCCCA TCTACACCAA CGTGACCTAT CCCATTACGG TCAATCCGCC  
CTACGCGGCT AGATGTGGTT GCACTGGATA GGGTAATGCC AGTTAGGCGG  
-----  
1801 GTTGTTCCTC ACGGAGAATC CGACGGGTG TTA CTGCTC ACATTTAATG  
CAAACAAGGG TGCTCTTAG GCTGCCAAC AATGAGCGAG TGTAATTAC  
-----  
1851 TTGATGAAG CTGGCTACAG GAAGGCCAGA CGCGAATTAT TTTGATGGC  
AACTACTTTC GACGATGTC CTTCGGTCT GCGCTTAATA AAACTACCG  
-----

1901 GTTAACTCGG CGTTTCATCT GTGGTGCAAC GGGCGCTGGG TCGGTTACGG  
CAATTGAGCC GCAAAGTAGA CACCACGTTG CCCGCGACCC AGCCAATGCC

1951 CCAGGACAGT CGTTTGCCGT CTGAATTTGA CCTGAGCGCA TTTTACGGG  
GGTCCTGTCA GCAAACGGCA GACTTAACT GGACTCGCGT AAAAATGCGC

2001 CCGGAGAAAA CCGCCTCGCG GTGATGGTGC TGGCTGGAG TGACGGCAGT  
GGCCTCTTTT GCGGAGCGC CACTACCAGC ACGCGACCTC ACTGCCGTCA

2051 TATCTGGAAG ATCAGGATAT GTGGCGGATG AGCGGCATTT TCCGTGACGT  
ATAGACCTTC TAGTCCTATA CACCGCCTAC TCGCCGTAAA AGGCACTGCA

2101 CTCGTTGCTG CATAAACCGA CTACACAAAT CAGCGATTTT CATGTTGCCA  
GAGCAAGCAC GTATTGGCT GATGTGTTA GTCGCTAAAG GTACAACGGT

2151 CTCGCTTTAA TGATGATTTC AGCCGCGCTG TACTGGAGGC TGAAGTTCAG  
GAGCGAAATT ACTACTAAAG TCGGCGCGAC ATGACCTCG ACTTCAAGTC

2201 ATGTGCGCGC AGTTGCGTGA CTACCTACGG GTAACAGTTT CTTTATGGCA  
TACACGCCGC TCAACGCACCT GATGGATGCC CATTGTCAAA GAATACCGT

2251 GGGTGAACG CAGGTCGCCA GCGGCACCGC GCCTTTCGGC GGTGAAATTA  
CCCACTTTGC GTCCAGCGGT CGCCGTGGCG CGGAAGCCG CCACTTTAAT

2301 TCGATGAGCG TGGTGGTTAT GCCGATCGCG TCACACTACG TCTGAACGTC  
AGCTACTCGC ACCACCAATA CGGCTAGCGC AGTGTGATGC AGACTTGCAG

2351 GAAACCCCGA AACTGTGGAG CGCCGAAATC CCGAATCTCT ATCGTGGGT  
CTTTGGGCT TTGACACCTC CGCGCTTTAG GGCTTAGAGA TAGCAGCCA

2401 GGTGAACTG CACACCGCGC ACGGCACGCT GATTGAAGCA GAAGCCTGCG  
CCAACCTTAC GTGTGGCGGC TCGCGTGCGA CTAACCTCGT CTTGGGACGC

2451 ATGTCGGTTT CCGCGAGGTG CGGATTGAAA ATGGTCTGCT GCTGCTGAAC  
TACAGCCAAA GCGGCTCCAC GCCTAAGTTT TACCAGACGA CGACGACTTG

2501 GGCAAGCCGT TGCTGATTCG AGCGGTTAAC CGTCACGAGC ATCATCCTCT  
CGGTTGCGCA ACGACTAAGC TCCGCAATTG GCAGTGCTCG TAGTAGGAGA

2551 GCATGGTCAG GTCATGGATG AGCAGACGAT GGTGCAGGAT ATCCTGCTGA  
CGTACCAGTC CAGTACCTAC TCGTCTGCTA CCACGTCCTA TAGGACGACT

2601 TGAAGCAGAA CAACTTTAAC GCCGTGCGCT GTTCGCATTA TCCGAACCAT  
ACTTCGTCTT GTTGAAATTG CGGCACGCGA CAAGCGTAAT AGGCTTGCTA

2651 CCGCTGTGGT ACACGCTGTG CGACCGCTAC GGCCTGTATG TGGTGGATGA  
GGCGACACCA TGTGCGACAC GCTGGCGATG CCGGACATAC ACCACCTACT

2701 AGCCAATATT GAAACCCACG GCATGGTGCC AATGAATCGT CTGACCGATG  
TCGTTTATAA CTTTGGGTGC CGTACCACGG TACTTAGCA GACTGGCTAC

2751 ATCCGCGCTG GCTACCGGCG ATGAGCGAAC GCGTAACGCG AATGGTGCAG  
TAGGCGCGAC CGATGGCCGC TACTCGCTTG CGCATTGCGC TTACCACGTC

2801 CGCGATCGTA ATCACCAGAG TGTGATCATC TGGTGGCTGG GGAATGAATC  
CGGCTAGCAT TAGTGGGCTC AACTAGTAG ACCAGCGACC CTTACTTAG



2851 AGGCCACGGC GCTAATCAGC ACGCGCTGTA TCGCTGGATC AAATCTGTCG  
TCCGGTGCCG CGATTAGTGC TCGCGGACAT AGCGACCTAG TTTAGACAGC  
-----  
2901 ATCCTTCCCG CCCGGTGCAG TATGAAGGCG GCGGAGCCGA CACCACGGCC  
TAGGAAGGGC GGGCCACGTC ATACTTCCGC CGCCTCGGCT GTGGTGCCGG  
-----  
2951 ACCGATATTA TTTGCCCGAT GTACGCGCGC GTGGATGAAG ACCAGCCCTT  
TGGCTATAAT AAACGGGCTA CATGCGCGCG CACCTACTTC TGGTCGGGAA  
-----  
3001 CCCGGCTGTG CCGAAATGGT CCATCAAAA ATGGCTTTCG CTACCTGGAG  
GGGCCGACAC GGCTTTACCA GGTAGTTTTT TACCGAAAGC GATGGACCTC  
-----  
3051 AGACGCGCCC GCTGATCCTT TCGAATACG CCCACGCGAT GGGTAACAGT  
TCTGCGCGGG CACTAGGAA ACGCTTATGC GGGTGCGCTA CCCATTGTCA  
-----  
3101 CTTGGCGGTT TCGCTAAATA CTGGCAGGCG TTTGCTCAGT ATCCCCGTTT  
GAACCGCCAA AGCGATTAT GACCGTCCGC AAAGCAGTCA TAGGGGCAAA  
-----  
3151 ACAGGGCGGC TTCGTCTGGG ACTGGGTGGA TCAGTCGCTG ATTAAATATG  
TGTCGCGCCG AAGCAGACCC TGACCCACCT AGTCAGCGAC TAATTTATAC  
-----  
3201 ATGAAAACGG CAACCCGTGG TCGGCTTACG GCGGTGATT TGGCGATACG  
TACTTTTGCC GTTGGGCACC AGCCGAATGC CGCCACTPAA ACCGCTATGC  
-----  
3251 CCGAACGATC GCCAGTTCTG TATGAACGGT CTGGTCTTTC CCGACCGCAC  
GGCTTGCTAG CGGTCAAGAC ATACTTGCCA GACCAGAAAC GGCTGGCGTG  
-----  
3301 GCCGCATCCA GCGCTGACGG AAGCAAAACA CCAGCAGCAG TTTTCCAGT  
CGGCGTAGGT CCGGACTGCC TTCGTTTTGT GGTGCTGCTC AAAAAGGTCA  
-----  
3351 TCCGTTTTATC CGGGCAAACC ATCGAAGTGA CCAGCGAATA CCTGTTCCGT  
AGGCAAATAG GCCCGTTTGG TAGCTTCACT GGTGCTTAT GGACAAGGCA  
-----  
3401 CATAGCGATA ACGAGCTCCT GCACTGGATG GTGGCGCTGG ATGTTAAGCC  
GTATCGCTAT TGCTCGAGGA CGTGACCTAC CACCGCGACC TACCATTGCG  
-----  
3451 GCTGGCAAGC GGTGAAGTGC CTCTGGATGT CGCTCCACAA GGTAACAGT  
CGACCGTTTC CCACTTCACG GAGACCTACA GCGAGGTGTT CCATTGTCA  
-----  
3501 TGATTGAACT GCCTGAACTA CCGCAGCCGG AGAGCGCCGG GCAACTCTGG  
ACTAACTTGA CGGACTTGAT GCGCTCGGCC TCTCGCGGCC CGTTGAGACC  
-----  
3551 CTCACAGTAC GCGTAGTGCA ACCGAACGCG ACCGCATGGT CAGAAGCCGG  
GAGTGTATG CGCATCACGT TGGCTTGCGC TGGCGTACCA GTCTTCGGCC  
-----  
3601 GCACATCAGC GCCTGGCAGC AGTGGCGTCT GCGGGAACAC CTCAGTGTGA  
CGTGTAGTCG CGGACCGTCG TCACCGCAGA CCGCCTTTTG GAGTCACACT  
-----  
3651 CGCTCCCCCG CGGTCCAC GGCATCCCGC ATCTGAACCAC CAGCGAAATG  
GCGAGGGGCG GCGCAGGGTG CGGTAGGGCG TAGACTGGTG GTCGCTTTAC  
-----  
3701 GATTTTTGCA TCGAGCTGGG TAATAAGCGT TGGCAATTA ACCGCCAGTC  
CTAAAAACGT AGCTCGACCC ATTATTCGCA ACCGTTAAAT TGGCGGTCAG  
-----  
3751 AGGCTTTCTT TCACAGATGT GGATTGGCGA TAAAAACAA CTGCTGACGC  
TCCGAAAGAA AGTGTCTACA CCTAACCGCT ATTTTTGTT GACGACTGCG  
-----

3801 CGCTGCGCGA TCAGTTCACC CGTGTGATA GATCTGGAGG TGGTGGCAGC  
GCGACGCGCT AGTCAAGTGG GCACAGCTAT CTAGACCTCC ACCACCGTCG  
-----  
3851 AGGCCCTTGGC GCGCCGGATC CTTAATTAAC AATTGACCGG TAATAATAGG  
TCCGGAACCG CGCGGCCTAG GAATTAATTG TTAAGTGGCC ATTATTATCC  
-----  
3901 TAGATAAGTG ACTGATTAGA TGCATTTCGA CTAGATCCCT CGACCAATTC  
ATCTATTAC TGACTAATCT ACGTAAAGCT GATCTAGGGA GCTGGTTAAG  
-----  
3951 CGGTTATTTT CCACCATATT GCCGTCTTTT GGCAATGTGA GGGCCCGGAA  
GCCAATAAAA GGTGGTATAA CGGCAGAAAA CCGTTACACT CCCGGGCCTT  
-----  
4001 ACCTGGCCCT GTCTTCTTGA CGAGCATYCC TAGGGGTCTT TCCCCTCTCG  
TGGACCGGGA CAGAAGAAT GCTCGTAAGG ATCCCAGAA AGGGGAGAGC  
-----  
4051 CCAAGGAAT GCAAGGTCTG TTGAATGTG TGAAGGAAGC AGTTCCTCTG  
GGTTCTCTTA CGTCCAGAC AACTTACAGC ACTTCTCTG TCAAGGAGAC  
-----  
4101 GAAGCTTCTT GAAGACAAAC AACGTCTGTA GCGACCTTT GCAGGCAGCG  
CTTCGAAGAA CTTCTGTTT TGCAGACAT CGCTGGGAAA CGTCCGTGCG  
-----  
4151 GAACCCCCCA CCTGCGGACA GTTGCTCTG CGGCCAAAG CCACGTGTAT  
CTTGGGGGT GGACCGCTGT CCACGGAGAC GCCCGTTTC GGTGCACATA  
-----  
4201 AAGATACACC TGCAAGGGG GCACAACCC AGTGCCACGT TGTGAGTTGG  
TTCTATGTG ACGTTTCGC CGTGTGGGG TCACGGTGCA AACTCAACC  
-----  
4251 ATAGTTGTGG AAAGAGTCAA ATGGCTCTCC TCAAGCGTAT TCAACAAGGG  
TATCAACACC TTTCTCAGT TACCGAGAGG AGTTCGCATA AGTTGTTOCC  
-----  
4301 GCTGAAGGAT GCCCAGAAGG TACCCATTG TATGGGATCT GATCTGGGGC  
CGACTTCTTA CGGGTCTTCC ATGGGGTAAC ATACCTAGA CTAGACCCG  
-----  
4351 CTCGGTGCAC ATGCTTTACA TGTGTTTGT CGAGGTTAAA AAACGTCTAG  
GAGCCACGTG TACGAAATGT ACACAAATCA GCTCCAATT TTTGCAGATC  
-----  
4401 GCGCCCGGAA CCACGGGGAC GTGGTTTCC TTTGAAAAAC ACGATGATAA  
CGGGGGGCTT GGTGCCCTG CACCAAAGG AAACTTTTT TGCTACTATT  
-----  
4451 TACCATGAAA AAGCCTGAAC TCACGCGAC GTCTGTGAG AAGTTTCTGA  
ATGGTACTTT TTCGGACTTG AGTGGCGCTG CAGACAGCTC TTCAAAGACT  
-----  
4501 TCGAAAAGTT CGACAGCGTC TCCGACCTGA TGCAGCTCTC GGAGGGCGAA  
AGCTTTTCAA GCTGTGCGAG AGGCTGGACT ACGTCGAGAG CCTCCGCTT  
-----  
4551 GAATCTCGTG CTTTCAGCTT CGATGTAGGA GGGCGTGGAT ATGCTCTGCG  
CTTAGAGCAC GAAGTCGAA GCTACATCCT CCGCACCTA TACAGGACGC  
-----  
4601 GGTAAATAGC TCGCCGATG GTTCTACAA AGATCGTTAT GTTATCGGC  
CCATTTATCG ACGCGGCTAC CAAAGATGTT TCTAGCAATA CAAATAGCCG  
-----  
4651 ACTTTGCATC GCGCGGCTC CCGATTCCGG AAGTGCTTGA CATTTGGGAA  
TGAAACGTAG CCGCGCGAG GGCTAAGGCC TTCACGAAT GTAACCCCTT  
-----  
4701 TTAGCGAGA GCCTGACCTA TTGCATCTCC CGCCGTGCAC AGGGTGTAC  
AAATCGCTCT CGGACTGGAT AACGTAGAGG GCGGCACTG TCCACAGTG  
-----

4751 GTTGCAAGAC CTGCCTGAAA CCGAACTGCC CGCTGTTCTG CAGCCGGTCC  
CAACGTTCTG GACGGACTTT GGCTTGACGG GCGACAAGAC GTCGGCCAGC

4801 CGGAGGCCAT GGATGCGATC GCTGCGGCCG ATCTTAGCCA GACGAGCGGG  
GCCTCCGGTA CCTACGCTAG CGACGCCGGC TAGAATCGGT CTGCTCGCCC

4851 TTCGGCCCAT TCGGACCGCA AGGAATCGGT CAATACACTA CATGGCGTGA  
AAGCCGGGTA AGCCTGGCGT TCCTTAGCCA GTTATGTGAT GTACCGCACT

4901 TTTCATATGC GCGATTGCTG ATCCCATGT GTATCACTGG CAACTGTGA  
AAAGTATACG CGCTAACGAC TAGGGGTACA CATAGTGACC GTTTGACACT

4951 TGGACGACAC CGTCAGTGGC TCCGTGCGGC AGGCTCTCGA TGAGCTGATG  
ACCTGCTGTG GCAGTCACGC AGGCAGCGCG TCCGAGAGCT ACTCGACTAC

5001 CTTTGGGCCG AGGACTGCCC CGAAGTCCGG CACCTCGTGC ACGCGGATT  
GAAACCCGGC TCCTGACGGG GCTTCAGGCC GTGGAGCAGC TCGCCCTAAA

5051 CGGCTCCAAC AATGTCCTGA CCGACAATGG CCGCATAACA GCGGTCAATT  
GCCGAGGTTG TTACAGGACT GCCTGTTACC GCGTATTGT CGCCAGTAAC

5101 ACTGGAGCGA GGCATGTTT GGGGATTCCC AATACGAGGT CGCCAACATC  
TGACCTCGCT CCGCTACAAG CCCCTAAGGG TTATGCTCCA GCGGTTGTAG

5151 TTCTTCTGGA GGCCGTGGTT GGCTGTATG GAGCAGCAGA CGCGCTACTT  
AAGAAGACCT CCGGCACCAA CCGAACATAC CTCGTCTGCT GCGCGATGAA

5201 CGAGCGGAGG CATCCGAGC TTGCAGGATC GCCGCGGCTC CGGGCGTATA  
GCTCGCCTCC GTAGGCCTCG AACGTCCTAG CGGCGCGAG GCCCGCATAT

5251 TGCTCCGCAT TGGCTTGAC CAACCTATC AGAGCTTGGT TGACGGCAAT  
ACGAGGCGTA ACCAGAACTG GTTGAGATAG TCTCGAACCA ACTGCCGTTA

5301 TTCGATGATG CAGCTTGGGC GCAGGTCGA TGGACGCAA TCGTCCGATC  
AAGCTACTAC GTCGAACCCG CGTCCAGCT ACGCTGCGTT AGCAGGCTAG

5351 CGGAGCCGGG ACTGTCGGGC GTACACAAAT CGCCCGCAGA AGCGCGGCCG  
GCCTCGGCCG TGACAGCCCG CATGTGTTA GCGGGCGTCT TCGCGCGGGC

5401 TCTGGACCGA TGGCTGTGTA GAAGTACTCG CCGATAGTGG AAACCGACGC  
AGACCTGGCT ACCGACACAT CTTCTGAGC GGCTATCACC TTTGGCTGCG

5451 CCCAGCACTC GTCCGAGGGC AAAGGAATAG AGTAGATGCC GACCGGGATC  
GGGTCTGTAG CAGGCTCCCG TTTCTTATC TCATCTACGG CTGGCCCTAG

5501 TATCGATAAA ATAAAGATT TTATTTAGTC TCCAGAAAAA GGGGGGAATG  
ATAGCTATTT TATTTTCTAA AATAAATCAG AGGTCTTTT CCCCCCTTAC

5551 AAAGACCCCA CTGTAGGTT TGGCAAGCTA GCTTAAGTAA CGCCATTTTG  
TTTCTGGGGT GGACATCCAA ACCGTTGAT CGAATTCATT GCGGTAAAC

5601 CAAGGCATGG AAAAATACAT AACTGAGAAT AGAGAAGTTC AGATCAAGGT  
GTTCCGTACC TTTTATGTA TTGACTCTTA TCTCTCAAG TCTAGTTCCA

5651 CAGGAACAGA TGGAACAGCT GAATATGGGC CAAACAGGAT ATCTGTGGTA  
GTCCTTGTCT ACCTTGTCGA CTTATACCCG GTTTGTCTTA TAGACACCAT

```

5701 AGCAGTTCCT GCCCGGCTC AGGGCCAAGA ACAGATGGAA CAGCTGAATA
TCGTCAAGGA CGGGGCCGAG TCCCGGTTCT TGTCTACCTT GTCGACTTAT
-----
5751 TGGGCCAAAC AGGATATCTG TGGTAAGCAG TTCCTGCCCC GGCTCAGGGC
ACCCGGTTTG TCCTATAGAC ACCATTCTGC AAGGACGGGG CCGAGTCCCC
-----
5801 CAAGAACAGA TGGTCCCCAG ATGCGGTCCA GCCCTCAGCA GTTCTAGAG
GTTCTTGTCT ACCAGGGGTC TACGCCAGGT CGGGAGTCGT CAAAGTCTC
-----
5851 AACCATCAGA TGTTCCAGG GTGCCCAAG GACCTGAAAT GACCCTGTGC
TTGGTAGTCT ACAAAGGTCC CACGGGGTTC CTGGACTTTA CTGGGACACG
-----
5901 CTTATTGAA CTAACCAATC AGTTCGCTTC TCGCTTCTGT TCGCGCGCTT
GAATAAATCT GATTGGTTAG TCAAGCGAAG AGCGAAGACA AGCGCGCGAA
-----
5951 CTGCTCCCCG AGCTCAATAA AAGAGCCAC AACCCCTCAC TCGGGCGCGC
GACGAGGGGC TCGAGTTATT TTCTCGGGTG TTGGGGAGTG AGCCCGCGG
-----
6001 AGTCCTCCGA TTGACTGAGT CGCCCGGTA CCCGTGTATC CAATAAACC
TCAGGAGGCT AACTGACTCA GCGGGCCAT GGGCACATAG GTTATTGGG
-----
6051 TCTTGCACTT GCATCCGACT TGTGGTCTCG CTGTTCTTGG GGAGGGTCTC
AGAACGTCAA CGTAGGCTGA ACACCAGAGC GACAAGGAAC CCTCCCAGAG
-----
6101 CTCTGAGTGA TTGACTACCC GTCAGCGGGG GTCTTTCATT CATGCAGCAT
GAGACTCACT AACTGATGGG CAGTCGCCCC CAGAAAGTAA GTACGTCGTA
-----
6151 GTATCAAAAT TAATTGGTT TTTTCTTA AGTATTACA TTAAATGCC
CATAGTTTAA ATTAACCAA AAAAAAGAA TCATAAATGT AATTACCGG
-----
6201 ATAGTTGCAT TAATGAATCG GCCAACGCGC GGGGAGAGGC GGTTCGCTA
TATCAACGTA ATTACTAGC CGGTTGCGCG CCCCTCTCCG CCAAACGCAT
-----
6251 TTGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTT
AACCGCGAGA AGGCGAAGGA GCGAGTGACT GAGCGACGCG AGCCAGCAAG
-----
6301 GGTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC
CCGACGCGCG TCGCCATAGT CGAGTGAGTT TCCGCCATTA TGCCAATAGG
-----
6351 ACAGAATCAG GGGATAACGC AGGAAGAAGC ATGTGAGCAA AAGGCCAGCA
TGTCTTAGTC CCTATTGCG TCCTTCTTG TACACTCGTT TTCCGGTCGT
-----
6401 AAAGGCCAGG AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC
TTTCCGGTCC TTGGCATTTT TCCGGCGCAA CGACCGCAA AAGGTATCCG
-----
6451 TCCGCCCCCC TGACGAGCAT CACAAAATC GACGCTCAAG TCAGAGGTGG
AGGCGGGGGG ACTGCTCGTA GTGTTTTAG CTGCGAGTTC AGTCTCCACC
-----
6501 CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC CTGGAAGCTC
GCTTTGGGCT GTCCTGATAT TTCTATGGTC CGCAAAGGGG GACCTTCGAG
-----
6551 CCTCGTGCGC TCTCTGTTT CGACCTGCC GCTTACGGGA TACCTGTCCG
GGAGCACGCG AGAGGACAAG GCTGGGACGG CGAATGGCCT ATGGACAGGC
-----
6601 CCTTCTCCCT TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG
GGAAAGAGGG AAGCCCTTCG CACCGCGAAA GAGTATCGAG TGCGACATCC
-----

```

6651 TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA  
ATAGAGTCAA GCCACATCCA GCAAGCGAGG TTCGACCCGA CACACGTGCT

6701 ACCCCCCGTT CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG  
TGGGGGGCAA GTCGGGCTGG CGACGCGGAA TAGGCCATTG ATAGCAGAAC

6751 AGTCCAAACC GGTAAGACAC GACTTATCGC CACTGGCAGC AGCCACTGGT  
TCAGGTGGGG CCATTCTGTG CTGAATAGCG GTGACCGTCG TCGGTGACCA

6801 AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG AGTTCCTGAA  
TTGTCTTAAT CGTCTCGCTC CATACTCCG CCACGATGTC TCAAGAACTT

6851 GTGGTGGCCT AACTACGGCT ACACTAGAAG AACAGTATTT GGTATCTGCG  
CACCACCGGA TTGATGCCGA TGTGATCTTC TTGTCATAAA CCATAGACGC

6901 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC  
GAGACGACTT CGGTCAATGG AAGCCTTTT CTCAACCATC GAGAAGTAGG

6951 GGCAAAACAA CCACCGCTGG TAGCGGTGGT TTTTGTGTT GCAAGCAGCA  
CCGTTTGTGTT GGTGGCGACC ATCGCCACCA AAAAAACAA CGTTCGTCGT

7001 GATTACGCGC AGAAAAAAG GATCTCAAGA AGATCCTTTG ATCTTTTCTA  
CTAATGCGCG TCTTTTTTC CTAGAGTTCT TCTAGGAAAC TAGAAAAGAT

7051 CGGGGTCTGA CGCTCAGTGG AACGAAAAC CACGTTAAGG GATTTTGGTC  
GCCCCAGACT GCGAGTCACC TTGCTTTTGA GTGCAATTCC CTAAAACAG

7101 ATGAGATTAT CAAAAGGAT CTTACCTAG ATCCTTTTGC GGCCGCAAA  
TACTCTAATA GTTTTCTTA GAAGTGGATC TAGGAAACG CCGGCGTTTA

7151 CAATCTAAAG TATATATGAG TAACTTGGT CTGACAGTTA CCAATGCTTA  
GTTAGATTIC ATATATACTC ATTTGAACCA GACTGTCAAT GGTACGAAT

7201 ATCAGTGAGG CACCTATCTC AGCGATCTGT CTATTTCGTT CATCCATAGT  
TAGTCACTCC GTGGATAGAG TCGTAGACA GATAAGCAA GTAGGTATCA

7251 TGCCTGACTC CCGCTCGTGT AGATAACTAC GATACGGGAG GGCTTACCAT  
ACGGACTGAG GGGCAGCACA TCTATTGATG CTATGCCCTC CCGAATGGTA

7301 CTGGCCCCAG TGCTGCAATG ATACCGCGAG ACCCAGCTC ACCGGCTCCA  
GACCGGGGTC ACGACGTTAC TATGGCGCTC TGGGTGCGAG TGGCCGAGGT

7351 GATTTATCAG CAATAAACCA GCCAGCCGGA AGGGCCGAGC GCAGAAGTGG  
CTAAATAGTC GTTATTGGT CGGTGGGCT TCCCGGCTCG CGTCTTCACC

7401 TCCTGCAACT TTATCCGCT CCATCCAGTC TATTAATGT TGCCGGGAAG  
AGGACGTTGA AATAGGCGGA GGTAGGTCAG ATAATTAACA ACGGCCCTTC

7451 CTAGAGTAAG TAGTTCGCCA GTTAATAGTT TGCGCAACGT TGTTGCCATT  
GATCTCATT ATCAAGCGGT CAATTATCAA ACGCGTTGCA ACAACGGTAA

7501 GCTACAGGCA TCGTGGTGTG ACGCTCGTCG TTTGGTATGG CTTCATTCAG  
CGATGTCCGT AGCACCACAG TCGAGCAGC AAACCATACC GAAGTAAGTC

7551 CTCCGGTTC CAACGATCAA GCGAGTTAC ATGATCCCC ATGTTGTGCA  
GAGGCCAAGG GTTGCTAGTT CCGCTCAATG TACTAGGGG TACAACAGT

7601 AAAAAGCGGT TAGCTCCTTC GGTCTCCGA TCGTTGTGAG AAGTAAGTTG  
TTTTTCGCCA ATCGAGGAAG CCAGGAGGCT AGCAACAGTC TTCATTCAAC

7651 GCCGCAGTGT TATCACTCAT GGTATGGCA GCACTGCATA ATTCTCTTAC  
CGGCGTCACA ATAGTGAGTA CCAATACCGT CGTGACGTAT TAAGAGAATG

7701 TGTGATGCCA TCCGTAAGAT GCTTTTCTGT GACTGGTGAG TACTCAACCA  
ACAGTACGGT AGGCATTCTA CGAAAAGACA CTGACCACTC ATGAGTTGGT

7751 AGTCATTCTG AGAATAGTGT ATGCGGCGAC CGAGTTGCTC TTGCCCGGCG  
TCAGTAAGAC TCTTATCACA TACGCCGCTG GCTCAACGAG AACGGGCGCG

7801 TCAATACGGG ATAATACCGC GCCACATAGC AGAACTTTAA AAGTGCTCAT  
AGTTATGCCC TATTATGGCG CGGTGTATCG TCTTGAAATT TTCACGAGTA

7851 CATTGGAAAA CGTTCTTCGG GCGGAAAACT CTCAGGATC TTACGCTGT  
GTAACCTTTT GCAAGAAGCC CCGCTTTTGA GAGTTCCTAG AATGGCGACA

7901 TGAGATCCAG TTCGATGTAA CCCACTCGTG CACCCAACTG ATCTTCAGCA  
ACTCTAGGTC AAGCTACATT GGGTGAGCAC GTGGGTTGAC TAGAAGTCGT

7951 TCTTTTACTT TCACCAGCGT TTCTGGGTGA GCAAAAACAG GAAGGCAAAA  
AGAAAATGAA AGTGGTCGCA AAGACCCACT CGTTTTTGTC CTTCCGTTTT

8001 TGCCGCAAAA AAGGGAATAA GGGCGACACG GAAATGTTGA ATACTCATAC  
ACGGCGTTTT TTCCCTTATT CCCGCTGTGC CTTTACAACT TATGAGTATG

8051 TCTTCCTTTT TCAATATTAT TGAAGCATT ATCAGGGTTA TTGTCTCATG  
AGAAGGAAAA AGTTATAATA ACTTCGTAAA TAGTCCCAAT AACAGAGTAC

8101 AGCGGATACA TATTGAATG TATTTAGAAA AATAAACAAA TAGGGGTTCC  
TCGCTATGT ATAACTTAC ATAAATCTTT TTATTTGTTT ATCCCCAAGG

8151 GCGCACATT C  
CGCGTGTAAG G




Figure 14




Figure 15






Figure 16




Figure 17.




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22






Figure 23





Vector for Expression of a GPCR with inserted  
Serine/Threonine amino acid sequences as a fusion with  $\beta$ -gal  $\Delta\alpha$ .

FIGURE 24



Vector for Expression of mutant (R170E)  $\beta$ -arrestin2 as a fusion with  $\beta$ -gal  $\Delta\omega$ .

FIGURE 25

Phosphorylation Insensitive Mutant R170E  $\beta$ -Arrestin2 $\Delta\omega$   
Binds to  $\beta_2$  AR $\Delta\alpha$  in Response to Agonist Activation







FIGURE 26



GPCR dimerization measured by  $\beta$ -gal complementation

FIGURE 27

Example-



Ligand Fishing for Orphan Receptors by β-galactosidase mutant complementation in ICAS<sup>TM</sup> System

FIGURE 28